0001558370-16-005699.txt : 20160509 0001558370-16-005699.hdr.sgml : 20160509 20160509165057 ACCESSION NUMBER: 0001558370-16-005699 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160509 DATE AS OF CHANGE: 20160509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 161632357 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 10-Q 1 incy-20160331x10q.htm 10-Q incy_Current folio_10Q

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2016

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from             to            

 

Commission File Number: 0-27488

 

INCYTE CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

 

Delaware

 

94-3136539

(State or other jurisdiction of
incorporation or organization)

 

(IRS Employer
Identification No.)

 

 

 

1801 Augustine Cut-Off

Wilmington, DE  19803

 

19803

(Address of principal executive offices)

 

(Zip Code)

 

(302) 498-6700

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes   No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes   No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

 

 

 

Large accelerated filer 

 

Accelerated filer 

 

 

 

Non-accelerated filer 

 

Smaller reporting company 

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes   No

 

The number of outstanding shares of the registrant’s Common Stock, $0.001 par value, was 187,619,384 as of May 3, 2016.

 

 

 

 


 

INCYTE CORPORATION

 

INDEX

 

 

 

PART I: FINANCIAL INFORMATION 

 

 

 

Item 1. 

Financial Statements

 

 

 

 

Condensed Consolidated Balance Sheets

 

 

 

 

Condensed Consolidated Statements of Operations

 

 

 

 

Condensed Consolidated Statements of Comprehensive Income (Loss)

 

 

 

 

Condensed Consolidated Statements of Cash Flows

 

 

 

 

Notes to Condensed Consolidated Financial Statements

 

 

 

Item 2. 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

25 

 

 

 

Item 3. 

Quantitative and Qualitative Disclosures about Market Risk

46 

 

 

 

Item 4. 

Controls and Procedures

46 

 

 

 

PART II: OTHER INFORMATION 

47 

 

 

 

Item 1A. 

Risk Factors

47 

 

 

 

Item 5. 

Other Information

63 

 

 

 

Item 6. 

Exhibits

65 

 

 

 

 

Signatures

66 

 

 

 

 

Exhibit Index

67 

 

 

 

2


 

PART I:    FINANCIAL INFORMATION

Item 1.    Financial Statements

 

INCYTE CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except number of shares and par value)

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

December 31,

 

 

    

2016

    

2015*

 

 

 

 

(unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

657,615

 

$

521,439

 

Marketable securities—available-for-sale

 

 

153,054

 

 

186,344

 

Restricted cash and investments

 

 

517

 

 

516

 

Accounts receivable

 

 

101,280

 

 

114,450

 

Inventory

 

 

1,309

 

 

1,783

 

Prepaid expenses and other current assets

 

 

21,806

 

 

17,843

 

Total current assets

 

 

935,581

 

 

842,375

 

 

 

 

 

 

 

 

 

Restricted cash and investments

 

 

13,866

 

 

13,977

 

Long term investment

 

 

32,298

 

 

35,248

 

Inventory

 

 

17,277

 

 

17,555

 

Property and equipment, net

 

 

92,622

 

 

86,006

 

Other assets, net

 

 

12,298

 

 

12,279

 

Total assets

 

$

1,103,942

 

$

1,007,440

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

 

$

31,899

 

$

30,085

 

Accrued compensation

 

 

23,197

 

 

38,117

 

Interest payable

 

 

2,285

 

 

762

 

Accrued and other current liabilities

 

 

133,641

 

 

86,531

 

Deferred revenue—collaborative agreements

 

 

9,297

 

 

12,512

 

Total current liabilities

 

 

200,319

 

 

168,007

 

 

 

 

 

 

 

 

 

Convertible senior notes

 

 

627,642

 

 

619,893

 

Other liabilities

 

 

48,233

 

 

48,385

 

Total liabilities

 

 

876,194

 

 

836,285

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding as of March 31, 2016 and December 31, 2015

 

 

 —

 

 

 —

 

Common stock, $0.001 par value; 400,000,000 shares authorized; 187,402,129 and 186,650,249 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively

 

 

187

 

 

187

 

Additional paid-in capital

 

 

1,982,104

 

 

1,950,764

 

Accumulated other comprehensive income (loss)

 

 

397

 

 

(809)

 

Accumulated deficit

 

 

(1,754,940)

 

 

(1,778,987)

 

Total stockholders’ equity

 

 

227,748

 

 

171,155

 

Total liabilities and stockholders’ equity

 

$

1,103,942

 

$

1,007,440

 


*   The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date.

 

See accompanying notes.

 

3


 

INCYTE CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited, in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2016

    

2015

 

Revenues:

 

 

 

 

 

 

 

Product revenues, net

 

$

183,267

 

$

115,330

 

Product royalty revenues

 

 

21,903

 

 

15,673

 

Contract revenues

 

 

58,214

 

 

28,214

 

Other revenues

 

 

80

 

 

58

 

 

 

 

 

 

 

 

 

Total revenues

 

 

263,464

 

 

159,275

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of product revenues

 

 

6,005

 

 

2,974

 

Research and development

 

 

156,824

 

 

118,365

 

Selling, general and administrative

 

 

64,596

 

 

44,871

 

 

 

 

 

 

 

 

 

Total costs and expenses

 

 

227,425

 

 

166,210

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

36,039

 

 

(6,935)

 

Interest and other income, net

 

 

1,492

 

 

1,630

 

Interest expense

 

 

(10,134)

 

 

(12,687)

 

Unrealized loss on long term investment

 

 

(2,950)

 

 

 —

 

 

 

 

 

 

 

 

 

Income (loss) before provision for income taxes

 

 

24,447

 

 

(17,992)

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

 

400

 

 

367

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

24,047

 

$

(18,359)

 

 

 

 

 

 

 

 

 

Net income (loss) per share:

 

 

 

 

 

 

 

Basic

 

$

0.13

 

$

(0.11)

 

Diluted

 

$

0.12

 

$

(0.11)

 

 

 

 

 

 

 

 

 

Shares used in computing  net income (loss) per share:

 

 

 

 

 

 

 

Basic

 

 

187,184

 

 

172,070

 

Diluted

 

 

192,625

 

 

172,070

 

 

See accompanying notes.

 

4


 

INCYTE CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2016

    

2015

 

Net income (loss)

 

$

24,047

 

$

(18,359)

 

 

 

 

 

 

 

 

 

Other comprehensive income:

 

 

 

 

 

 

 

Unrealized gain on restricted investments and marketable securities, net of tax

 

 

1,028

 

 

443

 

Reclassification adjustment for realized loss on marketable securities

 

 

178

 

 

 —

 

Other comprehensive income

 

 

1,206

 

 

443

 

 

 

 

 

 

 

 

 

Comprehensive income (loss)

 

$

25,253

 

$

(17,916)

 

 

See accompanying notes.

5


 

INCYTE CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2016

    

2015

 

Cash flows from operating activities:

 

 

 

 

 

 

 

Net income (loss)

 

$

24,047

 

$

(18,359)

 

Adjustments to reconcile net income (loss) to net cash used in operating activities:

 

 

 

 

 

 

 

Depreciation and amortization of debt discounts

 

 

11,058

 

 

11,835

 

Stock-based compensation

 

 

20,769

 

 

17,558

 

Other, net

 

 

178

 

 

 —

 

Unrealized loss on long term investment

 

 

2,950

 

 

 —

 

Excess tax benefit from stock-based compensation

 

 

 —

 

 

(3,833)

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

 

13,170

 

 

(11,671)

 

Prepaid expenses and other assets

 

 

(3,667)

 

 

(194)

 

Inventory

 

 

752

 

 

1

 

Accounts payable

 

 

1,814

 

 

2,124

 

Accrued and other liabilities

 

 

29,679

 

 

1,190

 

Deferred revenue—collaborative agreements

 

 

(3,215)

 

 

(3,237)

 

Net cash provided by (used in) operating activities

 

 

97,535

 

 

(4,586)

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Long term investment

 

 

 —

 

 

(39,829)

 

Capital expenditures

 

 

(5,562)

 

 

(3,553)

 

Purchases of marketable securities

 

 

(16,795)

 

 

(34,467)

 

Sale and maturities of marketable securities

 

 

51,114

 

 

19,274

 

Net cash provided by (used in) investing activities

 

 

28,757

 

 

(58,575)

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Restricted investments, net

 

 

110

 

 

125

 

Proceeds from issuance of common stock under stock plans

 

 

10,219

 

 

29,180

 

Direct financing arrangements repayments

 

 

(445)

 

 

(452)

 

Excess tax benefit from stock-based compensation

 

 

 —

 

 

3,833

 

Net cash provided by financing activities

 

 

9,884

 

 

32,686

 

Net increase in cash and cash equivalents

 

 

136,176

 

 

(30,475)

 

Cash and cash equivalents at beginning of period

 

 

521,439

 

 

452,297

 

Cash and cash equivalents at end of period

 

$

657,615

 

$

421,822

 

Supplemental Schedule of Cash Flow Information

 

 

 

 

 

 

 

Interest paid

 

$

846

 

$

839

 

Incomes taxes paid

 

$

14

 

$

13

 

Reclassification to common stock and additional paid in capital in connection with conversions of 1.25% convertible senior notes due 2020

 

$

4

 

$

 —

 

 

See accompanying notes.

 

 

6


 

INCYTE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2016

(Unaudited)

 

1.     Organization and business

 

Incyte Corporation (“Incyte,” “we,” “us,” or “our”) is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. Our pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI® (ruxolitinib). Our operations are treated as one operating segment.

 

2.     Summary of significant accounting policies

 

Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  The condensed consolidated balance sheet as of March 31, 2016 and the condensed consolidated statements of operations, comprehensive income (loss) and cash flows for the three months ended March 31, 2016 and 2015, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.  The condensed consolidated balance sheet at December 31, 2015 has been derived from audited financial statements.

 

Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission.

 

Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.

 

Principles of Consolidation.  The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries, including Incyte Holdings Corporation, Incyte International Holdings S.a.r.l. and Incyte Europe S.a.r.l. All inter-company accounts, transactions, and profits have been eliminated in consolidation.

 

Foreign Currency Translation. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month, which approximates the results that would be obtained using actual currency rates on the dates of individual transactions. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into the U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in interest and other income, net in the condensed consolidated statements of operations. To date, both the translation gains or losses in other comprehensive income (loss) and the transaction gains or losses in interest and other income, net have been immaterial.

 

Use of Estimates.  The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

 

Concentrations of Credit Risk.  Cash, cash equivalents, marketable securities, trade receivables and restricted investments are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in corporate debt securities and, by policy, limit the amount of credit exposure to any one issuer and to any one type of investment, other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales of JAKAFI and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash,

7


 

cash equivalents, marketable securities, trade receivables or restricted investments to date and do not require collateral on receivables.

 

Cash and Cash Equivalents.  Cash and cash equivalents are held in U.S. banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.

 

Marketable Securities—Available-for-Sale.  All marketable securities are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders’ equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in “Interest and other income, net.” The cost of securities sold is based on the specific identification method.

 

Accounts Receivable.  As of March 31, 2016 and December 31, 2015, we had no allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.

 

Inventory.  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. We began capitalizing inventory in mid-November 2011 once the U.S. Food and Drug Administration (“FDA”) approved JAKAFI as the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to approval of JAKAFI have been recorded as research and development expense in our statements of operations. As a result, cost of product revenues for the next 6 to 9 months will reflect a lower average per unit cost of materials.

 

The raw materials and work-in-process inventory is not subject to expiration and the shelf life for finished goods inventory is 36 months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.

 

Variable Interest Entities. We perform an initial and on-going evaluation of the entities with which we have variable interests, such as equity ownership, in order to identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (“VIE” or “VIEs”). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE’s economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE.  As of March 31, 2016, there were no entities in which we held a variable interest which we determined to be VIEs.

 

Equity Method Investments.  In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option under U.S. GAAP.   In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Under the equity method of accounting, we record within our results of operations our share of income or loss of the investee company.  Under the fair value option, our investment is carried at fair value on our condensed consolidated balance sheets as a long term investment and all changes in fair value are reported in our condensed consolidated statements of operations as an unrealized gain (loss) on long term investment.

 

Property and Equipment.  Property and equipment is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets (generally three to five years). Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.

 

Management continually reviews the estimated useful lives of technologically sensitive equipment and believes that those estimates appropriately reflect the current useful life of our assets. In the event that a currently unknown significantly advanced technology became commercially available, we would re-evaluate the value and estimated useful lives of our existing equipment, possibly having a material impact on the financial statements.

8


 

 

Lease Accounting.  We account for operating leases by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date we gain possession of leased property. We include tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease.

 

Capital leases are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets under capital leases are recorded in property and equipment, net on the condensed consolidated balance sheets and depreciated in a manner similar to other property and equipment.

 

Certain construction projects may be accounted for as direct financing arrangements, whereby we record, over the construction period, the full cost of the asset in property and equipment, net on the condensed consolidated balance sheets. A corresponding liability is also recorded, net of leasehold improvements paid for by us, and is amortized over the expected lease term through monthly rental payments using the effective interest method.

 

Income Taxes.  We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. In addition, we follow the guidance related to accounting for uncertainty in income taxes. This guidance creates a single model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before it is recognized in the financial statements.

 

Financing Costs Related to Long-term Debt.  Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the consolidated balance sheets.

 

Grant Accounting.  Grant amounts received from government agencies for operations are deferred and are amortized into income over the service period of the grant. Grant amounts received for purchases of capital assets are deferred and amortized into interest and other income, net over the useful life of the related capital assets. Such amounts are recorded in other liabilities on the condensed consolidated balance sheets.

 

Net Income (Loss) Per Share.  Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.

 

Accumulated Other Comprehensive Income (Loss).  Accumulated other comprehensive income (loss) consists of realized and unrealized gains or losses on marketable securities and restricted cash and investments.

 

Revenue Recognition.  Revenues are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured. Revenues are deferred for fees received before earned or until no further obligations exist. We exercise judgment in determining that collectability is reasonably assured or that services have been delivered in accordance with the arrangement. We assess whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. We assess collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.

 

Product Revenues

 

Our product revenues consist of U.S. sales of JAKAFI and are recognized once we meet all four revenue recognition criteria described above. In November 2011, we began shipping JAKAFI to our customers, which include specialty pharmacies and wholesalers. 

 

We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and Medicare Part D coverage gap reimbursements. Product shipping and handling costs are included in cost of product revenues.

 

Customer Credits:  Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.

9


 

 

Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launch. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Chargebacks:  Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received, we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel.  If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Medicare Part D Coverage Gap:  Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Co-payment Assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.

 

Product Royalty Revenues

 

Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI® outside the United States) by Novartis Pharmaceutical International Ltd. (“Novartis”) are based on net sales of licensed products in licensed territories as provided by Novartis. We recognize royalty revenues in the period the sales occur.

 

Cost of Product Revenues

 

Cost of product revenues includes all JAKAFI related costs that are recoverable through the commercialization of the product. Beginning in October 2014, we became obligated to pay tiered, low single digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States which are included in cost of product revenues.

 

Contract and License Revenues

 

Under agreements involving multiple deliverables, services and/or rights to use assets that we entered into prior to January 1, 2011, the multiple elements are divided into separate units of accounting when certain criteria are met, including whether the delivered items have stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered items. When separate units of accounting exist, consideration is allocated among the separate elements based on their respective fair values. The determination of fair value of each element is based on objective evidence from historical sales of the individual elements by us to other customers. If such evidence of fair value for each undelivered element of the arrangement does not exist, all revenue from the arrangement is deferred until such time that evidence of fair value for each undelivered element does exist or until all elements of the arrangement are delivered. When elements are specifically tied to a separate earnings process, revenue is recognized when the specific performance obligation tied to the element is completed. When revenues for an element are not specifically tied to a separate earnings process, they are recognized ratably over the term of the agreement. We assess whether a substantive milestone exists at the inception of our agreements. For all milestones within our arrangements that are considered substantive, we recognize revenue upon the achievement of the associated milestone. If a milestone is not considered substantive, we would recognize the applicable milestone payment over the remaining period of

10


 

performance under the arrangement. As of March 31, 2016, all remaining potential milestones under our collaborative arrangements are considered substantive.

 

On January 1, 2011, updated guidance on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements we may enter into on or after January 1, 2011. This updated guidance (i) relates to whether multiple deliverables exist, how the deliverables in a revenue arrangement should be separated and how the consideration should be allocated; (ii) requires companies to allocate revenues in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (iii) eliminates the use of the residual method and requires companies to allocate revenues using the relative selling price method. During the three months ended March 31, 2016 and 2015, we did not enter into any agreements that are subject to this updated guidance. If we enter into an agreement with multiple deliverables after January 1, 2011 or amend existing agreements, this updated guidance could have a material effect on our financial statements.

 

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events. These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraphs.

 

The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the FDA requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate’s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (“IND”), which must be reviewed by the FDA.

 

The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (“NDA”) or biologics license application (“BLA”) to the FDA for review and FDA approval of the NDA or BLA.

 

Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.

 

Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase I, Phase II or Phase III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.

 

Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.

 

Research and Development Costs.  Our policy is to expense research and development costs as incurred. We often contract with clinical research organizations (“CROs”) to facilitate, coordinate and perform agreed upon research

11


 

and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract.

 

These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period.

 

Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred.

 

Stock Compensation.  Share-based payment transactions with employees, which include stock options, restricted stock units (“RSUs”) and performance shares (“PSUs”), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates.  The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting.  The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method.  The fair value of RSUs, which are generally subject to cliff vesting, are recognized as compensation expense over the requisite service period using the straight line attribution method.  The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, over the remaining requisite service period. We recorded $20.8 million and $17.6 million of stock compensation expense on our condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015, respectively.

 

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which provides a five step approach to be applied to all contracts with customers. ASU No. 2014-09 also requires expanded disclosures about revenue recognition. This guidance is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein.  Early adoption is permitted for reporting periods beginning after December 15, 2016.  We are currently analyzing the impact of ASU No. 2014-09 on our results of operations and, at this time, we are unable to determine the impact of the new standard, if any, on our condensed consolidated financial statements.

 

In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements—Going Concern,” to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about our ability to continue as a going concern within one year from the date the financial statements are issued. This guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. We do not believe the pending adoption of ASU No. 2014-15 will have a material impact on our condensed consolidated financial statements.

 

In February 2015, the FASB issued ASU No. 2015-02, “Amendments to the Consolidation Analysis,” which affects reporting entities that are required to evaluate whether they should consolidate certain legal entities.  The amendments place more emphasis in the consolidation evaluation on variable interests other than fee arrangements such as principal investment risk (including debt or equity interests), guarantees of the value of the assets or liabilities of the variable interest entity (“VIE”), written put options on the assets of the VIE, or similar obligations. Additionally, the amendments reduce the extent to which related party arrangements cause an entity to be considered a primary beneficiary. This guidance is to be applied using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The amendments are effective for fiscal years beginning after December 15, 2015, and interim periods therein. We have concluded ASU No. 2015-02 has no impact on our condensed consolidated financial statements. 

12


 

 

In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which changes the accounting for certain aspects of share-based payments to employees.  The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled.  In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows.  The standard also clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on the statement of cash flows, and provides an accounting policy election to account for forfeitures as they occur.  The new standard is effective for our calendar year beginning January 1, 2017.  Early adoption is permitted however all of the guidance must be adopted in the same period. 

 

We have elected to early adopt ASU No. 2016-09 as of the first quarter of 2016 which requires us to reflect any adjustments as of January 1, 2016, the beginning of the annual period that includes the interim period of adoption.  The primary impact of adoption was the recognition of $325.6 million of accumulated excess tax benefits as deferred tax assets that under the previous guidance could not be recognized until the benefits were realized through a reduction in cash taxes paid.  This part of the guidance was applied using a modified retrospective method with a cumulative-effect adjustment to the accumulated deficit for the excess tax benefits not previously recognized. However, given the full valuation allowance placed on the additional $325.6 million of deferred tax assets, the recognition upon adoption had no impact to our accumulated deficit as of January 1, 2016.

 

Adoption of the standard also resulted in the recognition of excess tax benefits in our income tax provision rather than as paid-in capital. This guidance is to be applied prospectively and resulted in the recognition of $0.3 million of excess tax benefits in our income tax provision rather than paid-in capital for the three months ended March 31, 2016.  Amendments to the minimum statutory withholding tax requirements had no impact to the accumulated deficit as of January 1, 2016. In addition, we have elected to continue to estimate forfeitures expected to occur when determining the amount of compensation cost to be recognized in each period.

 

We elected to apply the presentation requirements for cash flows related to excess tax benefits prospectively which resulted in classification within operating cash flows of the excess tax benefits recognized during the three months ended March 31, 2016.  This classification is now consistent with all other cash flow impacts from income taxes. In addition, the amendments to the cash flow statement presentation to classify cash payments made on behalf of employees for shares withheld as a financing activity had no impact on our previously reported cash flows, as this requirement is consistent with our previous presentation of these cash flows.

 

3.     Fair value of financial instruments

 

FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (“the exit price”) in an orderly transaction between market participants at the measurement date. The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

 

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

 

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

 

Level 3—Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.

 

Our marketable securities consist of investments in corporate debt securities that are classified as available-for-sale.

 

At March 31, 2016 and December 31, 2015, our Level 2 corporate debt securities were valued using readily available pricing sources which utilize market observable inputs, including the current interest rate and other characteristics for similar types of investments.

 

13


 

The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurement at Reporting Date Using:

 

 

 

 

 

 

Quoted Prices in

 

Significant Other

 

Significant

 

 

 

 

 

 

Active Markets for

 

Observable

 

Unobservable

 

 

 

 

 

 

Identical Assets

 

Inputs

 

Inputs

 

Balance as of

 

 

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

March 31, 2016

 

Cash and cash equivalents

 

$

657,615

 

$

 —

 

$

 —

 

$

657,615

 

Corporate debt securities

 

 

 —

 

 

153,054

 

 

 —

 

 

153,054

 

Long term investment (Note 7)

 

 

32,298

 

 

 —

 

 

 —

 

 

32,298

 

Total assets

 

$

689,913

 

$

153,054

 

$

 —

 

$

842,967

 

 

The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis as of December 31, 2015 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurement at Reporting Date Using:

 

 

 

 

 

 

Quoted Prices in

 

Significant Other

 

Significant

 

 

 

 

 

 

Active Markets for

 

Observable

 

Unobservable

 

 

 

 

 

 

Identical Assets

 

Inputs

 

Inputs

 

Balance as of

 

 

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

December 31, 2015

 

Cash and cash equivalents

 

$

521,439

 

$

 —

 

$

 —

 

$

521,439

 

Corporate debt securities

 

 

 —

 

 

186,344

 

 

 —

 

 

186,344

 

Long term investment (Note 7)

 

 

35,248

 

 

 —

 

 

 —

 

 

35,248

 

Total assets

 

$

556,687

 

$

186,344

 

$

 —

 

$

743,031

 

 

The following is a summary of our marketable security portfolio as of March 31, 2016 and December 31, 2015, respectively.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net

 

Net

 

 

 

 

 

 

Amortized

 

Unrealized

 

Unrealized

 

Estimated

 

 

    

Cost

    

Gains

    

Losses

    

Fair Value

 

 

 

(in thousands)

 

March 31, 2016

    

 

 

    

 

 

    

 

 

    

 

 

 

Corporate debt securities

 

$

152,657

 

$

397

 

$

 —

 

$

153,054

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

187,153

 

$

 —

 

$

(809)

 

$

186,344

 

 

Our corporate debt securities generally have contractual maturity dates of between 12 to 18 months.

 

4.     Concentration of Credit Risk

 

In December 2009, we entered into a license, development and commercialization agreement with Eli Lilly and Company (“Lilly”). In November 2009, we entered into a collaboration and license agreement with Novartis. The concentration of credit risk related to our collaborative partners is as follows:

 

 

 

 

 

 

 

 

 

 

Percentage of Total

 

 

 

Contract Revenues for the

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2016

    

2015

    

 

Collaboration Partner A

    

 —

%  

89

%  

 

Collaboration Partner B

 

100

%  

11

%  

 

 

Collaboration Partner A and Collaboration Partner B comprised in the aggregate 22% and 39% of the accounts receivable balance as of March 31, 2016 and December 31, 2015, respectively.

 

14


 

In November 2011, we began commercialization and distribution of JAKAFI to a number of customers. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our product revenues is as follows:

 

 

 

 

 

 

 

 

 

 

Percentage of Total Net

 

 

 

Product Revenues for the

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2016

    

2015

    

 

Customer A

    

27

%  

28

%  

 

Customer B

 

18

%  

20

%  

 

Customer C

 

12

%  

13

%  

 

Customer D

 

8

%  

8

%  

 

 

We are exposed to risks associated with extending credit to customers related to the sale of products. Customer A, Customer B, Customer C and Customer D comprised in the aggregate 48% and 40% of the accounts receivable balance as of March 31, 2016 and December 31, 2015, respectively.

 

5.     Inventory

 

Our inventory balance consists of the following:

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

December 31,

 

 

    

2016

    

2015

 

 

 

(in thousands)

 

 

    

 

 

  

 

 

  

Work-in-process

 

$

17,277

 

$

17,555

 

Finished goods

 

 

1,309

 

 

1,783

 

 

 

 

18,586

 

 

19,338

 

Inventories-current

 

 

1,309

 

 

1,783

 

Inventories-non-current

 

$

17,277

 

$

17,555

 

 

Inventories, stated at the lower of cost or market, consist of work in process and finished goods. At March 31, 2016, $1.3 million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At March 31, 2016, $17.3 million of inventory was classified as non-current on the condensed consolidated balance sheet as we did not expect this inventory to be consumed for commercial use within the next twelve months.  We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.

 

The raw materials and work-in-process inventory is not subject to expiration and the shelf life for finished goods inventory is 36 months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage.

 

15


 

6.    Property and Equipment

 

Property and equipment consists of the following:

 

 

 

 

 

 

 

 

 

 

 

 

March 31,

December 31,

 

 

 

    

2016

    

2015

 

 

 

 

(in thousands)

 

 

Office equipment

    

$

8,115

 

$

6,753

    

 

Laboratory equipment

 

 

33,263

    

 

31,296

 

 

Computer equipment

 

 

26,186

 

 

22,491

 

 

Building and leasehold improvements

 

 

72,539

 

 

70,729

 

 

 

 

 

140,103

 

 

131,269

 

 

Less accumulated depreciation and amortization

 

 

(47,481)

 

 

(45,263)

 

 

 

 

$

92,622

 

$

86,006

 

 

 

In 2013, we entered into a lease agreement for a new corporate headquarters, which consists of approximately 190,000 square feet of laboratory and office space located in Wilmington, Delaware. The term of this lease is 15 years from the date of commencement. The construction of the facility was completed and the lease commenced on October 1, 2014 with a monthly lease rate of $0.5 million for the first 10 years of the lease and with the monthly lease rate increasing annually during the last five years of the lease.

 

We are accounting for the lease as a direct financing arrangement whereby over the construction period, we recorded the value of the facility (consisting of the estimated fair value of the existing shell, plus construction costs incurred) as a capital asset, with a corresponding lease liability, net of build out costs paid for by us during the construction period. The lease liability will be amortized over the term of the lease using the effective interest method. In addition, we have posted a $15.0 million letter of credit for the facility lease for the benefit of the landlord, which is collateralized by a restricted investments account for the same amount. This amount was recorded as restricted cash and investments on the condensed consolidated balance sheets and will be reduced over a period of time during the duration of the lease. The letter of credit could be subject to accelerated reductions if we meet certain pre-defined financial targets and will be cancelled as a condition of closing of the purchase as described in the paragraph below. Restricted investments related to this direct financing lease on the condensed consolidated balance sheets at March 31, 2016 and December 31, 2015 were $13.9 million and $14.0 million, respectively.

 

On August 21, 2015, we entered into an Agreement of Sale with Augustine Land II, L.P. (the “Seller”) to purchase the leased land and office building for approximately $79.9 million.  Pursuant to the terms of the Agreement of Sale, we initially made a $4.0 million deposit with a third party escrow agent and a $4.0 million deposit with the Seller. The escrow agent held the deposit until the building inspection process was completed, and the escrow agent released the $4.0 million to the Seller in October 2015 as an additional deposit. As of March 31, 2016, the $8.0 million Seller deposit is recorded in other assets, net on the condensed consolidated balance sheets.

 

7.    License agreements

 

Novartis

 

In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications.  Novartis also received worldwide exclusive development and commercialization rights to our c-MET inhibitor compound capmatinib and certain back-up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States.

 

Under this agreement, we received an upfront payment and immediate milestone payment totaling $210.0 million and were initially eligible to receive up to $1.2 billion in milestone payments across multiple indications upon the achievement of pre-specified events, including up to $174.0 million for the achievement of development milestones, up to $495.0 million for the achievement of regulatory milestones and up to $500.0 million for the achievement of commercialization milestones. Exclusive of the upfront payment of $150.0 million received in 2009 and the immediate milestone of $60.0 million earned in 2010, we have recognized and received in the aggregate $102.0 million for the achievement of development milestones and $175.0 million for the achievement of regulatory milestones and $20.0 million for the achievement of sales milestones through March 31, 2016.

16


 

 

During the year ended December 31, 2015, under this agreement, we recognized a $5.0 million development milestone based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib for a third indication and a $25.0 million regulatory milestone triggered by the Committee for Medicinal Products for Human Use of the European Medicines Agency adopting a positive opinion for JAKAVI (ruxolitinib) for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea, a $15.0 million regulatory milestone for the approval of JAKAVI in Japan for the treatment of patients with polycythemia vera, and a $20.0 million sales milestone for Novartis achieving annual net sales of a JAK licensed product of $300.0 million. In 2014, we recognized a $60.0 million regulatory milestone related to reimbursement of JAKAVI (ruxolitinib) in Europe, a $25.0 million regulatory milestone for the approval of JAKAVI in Japan for the treatment of patients with myelofibrosis and a $7.0 million development milestone based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib in non-small cell lung cancer.  In 2013, we recognized a $25.0 million development milestone under this agreement based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib. In 2012, we recognized a $40.0 million regulatory milestone payment under this agreement for the achievement of a predefined milestone for the European Union regulatory approval of JAKAVI. In 2011, we recognized a $15.0 million development milestone under this agreement for the achievement of a predefined milestone in the Phase I dose-escalation trial for capmatinib in patients with solid tumors and a $10.0 million regulatory milestone for the approval of JAKAFI in the United States. In 2010, we recognized $50.0 million in development milestones for the initiation of the global phase III trial, RESPONSE, in patients with polycythemia vera. We determined that each of these milestones were substantive as their achievement required substantive efforts by us and was at risk until the milestones were ultimately achieved. We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI net sales outside of the United States. Since the achievement of the $60.0 million regulatory milestone related to reimbursement of JAKAVI in Europe in September 2014, we are obligated to pay to Novartis tiered royalties in the low single digits on future JAKAFI net sales within the United States. During the three months ended March 31, 2016 and 2015, such royalties payable to Novartis on net sales within the United States totaled $5.2 million and $2.5 million, respectively, and are reflected in cost of product revenues on the condensed consolidated statements of operations.  Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.

 

The Novartis agreement will continue on a program-by-program basis until Novartis has no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. Royalties are payable by Novartis on a product-by-product and country-by-country basis until the latest to occur of (1) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (2) the expiration of regulatory exclusivity for the licensed product in such country and (3) a specified period from first commercial sale in such country of the licensed product by Novartis or its affiliates or sublicensees. The agreement may be terminated in its entirety or on a program-by-program basis by Novartis for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach.

 

We determined that there were two deliverables under the agreement: (i) the ex U.S. license for ruxolitinib and (ii) our obligations in connection with our participation on the joint development committee for myelofibrosis and polycythemia vera/essential thrombocythemia. We concluded that these deliverables should be accounted for as a single unit of accounting and the $150.0 million upfront payment received in December 2009 and the immediate $60.0 million milestone payment received in January 2010 should be recognized on a straight line basis through December 2013, when we estimated we would complete our obligations in connection with our participation on the joint development committee for myelofibrosis and polycythemia vera, our estimated performance period under the agreement. We completed this substantive performance obligation related to this arrangement in December 2013.

 

At December 31, 2009, we recorded $10.9 million of reimbursable costs incurred prior to the effective date of the agreement as deferred revenue on the consolidated balance sheet. These costs were recognized on a straight line basis through December 2013 consistent with the aforementioned upfront and milestone payments. Future reimbursable costs incurred after the effective date of the agreement with Novartis are recorded net against the related research and development expenses. At March 31, 2016 and December 31, 2015, $0.1 million and $0.3 million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets. Research and development expenses for the three months ended March 31, 2016 and 2015 were net of $0.3 million and $0.5 million, respectively, of costs reimbursed by Novartis.

 

Contract revenue under the Novartis agreement was $0.0 million and $25.0 million for the three months ended March 31, 2016 and 2015, respectively. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States was $21.9 million and $15.7 million for the three months ended March 31, 2016 and 2015, respectively. At March 31, 2016 and December 31, 2015, $21.8 million and $23.8 million, respectively, of product royalties were included in accounts receivable on the condensed consolidated balance sheets.

17


 

 

Lilly - Baricitinib

 

In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib, and certain back-up compounds for inflammatory and autoimmune diseases. We received an upfront payment of $90.0 million, and were initially eligible to receive up to $665.0 million in substantive milestone payments across multiple indications upon the achievement of pre-specified events, including up to $150.0 million for the achievement of development milestones, up to $365.0 million for the achievement of regulatory milestones and up to $150.0 million for the achievement of commercialization milestones. Exclusive of the upfront payment of $90.0 million received in 2009, we have recognized and received in the aggregate $99.0 million for the achievement of development milestones and $55.0 million for the achievement of regulatory milestones through March 31, 2016. 

 

In January 2016, under this agreement, we recognized a $35.0 million regulatory milestone for the submission of an NDA to the FDA for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis and a $20.0 million regulatory milestone for the submission of a Marketing Authorization Application to the Europe Medicines Agency for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis. In 2012, we recognized a $50.0 million development milestone for the achievement of a predefined milestone for the initiation of the rheumatoid arthritis Phase III program for baricitinib. In 2010, we recognized a $30.0 million development milestone based upon the initial three month data in the Phase IIa clinical trial of baricitinib for the treatment of rheumatoid arthritis and a $19.0 million development milestone for the Phase IIb clinical trial initiation of baricitinib for the treatment of rheumatoid arthritis. We determined the 2012 and 2010 milestones to be substantive as their achievement required substantive efforts by us and was at risk until the milestones were ultimately achieved. We also could receive tiered, double-digit royalty payments on future global net sales with rates ranging up to 20% if the product is successfully commercialized.

 

We retained options to co-develop our JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis. Lilly is responsible for all costs relating to the development and commercialization of the compounds unless we elect to co-develop any compounds or indications. If we elect to co-develop any compounds and/or indications, we would be responsible for funding 30% of the associated future global development costs from the initiation of a Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. We would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global net sales for compounds and/or indications that we elect to co-develop.  For indications that we elect not to co‑develop, we would receive tiered, double‑digit royalty payments on future global net sales with rates ranging up to 20% if the product is successfully commercialized. In July 2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis and we are responsible for funding 30% of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority.  We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement. 

 

Research and development expenses recorded under the Lilly agreement representing 30% of the global development costs for baricitinib for the treatment of rheumatoid arthritis were $5.1 million and $11.6 million for the three months ended March 31, 2016 and 2015, respectively. We have retained certain mechanisms to give us cost protection as baricitinib advances in clinical development. We can defer our portion of co-development study costs by indication if they exceed a predetermined level. This deferment would be credited against future milestones or royalties and we would still be eligible for the full incremental royalties related to the co-development option. In addition, even if we have started co-development funding for any indication, we can at any time opt out and stop future co-development cost sharing. If we elect to do this we would still be eligible for our base royalties plus an incremental pro-rated royalty commensurate with our contribution to the total co-development cost for those indications for which we co-funded. The Lilly agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. Royalties are payable by Lilly on a product-by-product and country-by-country basis until the latest to occur of (1) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (2) the expiration of regulatory exclusivity for the licensed product in such country and (3) a specified period from first commercial sale in such country of the licensed product by Lilly or its affiliates or sublicensees. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.

 

We determined that there were two deliverables under the agreement: (i) the worldwide license and (ii) our obligations in connection with a co-development option. We concluded that these deliverables should be accounted for as a single unit of accounting and the $90.0 million upfront payment should be recognized on a straight line basis as revenue through December 2016, our estimated performance period under the agreement.

 

18


 

Contract revenue under the Lilly agreement was $58.2 million and $3.2 million for the three months ended March 31, 2016 and 2015, respectively.

 

Lilly - Ruxolitinib

 

In March 2016, we entered into an amendment to the agreement with Lilly that amended the non-compete provision of the agreement to allow us to engage in the development and commercialization of ruxolitinib in the graft-versus-host-disease (“GVHD”) field. We agreed to pay Lilly an upfront payment of $35.0 million and Lilly is eligible to receive up to $40.0 million in additional regulatory milestone payments relating to ruxolitinib in the GVHD field. As of March 31, 2016, the $35.0 million upfront payment was recorded in research and development expense on the condensed consolidated statements of operations and was included in accrued and other current liabilities on the condensed consolidated balance sheet.

 

Agenus

 

In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly owned subsidiary, 4-Antibody AG, which we collectively refer to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus’ proprietary antibody discovery platforms. The agreement became effective on February 18, 2015, upon the expiration of the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976.

 

Under the terms of this agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial four program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, three more targets were added. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we will be responsible for all costs associated with discovery, preclinical activities, clinical development and commercialization activities. The programs relating to GITR and OX40 and two of the undisclosed targets are profit-share programs while the other targets currently under collaboration are royalty-bearing programs. All costs related to the collaboration are subject to a joint research plan.  For each royalty-bearing product, Agenus will be eligible to receive up to $155.0 million in future contingent development, regulatory and commercialization milestones as well as tiered royalties on global net sales ranging from 6% to 12%. For each profit share product, Agenus will be eligible to receive up to $20.0 million in future contingent development milestones. Additionally, Agenus retains co-promotion participation rights in the United States on any profit share product. For each royalty bearing product, Agenus has reserved the right to elect to co fund 30% of development costs for a commensurate increase in royalties. The agreement may be terminated by us for convenience upon 12 months’ notice and may also be terminated under certain other circumstances, including material breach.  We agreed to certain standstill provisions that allow us to acquire up to 15% of Agenus Inc.’s outstanding voting stock, including shares acquired pursuant to the Stock Purchase Agreement described below, solely for investment purposes.

 

In January 2015, we also entered into a Stock Purchase Agreement with Agenus Inc. pursuant to which we agreed to purchase approximately 7.76 million shares of Agenus Inc. common stock for an aggregate purchase price of $35.0 million in cash, or approximately $4.51 per share. We completed the purchase of the shares on February 18, 2015. On February 18, 2015 the closing price of Agenus Inc. common shares on The NASDAQ Stock Market was $5.13 per share and, therefore, the value of the 7.76 million shares acquired by us was $39.8 million. We agreed not to dispose of any of the shares of common stock for a period of 12 months and Agenus Inc. has agreed to certain registration rights with respect to the shares of common stock.

 

Upon closing of the Agenus transaction on February 18, 2015, we paid total consideration of $60.0 million to Agenus Inc.  Of the $60.0 million, $39.8 million was allocated to our stock purchase in Agenus Inc. and was recorded as a long term investment on the condensed consolidated balance sheets and $20.2 million was allocated to research and development expense on the condensed consolidated statement of operations. 

 

We have concluded Agenus Inc. is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. We own approximately 9% of the outstanding shares of Agenus Inc. common stock and conclude that we have the ability to exercise significant influence, but not control, over Agenus Inc. based primarily on our ownership interest, the level of intra-entity transactions between us and Agenus related to development expenses, as well as other qualitative factors. We have elected the fair value option to account for our long term investment in Agenus Inc. whereby the investment is marked to market through earnings in each reporting period.  We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three months ended March 31, 2016, we recorded an unrealized loss of $3.0 million based on the decrease in the market price of Agenus Inc.’s common stock from the date of purchase to $4.16 per share at March 31,

19


 

2016. For the three months ended March 31, 2015, there was no gain or loss recorded as the market price of Agenus Inc.’s common stock at March 31, 2015 was consistent with the fair value on the acquisition date of the investment. For the year ended December 31, 2015, Agenus Inc. reported total revenues of $24.8 million and a net loss of $87.9 million within their consolidated financial statements.

 

Research and development expenses for the three months ended March 31, 2016 and 2015, included $4.1 million and $1.8 million, respectively, of development costs incurred pursuant to the Agenus arrangement. At March 31, 2016, a total of $10.0 million of such costs were included in accrued and other liabilities on the condensed consolidated balance sheet.

 

Hengrui

 

In September 2015, we entered into a License and Collaboration Agreement with Jiangsu Hengrui Medicine Co., Ltd. (“Hengrui”). Under the terms of this agreement, we received exclusive development and commercialization rights worldwide, with the exception of Mainland China, Hong Kong, Macau and Taiwan, to INCSHR1210, an investigational PD-1 monoclonal antibody, and certain back-up compounds. INCSHR1210 is currently in clinical development. 

 

Under the terms of this agreement, we paid Hengrui an upfront payment of $25.0 million in 2015 which was recorded in research and development expense on the condensed consolidated statement of operations. Hengrui is also eligible to receive potential milestone payments of up to $770.0 million, consisting of $90.0 million for regulatory approval milestones, $530.0 million for commercial performance milestones, and $150.0 million for a clinical superiority milestone.  Also, Hengrui may be eligible to receive tiered royalties in the high-single digits to mid-double digits based on net sales in our territories. Each company will be responsible for costs relating to the development and commercialization of the PD-1 monoclonal antibody in their respective territories.  The agreement will continue on a country-by-country basis until we have no royalty payment obligations with respect to such country or, if earlier, the termination of the agreement in accordance with its terms.  The agreement may be terminated in its entirety by us for convenience, and may also be terminated under certain other circumstances, including material breach.

 

Research and development expenses for the three months ended March 31, 2016, included $0.7 million of development costs incurred pursuant to the Hengrui agreement.

 

8.     Stock compensation

 

We recorded $20.8 million and $17.6 million of stock compensation expense on our condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015, respectively. Stock compensation expense included within our condensed consolidated statements of operations included research and development expense of $13.0 million and $10.3 million for the three months ended March 31, 2016 and 2015, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included selling, general and administrative expense of $7.8 million and $7.3 million for the three months ended March 31, 2016 and 2015, respectively.

 

We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee Stock Options For the Three Months Ended

 

Employee Stock Purchase Plan For the Three Months Ended

 

 

 

March 31,

 

March 31,

 

 

 

2016

       

2015

      

 

2016

      

2015

      

 

 

Average risk-free interest rates

1.50

%  

1.35

%  

 

0.73

%  

0.56

%  

 

 

Average expected life (in years)

5.00

 

5.05

 

 

0.25

 

0.25

 

 

 

Volatility

49

%  

50

%  

 

61

%  

38

%  

 

 

Weighted-average fair value (in dollars)

41.56

 

32.59

 

 

26.67

 

9.56

 

 

 

 

The risk-free interest rate is derived from the U.S. Federal Reserve rate in effect at the time of grant. The expected life calculation is based on the observed and expected time to the exercise of options by our employees based on historical exercise patterns for similar type options. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the options. A dividend yield of zero is assumed based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends.

 

20


 

Option activity under the 2010 Stock Plan was as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares Subject to

 

 

 

 

 

Outstanding Options

 

 

 

Shares Available

 

 

 

Weighted Average

 

 

    

for Grant

    

Shares

    

Exercise Price

 

Balance at December 31, 2015

 

3,846,717

 

11,052,279

 

$

33.55

 

Options granted

 

(1,412,583)

 

1,412,583

 

$

94.69

 

Options exercised

 

 —

 

(751,784)

 

$

14.06

 

Options cancelled

 

68,324

 

(68,324)

 

$

73.24

 

Options expired

 

 —

 

(1,834)

 

$

3.11

 

Balance at March 31, 2016

 

2,502,458

 

11,642,920

 

$

42.00

 

 

RSU and PSU award activity under the 2010 Stock Plan was as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares Subject to

 

 

 

Shares Available

 

Outstanding Awards

 

 

    

for Grant

    

Shares

    

Grant Date Value

 

Balance at December 31, 2015

    

834,433

    

565,567

    

 

 —

 

RSUs granted

 

(216,711)

 

216,711

 

$

88.28

 

PSUs granted

 

 —

 

 —

 

 

 —

 

RSUs cancelled

 

12,843

 

(12,843)

 

$

67.62

 

PSUs cancelled

 

 —

 

 —

 

 

 —

 

Balance at March 31, 2016

 

630,565

 

769,435

 

 

 —

 

 

In January 2014, we began granting RSUs and PSUs to our employees at the share price on the date of grant.   Each RSU represents the right to acquire one share of our common stock. We granted a total of 216,711 RSUs during the three months ended March 31, 2016 which will cliff vest in three years and will be recognized as stock compensation expense over this period.  Also, in January 2014, Hervé Hoppenot, our President and Chief Executive Officer, was granted a one-time grant of 400,000 RSUs outside of our 2010 Stock Incentive Plan. Vesting of the RSUs will be subject to Mr. Hoppenot’s continued employment on the applicable vesting dates, with one-sixth of the RSUs vesting at the end of each of the calendar years 2014 through 2019, subject to earlier acceleration of vesting upon the occurrence of certain events in accordance with the terms of his employment agreement. As of March 31, 2016, a total of 133,333 RSUs granted to Mr. Hoppenot vested and were released leaving 266,667 RSUs outstanding.

 

At March 31, 2016, we have only recognized stock compensation expense relating to performance conditions of the outstanding PSUs that are deemed probable of achievement at that date. For PSUs containing performance conditions which have not been deemed probable of achievement at March 31, 2016, no stock compensation expense has been recognized for these awards. The actual number of shares of our common stock into which each PSU may convert are subject to a multiplier of up to 125% based on the level at which the performance conditions are achieved.

 

Based on our historical experience of employee turnover, we have assumed an annualized forfeiture rate of 5% for our options, PSUs and RSUs.  Under the true-up provisions of the stock compensation guidance, we will record additional expense if the actual forfeiture rate is lower than we estimated, and will record a recovery of prior expense if the actual forfeiture is higher than we estimated.

 

Total compensation cost of options granted but not yet vested, as of March 31, 2016, was $68.7 million, which is expected to be recognized over the weighted average period of 3.0 years. Total compensation cost of RSUs granted but not yet vested, as of March 31, 2016, was $35.4 million, which is expected to be recognized over the weighted average period of 3.0 years. Total compensation cost of PSUs granted but not yet vested, as of March 31, 2016, was $0.7 million, which is expected to be recognized over the weighted average period of 3.0 years, should the underlying performance conditions be deemed probable of achievement.

 

21


 

9.     Debt

 

The components of the convertible notes are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Carrying Amount,

 

 

 

Interest Rates

 

 

 

March 31,

 

December 31,

 

Debt

    

March 31, 2016

    

Maturities

    

2016

    

2015

 

0.375% Convertible Senior Notes due 2018

 

0.375

%  

2018

 

$

328,173

 

 

324,031

 

1.25% Convertible Senior Notes due 2020

 

1.25

%  

2020

 

 

299,469

 

 

295,862

 

 

 

 

 

 

 

 

627,642

 

 

619,893

 

Less current portion

 

 

 

 

 

 

 —

 

 

 —

 

 

 

 

 

 

 

$

627,642

 

$

619,893

 

 

The carrying amount and fair value of our convertible notes are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2016

 

December 31, 2015

 

 

    

Carrying

    

 

 

    

Carrying

    

 

 

 

 

 

Amount

 

Fair Value

 

Amount

 

Fair Value

 

0.375% Convertible Senior Notes due 2018

 

 

328,173

 

 

574,922

 

 

324,031

 

 

807,422

 

1.25% Convertible Senior Notes due 2020

 

 

299,469

 

 

588,427

 

 

295,862

 

 

816,123

 

 

 

$

627,642

 

$

1,163,349

 

$

619,893

 

$

1,623,545

 

 

The fair values of the 0.375% Convertible Senior Notes due 2018 (the “2018 Notes”) and the 1.25% Convertible Senior Notes due 2020 (the “2020 Notes”) are based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments, and, therefore, these convertible senior notes are classified within Level 2 in the fair value hierarchy.

 

Prior to May 14, 2014, the 2018 and 2020 Notes were not convertible except in connection with a make whole fundamental change, as defined in the respective indentures. Beginning on, and including, May 15, 2014, the 2018 and 2020 Notes are convertible prior to the close of business on the business day immediately preceding May 15, 2018, in the case of the 2018 Notes, and May 15, 2020, in the case of the 2020 Notes, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2018 Notes or 2020 Notes, as applicable, on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of 2018 Notes or 2020 Notes, as applicable, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the 2018 Notes or 2020 Notes, as applicable, on each such trading day; or (3) upon the occurrence of specified corporate events. On or after May 15, 2018, in the case of the 2018 Notes, and May 15, 2020, in the case of the 2020 Notes, until the close of business on the second scheduled trading day immediately preceding the relevant maturity date, the Notes are convertible at any time, regardless of the foregoing circumstances. Upon conversion we will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at our election.

 

On April 1, 2016, the 2018 Notes and 2020 Notes became convertible through at least June 30, 2016, based on meeting the conversion criteria related to the sale price of our common stock during the calendar quarter ended March 31, 2016 as described in (1) above. Management’s intent is to settle any conversions of 2018 Notes or 2020 Notes during this period in shares of our common stock and, therefore, the 2018 Notes and 2020 Notes are reflected in long term liabilities on the condensed consolidated balance sheet at March 31, 2016.

 

10.     Income taxes

 

In January 2015, we licensed certain intellectual property rights related to our non-partnered clinical programs to our wholly-owned subsidiary in Switzerland. Although the license of intellectual property rights did not result in any gain or loss in the condensed consolidated statements of operations, the transaction generated a taxable gain in the U.S, and we are utilizing available federal and state net operating loss carryforwards to offset the majority of this gain. Any taxes incurred related to intercompany transactions are treated as prepaid tax in our condensed consolidated balance sheets and amortized to income tax expense over the life of the intellectual property.   Any cash taxes anticipated to be paid related to this intercompany transaction are immaterial.

 

22


 

In January 2016, the Delaware Competes Act (the “Act”) was enacted by the State of Delaware, which changes the corporate income tax apportionment formula to a single sales factor apportionment formula by 2020.  As a qualified Delaware headquarter company under the Act, we may elect to use either a three-factor apportionment or single sales factor starting in 2017.  We are currently evaluating the impact of the law change and the apportionment election available to us starting in 2017.

 

11.    Net income (loss) per share

 

Net income (loss) per share was calculated as follows for the periods indicated:

 

 

 

 

 

 

 

 

  

Three Months Ended

 

 

March 31,

(in thousands, except per share data)

    

 

2016

    

2015

Basic Net Income (Loss) Per Share

  

 

 

  

 

 

Basic net income (loss)

 

$

24,047

 

$

(18,359)

Weighted average common shares outstanding

 

 

187,184

 

 

172,070

 

  

 

 

  

 

 

Basic net income (loss) per share

  

$

0.13

  

$

(0.11)

 

  

 

 

  

 

 

Diluted Net Income (Loss) Per Share

  

 

 

  

 

 

Diluted net income (loss)

 

$

24,047

  

$

(18,359)

Weighted average common shares outstanding

 

 

187,184

 

 

172,070

 

 

 

 

 

 

 

Dilutive stock options and RSU’s

 

 

5,441

 

 

 —

 

 

 

 

 

 

 

Weighted average shares used to compute diluted net income (loss) per share

  

 

192,625

 

 

172,070

 

 

 

 

 

 

 

Diluted net income (loss) per share

  

$

0.12

  

$

(0.11)

 

The following potential common shares were excluded from the calculations as their effect would be anti-dilutive:

 

 

 

 

 

 

 

Three Months Ended

 

 

March 31,

 

    

2016

    

2015

Outstanding stock options and awards

 

2,652,265

 

14,626,717

Common shares issuable upon conversion of the 4.75% Convertible Senior Notes due 2015

 

 —

 

10,353,076

Common shares issuable upon conversion of the 2018 Notes

 

7,245,244

 

7,245,263

Common shares issuable upon conversion of the 2020 Notes

 

7,241,284

 

7,245,263

Total potential common shares excluded from diluted net loss per share computation

 

17,138,793

 

39,470,319

 

12.Contingencies

 

In February 2016, we received a Paragraph IV certification notice (the “Notice Letter”) regarding an Abbreviated New Drug Application submitted to the U.S. Food and Drug Administration requesting approval to market a generic version of Jakafi (ruxolitinib).  The Notice Letter purports to challenge patents covering ruxolitinib phosphate and its use that expire in 2028.  The Notice Letter does not challenge the ruxolitinib composition of matter patent, which expires on December 24, 2027.  We do not believe there is any kind of loss that is probable or estimable related to this matter at this time.

 

23


 

13.    Subsequent event

 

In April 2016, we entered into an amendment to the agreement with Novartis under which Novartis received exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in the GVHD field.  We are eligible to receive future additional payments from Novartis if defined development and regulatory milestones relating to ruxolitinib for GVHD outside of the United States are achieved. In addition, we remain eligible to receive potential milestone payments and royalties on total sales of ruxolitinib (including GVHD) by Novartis outside of the United States.

 

In April 2016, we closed on the agreement of sale with Augustine Land II, L.P. for the purchase of the previously leased land and office building. 

 

In May 2016, we entered into a share purchase agreement with ARIAD Pharmaceuticals, Inc. (“ARIAD”) and a wholly-owned subsidiary of ARIAD pursuant to which we will acquire all of the outstanding shares of a wholly-owned subsidiary of ARIAD that is the parent company of ARIAD’s European subsidiaries responsible for the development and commercialization of Iclusig® (ponatinib) in the European Union and 22 other countries (the “Territory”) for an upfront payment of $140.0 million.  In addition, we agreed upon the terms of a license agreement to be entered into by ARIAD and us, pursuant to which we will be granted an exclusive license to develop and commercialize Iclusig in the Territory.  ARIAD will be eligible to receive from us tiered royalties on net sales of Iclusig in the Territory and up to $135.0 million in potential future oncology development and regulatory approval milestone payments.  The closing under the share purchase agreement and effectiveness of the license agreement is expected to occur on June 1, 2016, pending satisfaction of customary closing conditions.  We believe that the transaction will be accounted for as a business combination.  Please see Item 5(a) of Part II of this Quarterly Report on Form 10-Q for a more detailed description of the share purchase agreement and license agreement.

 

24


 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion of our financial condition and results of operations as of and for the three months ended March 31, 2016 should be read in conjunction with the unaudited condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements as of and for the year ended December 31, 2015 included in our Annual Report on Form 10-K for the year ended December 31, 2015 previously filed with the SEC.

 

This report contains forward-looking statements that involve risks and uncertainties. These statements relate to future periods, future events or our future operating or financial plans or performance. Often, these statements include the words “believe,” “expect,” “target,” “anticipate,” “intend,” “plan,” “seek,” “estimate,” “potential,” or words of similar meaning, or future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” or “may,” or the negative of these terms, and other similar expressions. These forward-looking statements include statements as to:

 

·

the discovery, development, formulation, manufacturing and commercialization of our compounds, our drug candidates and JAKAFI®/JAKAVI® (ruxolitinib);

 

·

our plans to conduct our European clinical development operations from our offices in Geneva, Switzerland;

 

·

conducting clinical trials internally, with collaborators, or with clinical research organizations;

 

·

our collaboration and strategic relationship strategy; anticipated benefits and disadvantages of entering into collaboration agreements;

 

·

our licensing, investment and commercialization strategies, including our plans to commercialize JAKAFI;

 

·

the regulatory approval process, including obtaining U.S. Food and Drug Administration and other international health authorities approval for our products in the United States and abroad;

 

·

the safety, effectiveness and potential benefits and indications of our drug candidates and other compounds under development;

 

·

the timing and size of our clinical trials; the compounds expected to enter clinical trials; timing of clinical trial results;

 

·

our ability to manage expansion of our drug discovery and development operations;

 

·

future required expertise relating to clinical trials, manufacturing, sales and marketing;

 

·

obtaining and terminating licenses to products, drug candidates or technology, or other intellectual property rights;

 

·

the receipt from or payments pursuant to collaboration or license agreements resulting from milestones or royalties;

 

·

plans to develop and commercialize products on our own;

 

·

plans to use third party manufacturers;

 

·

expected expenses and expenditure levels; expected uses of cash; expected revenues and sources of revenues;

 

·

expected losses; fluctuation of losses; currency translation impact associated with collaboration royalties;

 

·

our profitability; the adequacy of our capital resources to continue operations;

 

·

the need to raise additional capital;

 

·

the costs associated with resolving matters in litigation;

 

·

our expectations regarding competition;

 

25


 

·

our investments, including anticipated expenditures, losses and expenses;

 

·

our patent prosecution and maintenance efforts; and

 

·

our indebtedness, and debt service obligations.

 

These forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. These risks and uncertainties could cause actual results to differ materially from those projected and include, but are not limited to:

 

·

our ability to successfully commercialize JAKAFI;

 

·

our ability to maintain at anticipated levels, reimbursement for JAKAFI from government health administration authorities, private health insurers and other organizations;

 

·

our ability to establish and maintain effective sales, marketing and distribution capabilities;

 

·

the risk of reliance on other parties to manufacture JAKAFI, which could result in a short supply of JAKAFI, increased costs, and withdrawal of regulatory approval;

 

·

our ability to maintain regulatory approvals to market JAKAFI;

 

·

our ability to achieve a significant market share in order to achieve or maintain profitability;

 

·

the risk of civil or criminal penalties if we market JAKAFI in a manner that violates health care fraud and abuse and other applicable laws, rules and regulations;

 

·

our ability to discover, develop, formulate, manufacture and commercialize our drug candidates;

 

·

the risk of unanticipated delays in, or discontinuations of, research and development efforts;

 

·

the risk that previous preclinical testing or clinical trial results are not necessarily indicative of future clinical trial results;

 

·

risks relating to the conduct of our clinical trials;

 

·

changing regulatory requirements;

 

·

the risk of adverse safety findings;

 

·

the risk that results of our clinical trials do not support submission of a marketing approval application for our drug candidates;

 

·

the risk of significant delays or costs in obtaining regulatory approvals;

 

·

risks relating to our reliance on third party manufacturers, collaborators, and clinical research organizations;

 

·

risks relating to the development of new products and their use by us and our current and potential collaborators;

 

·

risks relating to our inability to control the development of out-licensed compounds or drug candidates;

 

·

risks relating to our collaborators’ ability to develop and commercialize drug candidates;

 

·

costs associated with prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights;

 

·

our ability to maintain or obtain adequate product liability and other insurance coverage;

 

·

the risk that our drug candidates may not obtain or maintain regulatory approval;

 

·

the impact of technological advances and competition, including potential generic competition;

26


 

 

·

our ability to compete against third parties with greater resources than ours;

 

·

risks relating to changes in pricing and reimbursements in the markets in which we may compete;

 

·

competition to develop and commercialize similar drug products;

 

·

our ability to obtain and maintain patent protection and freedom to operate for our discoveries and to continue to be effective in expanding our patent coverage;

 

·

the impact of changing laws on our patent portfolio;

 

·

developments in and expenses relating to litigation;

 

·

our ability to in-license drug candidates or other technology;

 

·

our substantial leverage;

 

·

our ability to obtain additional capital when needed;

 

·

fluctuations in net cash provided and used by operating, financing and investing activities;

 

·

our history of operating losses; and

 

·

the risks set forth under “Risk Factors.”

 

Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

 

In this report all references to “Incyte,” “we,” “us,” “our” or the “Company” mean Incyte Corporation and our subsidiaries, except where it is made clear that the term means only the parent company.

 

Incyte and JAKAFI are our registered trademarks. We also refer to trademarks of other corporations and organizations in this Quarterly Report on Form 10-Q.

 

Overview

 

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Our global headquarters are located in Wilmington, Delaware and we conduct our European clinical development operations from our offices in Geneva, Switzerland. JAKAFI (ruxolitinib) is our first product to be approved for sale in the United States. It was approved by the U.S. Food and Drug Administration (FDA) in November 2011 for the treatment of patients with intermediate or high‑risk myelofibrosis and in December 2014 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Myelofibrosis and polycythemia vera are both rare blood cancers. Under our collaboration agreement with Novartis International Pharmaceutical Ltd., Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications and sells ruxolitinib outside of the United States under the name JAKAVI.

 

In May 2016, we entered into a share purchase agreement with ARIAD Pharmaceuticals, Inc. and a wholly-owned subsidiary of ARIAD pursuant to which we will acquire all of the outstanding shares of a wholly-owned subsidiary of ARIAD that is the parent company of ARIAD’s European subsidiaries responsible for the development and commercialization of Iclusig® (ponatinib) in the European Union and 22 other countries (the “Territory”) for an upfront payment of $140 million.  In addition, we agreed upon the terms of a license agreement to be entered into by ARIAD and us, pursuant to which we will be granted an exclusive license to develop and commercialize Iclusig in the Territory.  ARIAD will be eligible to receive from us tiered royalties on net sales of Iclusig in the Territory and up to $135 million in potential future oncology development and regulatory approval milestone payments.  The closing under the share purchase agreement and effectiveness of the license agreement is expected to occur on June 1, 2016, pending satisfaction of customary closing conditions.  Please see Item 5(a) of Part II of this Quarterly Report on Form 10-Q for a more detailed description of the share purchase agreement and license agreement.

 

27


 

Marketed Indications - JAKAFI (ruxolitinib)

 

In 2003, we initiated a research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The JAK family is composed of four tyrosine kinases—JAK1, JAK2, JAK3 and Tyk2—that are involved in the signaling of a number of cytokines and growth factors. JAKs are central to a number of biologic processes, including the formation and development of blood cells and the regulation of immune functions. Dysregulation of the JAK‑STAT signaling pathway has been associated with a number of diseases, including myeloproliferative neoplasms, other hematological malignancies, solid tumors, rheumatoid arthritis, psoriasis and other chronic inflammatory diseases. Myeloproliferative neoplasms are a closely related group of blood diseases in which blood cells, specifically platelets, white blood cells, and red blood cells, grow or act abnormally in the bone marrow. These diseases include myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia.

 

We have discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the most advanced compound in our JAK program. It is an oral JAK1 and JAK2 inhibitor.

 

JAKAFI is marketed in the United States through our own specialty sales force and commercial team. JAKAFI was the first FDA‑approved JAK inhibitor for any indication and was the first and remains the only product approved by the FDA for use in MF and also now in PV. The FDA has granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia.

 

To help ensure that all eligible MF and PV patients have access to JAKAFI, we have established a patient assistance program called IncyteCARES (CARES stands for Connecting to Access, Reimbursement, Education and Support). IncyteCARES helps ensure that any patient with intermediate or high‑risk MF or uncontrolled PV who meets certain eligibility criteria and is prescribed JAKAFI has access to the product regardless of ability to pay and has access to ongoing support and educational resources during treatment. In addition, IncyteCARES works closely with payers to help facilitate insurance coverage of JAKAFI.

 

JAKAFI is distributed primarily through a network of specialty pharmacy providers and wholesalers that allow for efficient delivery of the medication by mail directly to patients or direct delivery to the patient’s pharmacy. Our distribution process uses a model that is well‑established and familiar to physicians who practice within the oncology field.

 

To further support appropriate use and future development of JAKAFI, our Medical Affairs department is responsible for providing appropriate scientific and medical education and information to physicians, preparing scientific presentations and publications, and overseeing the process for supporting investigator sponsored trials.

 

Myelofibrosis.  Myelofibrosis is a rare, life‑threatening condition. MF, considered the most serious of the myeloproliferative neoplasms, can occur either as primary MF, or as secondary MF that develops in some patients who previously had polycythemia vera or essential thrombocythemia. We estimate there are between 16,000 and 18,500 patients with MF in the United States. Based on the modern prognostic scoring systems referred to as International Prognostic Scoring System and Dynamic International Prognostic Scoring System, we believe intermediate and high‑risk patients represent 80%  to 90%  of all patients with MF in the United States and encompass patients over the age of 65, or patients who have or have ever had any of the following: anemia, constitutional symptoms, elevated white blood cell or blast counts, or platelet counts less than 100,000 per microliter of blood.

 

Most MF patients have enlarged spleens and many suffer from debilitating symptoms, including abdominal discomfort, pruritus (itching), night sweats and cachexia (involuntary weight loss). There were no FDA approved therapies for MF until the approval of JAKAFI.

 

The FDA approval was based on results from two randomized Phase III trials (COMFORT‑I and COMFORT‑II), which demonstrated that patients treated with JAKAFI experienced significant reductions in splenomegaly (enlarged spleen). COMFORT‑I also demonstrated improvements in symptoms. The most common hematologic adverse reactions in both trials were thrombocytopenia and anemia. These events rarely led to discontinuation of JAKAFI treatment. The most common non‑hematologic adverse reactions were bruising, dizziness and headache.

 

In August 2014, the FDA approved supplemental labeling for JAKAFI to include Kaplan‑Meier overall survival curves as well as additional safety and dosing information. The overall survival information is based on three‑year data from COMFORT‑I and II, and shows that at three years the probability of survival for patients treated with JAKAFI in COMFORT‑I was 70% and for those patients originally randomized to placebo it was 61%. In COMFORT‑II, at three years the probability of survival for patients treated with Jakafi was 79% and for patients originally randomized to best available therapy it was 59%.

28


 

 

Polycythemia Vera.  PV is a myeloproliferative neoplasm typically characterized by elevated hematocrit, the volume percentage of red blood cells in whole blood, which can lead to a thickening of the blood and an increased risk of blood clots, as well as an elevated white blood cell and platelet count. When phlebotomy can no longer control PV, chemotherapy such as hydroxyurea, or interferon, is utilized. Approximately 25,000 patients with PV in the United States are considered uncontrolled because they have an inadequate response to or are intolerant of hydroxyurea, the most commonly used chemotherapeutic agent for the treatment of PV.

 

In December 2014, the FDA approved JAKAFI for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. The approval of JAKAFI for PV was based on data from the pivotal Phase III RESPONSE trial. In this trial, patients treated with JAKAFI demonstrated superior hematocrit control and reductions in spleen volume compared to best available therapy. In addition, a greater proportion of patients treated with JAKAFI achieved complete hematologic remission—which was defined as achieving hematocrit control, and lowering platelet and white blood cell counts. In the RESPONSE trial, the most common hematologic adverse reactions (incidence > 20%) were thrombocytopenia and anemia. The most common non‑hematologic adverse events (incidence >10%) were headache, abdominal pain, diarrhea, dizziness, fatigue, pruritus, dyspnea and muscle spasms.

 

In March 2016, the FDA approved supplemental labeling for JAKAFI to include additional safety data as well as efficacy analyses from the RESPONSE trial to assess the durability of response in JAKAFI treated patients after 80 weeks. At this time, 83% patients were still on treatment, and 76% of the responders at 32 weeks maintained their response through 80 weeks.

 

We have retained all development and commercialization rights to JAKAFI in the United States and are eligible to receive development and commercial milestones as well as royalties from product sales outside the United States. We hold patents that cover the composition of matter and use of ruxolitinib through late 2026, which patents have been granted extensions through late 2027.

 

Clinical Programs in Oncology

 

We believe that the future of cancer treatment lies in the use of immune therapies, which seek to recruit the patient’s own immune system to tackle cancer, and targeted therapies, which aim to block, directly or indirectly, the effects of cancer-causing mutations. Our most advanced programs are detailed below.

 

We also have a number of other early programs at various stages of preclinical and clinical testing. We intend to describe these programs once we have obtained clinical proof‑of‑concept and established that a compound within a specific program warrants further development.

 

Targeted Therapies

 

We have a portfolio of wholly-owned selective JAK1 inhibitors, including INCB39110 and INCB52793. The clinical program to evaluate INCB39110 in solid tumors includes clinical trials in combination with the EGFR inhibitor osimertinib. We have another JAK1 inhibitor, INCB52793, which is in a Phase I/II trial in patients with advanced malignancies. INCB52793 has shown synergistic efficacy in combination with standard of care in preclinical models of multiple myeloma.

 

The PI3K‑delta pathway mediates oncogenic signaling in B cell malignancies. Our PI3K-delta inhibitor clinical development program now focuses on INCB50465, which we believe provides a better opportunity to differentiate from competitor agents on potency, pharmacokinetics and safety, thereby potentially providing more attractive combination opportunities. A Phase I/II trial of INCB50465, both as monotherapy and in combination with the JAK1 inhibitor INCB39110, is underway. In‑house preclinical studies have demonstrated that the JAK1 and PI3K‑delta signaling pathways play inter‑related functions in maintaining the growth and survival of B‑lymphoid cells, and the data suggest that concurrent inhibition of the two pathways may achieve synergistic cellular efficacy.

 

c‑MET is a clinically validated receptor kinase cancer target. Abnormal c‑MET activation in cancer correlates with poor prognosis. Dysregulation of the c‑MET pathway triggers tumor growth, formation of new blood vessels that supply the tumor with nutrients, and causes cancer to spread to other organs. Dysregulation of the c‑MET pathway is seen in many types of cancers, including lung, kidney, liver, stomach, breast and brain.

 

Several small molecule c‑MET kinase inhibitors have demonstrated clinical efficacy in a number of cancers; however, these molecules have limited potency and are relatively non‑selective, which could lead to off‑target toxicities. We believe our lead c‑MET inhibitor, capmatinib, which is licensed to Novartis, has the requisite properties to overcome these limitations, including greater selectivity, improved potency and more effective inhibition of c‑MET. Under our agreement, Novartis received worldwide exclusive development and commercialization rights to capmatinib and certain

29


 

back‑up compounds in all indications. Capmatinib is being evaluated in patients with hepatocellular carcinoma, non‑small cell lung cancer, glioblastoma multiforme and other solid tumors, and may have potential utility as a combination agent.

 

INCB54828 is an inhibitor of the FGFR isoforms 1, 2 and 3 that has demonstrated potency and selectivity in preclinical studies. The FGFR family of receptor tyrosine kinases can act as oncogenic drivers in a number of liquid and solid tumor types. INCB54828 is currently being studied in an open-label, dose-escalation trial in patients with advanced malignancies.

 

INCB54329 is a BRD inhibitor. BRDs are a family of proteins which play important roles in mediating gene transcription, most notably by facilitating the expression of oncogenes such as MYC, one of the most frequently dysregulated oncogenes in all human cancer. INCB54329 is being studied in an open-label dose-escalation trial in patients with advanced malignancies.

 

INCB53914 is a pan-PIM kinase inhibitor that has demonstrated potency and selectivity in preclinical studies. PIM kinases integrate signals from multiple pathways important for the survival and proliferation of malignant cells. Over expression of PIM kinases has been reported in human hematological cancers with each isoform showing a distinct expression pattern among the various malignancy subtypes. A clinical trial of INCB53914 in advanced malignancies is now underway.

 

INCB59872 is an LSD1 inhibitor. LSD1 is a key enzyme that is involved in epigenetic regulation of gene transcription. Dysregulated LSD1 activity can perturb normal gene expression, leading to cellular transformation.  In particular, the function of LSD1 has been reported to maintain stem cell-like gene expression patterns in various cancers, including acute myeloid leukemia and small cell lung cancer. A proof-of-concept clinical trial of INCB59872 is now underway.

 

 

 

 

 

Indication

Status Update

INCB39110 (JAK1)

Lung cancer

Phase I/II in combination with osimertinib (EGFR) expected to initiate mid-year 2016

INCB52793 (JAK1)

Advanced malignancies

Phase I/II dose-escalation

INCB50465 (PI3Kδ)

B-cell malignancies

Phase I/II as monotherapy and in combination with INCB39110 (JAK1); expansion cohorts initiating

Capmatinib (c-MET, licensed to Novartis)

Non-small cell lung cancer, glioblastoma, liver cancer

Phase II in EGFR wild-type ALK negative NSCLC patients with c-MET amplification and mutation

INCB54828 (FGFR)

Advanced malignancies

Phase I/II dose escalation; expansion cohorts in genetically-defined tumor types now underway

INCB54329 (BRD)

Advanced malignancies

Phase I/II dose-escalation

INCB53914 (PIM)

Advanced malignancies

Phase I/II dose-escalation

INCB59872 (LSD1)

Acute myeloid leukemia,
small cell lung cancer

Phase I/II dose-escalation

 

Immune Therapies

 

The enzyme, indoleamine 2, 3‑dioxygenase‑1, IDO1, is a key regulator of the mechanisms that are responsible for allowing tumors to escape from a patient’s immune surveillance. IDO1 expression by tumor cells, or by antigen presenting cells such as macrophages and dendritic cells in tumors, creates an environment in which tumor specific cytotoxic T lymphocytes are rendered functionally inactive or are no longer able to attack a patient’s cancer cells. By inhibiting IDO1, it is proposed that this “brake” on the anti‑tumor immune response is removed, allowing anti‑tumor specific cytotoxic T cells, generated in a patient spontaneously in response to the tumor, or through a therapy designed to stimulate the immune response, to have greater anti‑tumor efficacy.

 

Epacadostat is a novel, potent and selective inhibitor of the enzyme IDO1. We believe that the optimal development strategy for epacadostat is for the compound to be developed in combination with other immuno‑oncology agents. During 2014, we signed clinical trial collaboration agreements with Merck, Bristol-Myers Squibb, AstraZeneca / MedImmune and Roche / Genentech to evaluate epacadostat with their respective anti-PD-1 and anti-PD-L1 agents in

30


 

Phase I/II trials, and all four of these trials are in progress. We have global development and commercialization rights to epacadostat for all indications.

 

In October 2015, we and Merck announced an expansion of the companies’ ongoing clinical trial collaboration to include ECHO-301, a Phase III study evaluating the combination of epacadostat with pembrolizumab as a first-line treatment for patients with advanced or metastatic melanoma. This trial is expected to begin in the first half of 2016.

 

INCSHR1210 is an anti-PD-1 monoclonal antibody that we have licensed under our agreement with Jiangsu Hengrui Medicine Co., Ltd. (Hengrui). Many tumor cells express PD-L1, an immunosuppressive PD-1 ligand. Inhibition of the interaction between PD-1 and PD-L1, known as immune checkpoint blockade, can enhance T-cell responses and mediate preclinical antitumor activity. A proof-of-concept clinical trial of INCSHR1210 in patients with advanced solid tumors is now underway.

 

INCAGN1876 is an anti-GITR agonist antibody and is a program within our antibody discovery and development collaboration with Agenus Inc. GITR is a costimulatory receptor that is expressed on effector T cells and is important for T cell survival and enhanced cytokine production. It is also expressed on regulatory T cells and can abrogate their suppressive function. Preclinical data demonstrate that anti-GITR agonist antibodies inhibit tumor growth by enhancing the levels and function of effector T cells and by decreasing regulatory T cells. A proof-of-concept clinical trial of INCAGN1876 is expected to begin in the first half of 2016.

 

 

 

 

 

Indication

Status Update

Epacadostat (IDO1)

1st line, advanced melanoma

Phase III (ECHO-301) in combination with Merck’s pembrolizumab (PD-1)1

 

Multiple tumor types

Phase II (ECHO-202) expansion cohorts now recruiting in combination with Merck’s pembrolizumab (PD-1)

 

Multiple tumor types

Phase II (ECHO-204) expansion cohorts now recruiting in combination with Bristol-Myers Squibb’s nivolumab (PD-1)

 

Multiple tumor types

Phase II (ECHO-203) expansion cohorts now recruiting in combination with AstraZeneca/MedImmune’s durvalumab (PD-L1)

 

Non-small cell lung cancer

Phase I/II (ECHO-110) dose-escalation ongoing in combination with Roche/Genentech’s atezolizumab (PD-L1)

INCSHR1210 (PD-1,
licensed from Hengrui)

Solid tumors

Phase I/II dose-escalation

INCAGN1876 (GITR,
co-developed with Agenus)

Solid tumors

Phase I/II dose-escalation1

INCAGN1949 (OX40,
co-developed with Agenus)

Solid tumors

Phase I/II dose-escalation2

PD-1 platform study

Solid tumors

Phase I/II, pembrolizumab (PD-1) in combination with INCB39110 (JAK1) or INCB50465 (PI3Kδ)

JAK1 platform study

Solid tumors

Phase I/II, INCB39110 (JAK1) in combination with epacadostat (IDO1) or INCB50465 (PI3Kδ)

 

1. Expected to begin in the first half of 2016.

 

2. Expected to begin in the second half of 2016.

 

We have also launched two platform studies to investigate the effects of PD-1, JAK1, IDO1 and PI3Kδ inhibition on the tumor microenvironment. The PD-1 platform study will investigate the effects of adding either INCB39110 (JAK1) or INCB50465 (PI3Kδ) to pembrolizumab (PD-1). The JAK1 platform study will investigate all-oral doublets combining either INCB50465 (PI3Kδ) or epacadostat (IDO1) with INCB39110 (JAK1).

 

Clinical Programs outside Oncology

 

Alopecia Areata. In October 2015, we initiated a Phase II trial of ruxolitinib cream for the topical treatment of alopecia areata. This new study builds on published data showing efficacy of oral JAK inhibitors, including ruxolitinib, in alopecia areata. Alopecia areata is an autoimmune skin disease resulting in the loss of hair on the scalp and elsewhere on the body. Alopecia areata occurs in males and females of all ages, but onset often occurs in childhood. We estimate that over 6.6 million people in the United States and 147 million people worldwide have, had or will develop alopecia

31


 

areata at some point in their lives.

 

Graft-Versus-Host-Disease. Building upon positive, independently published third-party data of ruxolitinib in graft-versus-host-disease (GVHD), we intend to initiate a U.S. registration program for ruxolitinib in GVHD in the second half of 2016. We recently announced an agreement with Lilly enabling us to develop and commercialize ruxolitinib in the U.S. for the treatment of GVHD. We also announced an agreement with Novartis granting Novartis exclusive research, development and commercialization rights for ruxolitinib in GVHD outside the U.S. In addition, we have begun a proof-of-concept trial of INCB39110, a selective JAK1 inhibitor, for the treatment of patients with GVHD.

 

GVHD is a condition that can occur after an allogeneic transplant (the transfer of genetically dissimilar stem cells or tissue). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body. We estimate that the long-term survival in patients with corticosteroid-refractory GVHD is approximately 5% to 30% and that the diagnosed incidence of acute and chronic GVHD is approximately 17,000 per year across the U.S. and Europe.

 

Rheumatoid Arthritis.  Rheumatoid arthritis is an autoimmune disease characterized by aberrant or abnormal immune mechanisms that lead to joint inflammation and swelling and, in some patients, the progressive destruction of joints. Rheumatoid arthritis can also affect connective tissue in the skin and organs of the body.

 

Current rheumatoid arthritis treatments include the use of non‑steroidal anti‑inflammatory drugs, disease‑modifying anti‑rheumatic drugs, such as methotrexate, and the newer biological response modifiers that target pro‑inflammatory cytokines, such as tumor necrosis factor, implicated in the pathogenesis of rheumatoid arthritis. None of these approaches to treatment is curative; therefore, there remains an unmet need for new safe and effective treatment options for these patients. Rheumatoid arthritis is estimated to affect about 1% of the world’s population.

 

We have a second JAK1 and JAK2 inhibitor, baricitinib, which is subject to our collaboration agreement with Eli Lilly and Company, in which Lilly received exclusive worldwide development and commercialization rights to the compound for inflammatory and autoimmune diseases. The Phase III program of baricitinib in patients with rheumatoid arthritis incorporated all three rheumatoid arthritis populations (methotrexate naïve, biologic naïve, and tumor necrosis factor (TNF) inhibitor inadequate responders); used event rates to fully power the baricitinib program for structural comparison and non-inferiority vs. adalimumab; and evaluated patient-reported outcomes. All four Phase III trials met their respective primary endpoints.

 

In January 2016, Lilly submitted a New Drug Application (NDA) to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency for baricitinib as treatment for mild-to-moderately severe rheumatoid arthritis. We have exercised our co-development option in rheumatoid arthritis to fund 30% of development costs from Phase IIb through regulatory approval, including post-launch studies required by a regulatory authority, in exchange for increased tiered royalties ranging up to the high twenties on potential future sales.

 

Psoriasis.  Baricitinib has completed a Phase II trial as a treatment for psoriasis. Psoriasis is a skin disease that causes visible scaling and inflammation. Most psoriasis patients have patches of thick, red skin with silvery scales that can occur on the elbows, knees, other parts of the legs, scalp, lower back, face, palms, and soles of the feet. Market research suggests that neither physicians nor patients are satisfied with existing psoriasis treatments primarily because these require constant monitoring to balance safety and efficacy outcomes. There is clear unmet need for a better tolerated and effective treatment. The U.S. psoriasis market consists of approximately six million patients, of which moderate‑to‑severe patients account for approximately 20% of the market.  We have decided not to exercise our co-development option for psoriasis.

 

Atopic Dermatitis. Lilly has initiated a Phase IIa trial to evaluate the safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis. The JAK-STAT pathway has been shown to play an essential role in the dysregulation of immune responses in atopic dermatitis. A recent study of six patients with moderate to severe atopic dermatitis who had failed standard treatment showed that treatment with the JAK inhibitor tofacitinib showed promising results. Therefore, we believe that inhibiting cytokine pathways dependent on JAK1 and JAK2 may lead to positive clinical outcomes in atopic dermatitis.

 

Systemic Lupus Erythematosus. Lilly has initiated a Phase II trial to evaluate the safety and efficacy of baricitinib in patients with systemic lupus erythematosus (SLE). Baricitinib’s activity profile suggests that it inhibits cytokines implicated in SLE such as type I interferon (IFN), type II IFN-γ, IL-6, and IL-23 as well as other cytokines that may have a role in SLE, including granulocyte macrophage colony stimulating factor (GM-CSF) and IL-12. The potential impact of baricitinib on the IFN pathway is highly relevant to SLE, as clinical and preclinical studies have established that this pathway is involved in the pathogenesis of SLE.

 

32


 

Diabetic Nephropathy.  Baricitinib has also completed a Phase IIa trial in patients with diabetic nephropathy. Data suggest that ongoing renal inflammation plays a key role in diabetic nephropathy, and biopsies from the kidneys of early‑ and late‑stage diabetic kidney disease patients suggest that over‑activation of the JAK/STAT pathway leads to increased levels of pro‑inflammatory cytokines. This dose‑ranging placebo‑controlled Phase IIa trial met its primary endpoint of a change from baseline in the urinary albumin/creatinine ratio at 24 weeks.

 

 

 

 

 

Indication

Status Update

Baricitinib (JAK1/JAK2)
(licensed to Lilly)

Rheumatoid arthritis

NDA and MAA submitted

 

Psoriasis

Phase II studies completed

 

Atopic dermatitis, systemic lupus erythematosus

Phase II

Ruxolitinib (JAK1/JAK2)

Alopecia areata

Phase II (topical formulation1)

Ruxolitinib (JAK1/JAK2)

Graft-versus-host-disease

Phase III2

INCB39110 (JAK1)

Graft-versus-host-disease

Phase I/II

 

1. The Collaboration and License Agreement with Novartis for ruxolitinib ex-U.S. does not include topical   administration.

 

2. The pivotal program for ruxolitinib in graft-versus-host-disease is expected to begin in the second half of 2016.

 

License Agreements and Business Relationships

 

As part of our business strategy, we establish business relationships, including collaborative arrangements with other companies and medical research institutions to assist in the clinical development and/or commercialization of certain of our drugs and drug candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies and medical research institutions.

 

Below is a brief description of our significant business relationships and collaborations and related license agreements that expand our pipeline and provide us with certain rights to existing and potential new products and technologies.

 

Novartis

 

In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to ruxolitinib and certain back‑up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. Novartis also received worldwide exclusive development and commercialization rights to our c‑MET inhibitor compound capmatinib and certain back‑up compounds in all indications. We retained options to co‑develop and to co‑promote capmatinib in the United States.

 

Under this agreement, we received an upfront payment and immediate milestone payment totaling $210 million and were initially eligible to receive additional payments of up to approximately $1.2 billion if defined development and commercialization milestones are achieved. We are also eligible to receive tiered, double‑digit royalties ranging from the upper‑teens to the mid‑twenties on future ruxolitinib net sales outside of the United States. In addition, Novartis has received reimbursement and pricing approval for ruxolitinib in a specified number of countries, and we are now obligated to pay to Novartis tiered royalties in the low single digits on future ruxolitinib net sales within the United States. Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.

 

33


 

In April 2016, we entered into an amendment with Novartis under which we granted Novartis exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in GVHD. We are eligible to receive future additional payments from Novartis if defined development and regulatory milestones relating to ruxolitinib for GVHD outside of the United States are achieved.

 

The Novartis agreement will continue on a program‑by‑program basis until Novartis has no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. Royalties are payable by Novartis on a product‑by‑product and country‑by‑country basis until the latest to occur of (1) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (2) the expiration of regulatory exclusivity for the licensed product in such country and (3) a specified period from first commercial sale in such country of the licensed product by Novartis or its affiliates or sublicensees. The agreement may be terminated in its entirety or on a program‑by‑program basis by Novartis for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach.

 

Lilly - Baricitinib

 

In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to baricitinib and certain back‑up compounds for inflammatory and autoimmune diseases. We received an initial payment of $90 million, and were initially eligible to receive additional payments of up to $665 million based on the achievement of defined development, regulatory and commercialization milestones.

 

We retained options to co‑develop our JAK1/JAK2 inhibitors with Lilly on a compound‑by‑compound and indication‑by‑indication basis. Lilly is responsible for all costs relating to the development and commercialization of the compounds unless we elect to co‑develop any compounds or indications. If we elect to co‑develop any compounds and/or indications, we would be responsible for funding 30% of the associated future global development costs from the initiation of a Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. We would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global net sales for compounds and/or indications that we elect to co-develop.  For indications that we elect not to co‑develop, we would receive tiered, double‑digit royalty payments on future global net sales with rates ranging up to 20% if the product is successfully commercialized. We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement. 

 

In July 2010, we elected to co‑develop baricitinib with Lilly in rheumatoid arthritis and we are responsible for funding 30% of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. Baricitinib is also being developed in psoriasis, atopic dermatitis and systemic lupus erythematosus. We have decided not to exercise our co‑development option for psoriasis.

 

The Lilly agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. Royalties are payable by Lilly on a product‑by‑product and country‑by‑country basis until the latest to occur of (1) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (2) the expiration of regulatory exclusivity for the licensed product in such country and (3) a specified period from first commercial sale in such country of the licensed product by Lilly or its affiliates or sublicensees. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.

 

Lilly - Ruxolitinib

 

In March 2016, we entered into an amendment to the agreement with Lilly which allows us to engage in the development and commercialization of ruxolitinib in the GVHD field. We have agreed to pay Lilly an upfront payment of $35 million and Lilly is eligible to receive up to $40 million in additional regulatory milestone payments relating to ruxolitinib in the GVHD field.

 

Agenus

 

In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly‑owned subsidiary, 4‑Antibody AG, which we collectively refer to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno‑therapeutics using Agenus’ proprietary antibody discovery platforms.

 

34


 

Under the terms of this agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG‑3 and TIM‑3. In addition to the initial four program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, three more targets were added. Targets may be designated profit‑share programs, where all costs and profits are shared equally by us and Agenus, or royalty‑bearing programs, where we will be responsible for all costs associated with discovery, preclinical activities, clinical development and commercialization activities. The programs relating to GITR and OX40 and two of the undisclosed targets are profit‑share programs while the other targets currently under collaboration are royalty‑bearing programs.  All costs related to the collaboration are subject to a joint research plan. For each royalty‑bearing product, Agenus will be eligible to receive up to $155 million in future contingent development, regulatory and commercialization milestones as well as tiered royalties on global net sales ranging from 6% to 12%. For each profit‑share product, Agenus will be eligible to receive up to $20 million in future contingent development milestones. Additionally, Agenus retains co‑promotion participation rights in the United States on any profit‑share product. For each royalty‑bearing product, Agenus has reserved the right to elect to co‑fund 30% of development costs for a commensurate increase in royalties. The agreement may be terminated by us for convenience upon 12 months’ notice and may also be terminated under certain other circumstances, including material breach. We agreed to certain standstill provisions that allow us to acquire up to 15% of Agenus Inc.’s outstanding voting stock, including shares acquired pursuant to the Stock Purchase Agreement described below, solely for investment purposes.

 

In January 2015, we also entered into a Stock Purchase Agreement with Agenus Inc., pursuant to which we purchased approximately 7.76 million shares of Agenus Inc. common stock for an aggregate purchase price of $35 million in cash, or approximately $4.51 per share. We agreed not to dispose of any of the shares of common stock for a period of 12 months and Agenus Inc. has agreed to certain registration rights with respect to the shares of common stock.

 

Hengrui

 

In September 2015, we entered into a License and Collaboration Agreement with Hengrui.  Under the terms of this agreement, we received exclusive development and commercialization rights worldwide, with the exception of Mainland China, Hong Kong, Macau and Taiwan, to INCSHR1210, an investigational PD-1 monoclonal antibody, and certain back-up compounds.  We paid to Hengrui an upfront payment of $25 million. Hengrui is also eligible to receive potential milestone payments of up to $770 million, consisting of $90 million for regulatory approval milestones, $530 million for commercial performance milestones, and $150 million for a clinical superiority milestone.  Also, Hengrui may be eligible to receive tiered royalties in the high single digits to mid-double digits based on net sales in our territories. Each company will be responsible for costs relating to the development and commercialization of the PD-1 monoclonal antibody in its respective territories.

 

The agreement will continue on a country-by-country basis until we have no royalty payment obligations with respect to such country or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated in its entirety by us for convenience, and may also be terminated under certain other circumstances, including material breach. 

 

Critical Accounting Policies and Significant Estimates

 

The preparation of financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an on-going basis, we evaluate our estimates. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.

 

We believe the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our condensed consolidated financial statements:

 

·

Revenue recognition;

 

·

Research and development costs;

 

·

Stock compensation;

 

·

Investments;

 

35


 

·

Inventory;

 

·

Convertible debt accounting; and

 

·

Income taxes

 

Revenue Recognition. Revenues are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured. Revenues are deferred for fees received before earned or until no further obligations exist. We exercise judgment in determining that collectability is reasonably assured or that services have been delivered in accordance with the arrangement. We assess whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. We assess collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.

 

Product Revenues

 

Our product revenues consist of U.S. sales of JAKAFI and are recognized once we meet all four revenue recognition criteria described above. In November 2011, we began shipping JAKAFI to our customers, which include specialty pharmacies and wholesalers.

 

We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and Medicare Part D coverage gap reimbursements. Product shipping and handling costs are included in cost of product revenues.

 

Customer Credits:  Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.

 

Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launch. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Chargebacks:  Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received, we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel.  If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Medicare Part D Coverage Gap:  Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Co-payment Assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.

 

36


 

Product Royalty Revenues

 

Royalty revenues on commercial sales for JAKAVI by Novartis are estimated based on information provided by Novartis. We exercise judgment in determining whether the information provided is sufficiently reliable for us to base our royalty revenue recognition thereon. If actual royalties vary from estimates, we may need to adjust the prior period, which would affect royalty revenue in the period of adjustment.

 

Cost of Product Revenues

 

Cost of product revenues includes all JAKAFI related costs that are recoverable through the commercialization of the product. Beginning in October 2014, we became obligated to pay tiered, low single digit royalties to Novartis on all future sales of JAKAFI in the United States, which are included in cost of product revenues.

 

Contract and License Revenues

 

Under agreements involving multiple deliverables, services and/or rights to use assets that we entered into prior to January 1, 2011, the multiple elements are divided into separate units of accounting when certain criteria are met, including whether the delivered items have stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered items. When separate units of accounting exist, consideration is allocated among the separate elements based on their respective fair values. The determination of fair value of each element is based on objective evidence from historical sales of the individual elements by us to other customers. If such evidence of fair value for each undelivered element of the arrangement does not exist, all revenue from the arrangement is deferred until such time that evidence of fair value for each undelivered element does exist or until all elements of the arrangement are delivered. When elements are specifically tied to a separate earnings process, revenue is recognized when the specific performance obligation tied to the element is completed. When revenues for an element are not specifically tied to a separate earnings process, they are recognized ratably over the term of the agreement. We assess whether a substantive milestone exists at the inception of our agreements. For all milestones within our arrangements that are considered substantive, we recognize revenue upon the achievement of the associated milestone. If a milestone is not considered substantive, we would recognize the applicable milestone payment over the remaining period of performance under the arrangement. As of March 31, 2016, all remaining potential milestones under our collaborative arrangements are considered substantive.

 

On January 1, 2011, updated guidance on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements we may enter into on or after January 1, 2011. This updated guidance (i) relates to whether multiple deliverables exist, how the deliverables in a revenue arrangement should be separated and how the consideration should be allocated; (ii) requires companies to allocate revenues in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (iii) eliminates the use of the residual method and requires companies to allocate revenues using the relative selling price method. During the three months ended March 31, 2016 and 2015, we did not enter into any agreements that are subject to this updated guidance. If we enter into an agreement with multiple deliverables after January 1, 2011 or amend existing agreements, this updated guidance could have a material effect on our financial statements.

 

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events. These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraphs.

 

The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the U.S. Food and Drug Administration (FDA) requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate’s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (IND), which must be reviewed by the FDA.

 

The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (NDA) or biologics license application (BLA) to the FDA for review and FDA approval of the NDA or BLA.

 

37


 

Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.

 

Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase I, Phase II or Phase III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.

 

Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.

 

Research and Development Costs.  Our policy is to expense research and development costs as incurred. We often contract with clinical research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract.

 

These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period.

 

Under our clinical trial collaboration agreements, we may be reimbursed for certain development costs incurred.  Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred.

 

Stock Compensation.  Share-based payment transactions with employees, which include stock options, restricted stock units (RSUs) and performance shares (PSUs), are recognized as compensation expense over the requisite service period based on their estimated fair values on the dates of grant.  The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting.  The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method.  The fair value of RSUs, which are generally subject to cliff vesting, are recognized as compensation expense over the requisite service period using the straight line attribution method.  The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, over the remaining requisite service period. We recorded

38


 

$20.8 million and $17.6 million of stock compensation expense for the three months ended March 31, 2016 and 2015, respectively.

 

Investments.  We carry our investments at their respective fair values. We periodically evaluate the fair values of our investments to determine whether any declines in the fair value of investments represent an other-than-temporary impairment. This evaluation consists of a review of several factors, including the length of time and extent that a security has been in an unrealized loss position, the existence of an event that would impair the issuer’s future repayment potential, the near term prospects for recovery of the market value of a security and if we intend to sell or if it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If management determines that such an impairment exists, we would recognize an impairment charge. Because we may determine that market or business conditions may lead us to sell our marketable securities prior to maturity, we classify our marketable securities as “available-for-sale.” Investments in securities that are classified as available-for-sale and have readily determinable fair values are measured at fair market value in the balance sheets, and unrealized holding gains and losses for these investments are reported as a separate component of stockholders’ equity until realized. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets.

 

We carry our long term investment in Agenus at fair value on the condensed consolidated balance sheets.  Fair value of the long term investment is based on the quoted market price of Agenus as of the balance sheet date.   All changes in fair value are reported in our condensed consolidated statements of operations as an unrealized gain (loss) on long term investment.

 

Inventory.  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. We began capitalizing inventory in mid-November 2011 once the FDA approved JAKAFI as the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to approval of JAKAFI have been recorded as research and development expense in our statements of operations. As a result, cost of product revenues for the next 6 to 9 months will reflect a lower average per unit cost of materials.

 

The raw materials and work-in-process inventory is not subject to expiration and the shelf life for finished goods inventory is 36 months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.

 

Convertible Debt Accounting.  We perform an assessment of all embedded features of a debt instrument to determine if (1) such features should be bifurcated and separately accounted for, and (2) if bifurcation requirements are met, whether such features should be classified and accounted for as equity or liability instruments. If the embedded feature meets the requirements to be bifurcated and accounted for as a liability, the fair value of the embedded feature is measured initially, included as a liability on the condensed consolidated balance sheets, and re-measured to fair value at each reporting period. Any changes in fair value are recorded in the condensed consolidated statement of operations. We monitor, on an ongoing basis, whether events or circumstances could give rise to a change in our classification of embedded features.

 

We determined the embedded conversion options in the 0.375% convertible senior notes due 2018 (the 2018 Notes) and the 1.25% convertible senior notes due 2020 (the 2020 Notes) are not required to be separately accounted for as derivatives. However, since the 2018 Notes and the 2020 Notes can be settled in cash or common shares or a combination of cash and common shares at our option, we are required to separate the 2018 Notes and 2020 Notes into a liability and equity component. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability that does not have an associated equity component. The carrying amount of the equity component representing the embedded conversion option is determined by deducting the fair value of the liability component from the initial proceeds. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of the 2018 Notes and 2020 Notes using the effective interest method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification for contracts in an entity’s own equity.

 

The fair value of the liability component of the 2018 Notes was estimated at $299.4 million at issuance. Therefore, the difference between the $375.0 million face value of the 2018 Notes and the $299.4 million estimated fair value of the liability component will be amortized to interest expense over the term of the 2018 Notes through November 15, 2018 using the effective interest method.

 

The fair value of the liability component of the 2020 Notes was estimated at $274.8 million at issuance. Therefore, the difference between the $375.0 million face value of the 2020 Notes and the $274.8 million estimated fair

39


 

value of the liability component will be amortized to interest expense over the term of the 2020 Notes through November 15, 2020 using the effective interest method.

 

The estimated fair value of the liability components at the date of issuance for the 2018 Notes and 2020 Notes were determined using valuation models and are complex and subject to judgment. Significant assumptions within the valuation models included an implied credit spread, the expected volatility and dividend yield of our common stock and the risk free interest rate for notes with a similar term.

 

Prior to May 14, 2014, the 2018 Notes and 2020 Notes were not convertible except in connection with a make-whole fundamental change, as defined in the respective indentures. Beginning on, and including, May 15, 2014, the 2018 Notes and 2020 Notes are convertible prior to the close of business on the business day immediately preceding May 15, 2018, in the case of the 2018 Notes, and May 15, 2020, in the case of the 2020 Notes, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2018 Notes or 2020 Notes, as applicable, on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of 2018 Notes or 2020 Notes, as applicable, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the 2018 Notes or 2020 Notes, as applicable, on each such trading day; or (3) upon the occurrence of specified corporate events. On or after May 15, 2018, in the case of the 2018 Notes, and May 15, 2020, in the case of the 2020 Notes, until the close of business on the second scheduled trading day immediately preceding the relevant maturity date, the Notes are convertible at any time, regardless of the foregoing circumstances. Upon conversion we will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at our election.

 

On a quarterly basis, we perform an assessment in order to determine whether the 2018 Notes or 2020 Notes have become convertible at the option of the holder, based on meeting any of the conversion criteria described above. Should either the 2018 Notes or the 2020 Notes become convertible, we then assess our intent and ability to settle the 2018 Notes or the 2020 Notes in cash, shares of common stock, or a combination of cash and shares of common stock, in order to determine the appropriate classification of the 2018 Notes and the 2020 Notes at the balance sheet date. On April 1, 2016, the 2018 Notes and 2020 Notes became convertible through at least June 30, 2016, based on meeting the conversion criteria related to the sale price of our common stock during the calendar quarter ended March 31, 2016 as described above. Management’s intent is to settle any conversions of 2018 Notes or 2020 Notes in common shares and, therefore, the 2018 and 2020 Notes are reflected in long term liabilities on the condensed consolidated balance sheet as of March 31, 2016.

 

Income Taxes. We account for income taxes using an asset and liability approach to financial accounting for income taxes.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which the basis differences are expected to reverse. We periodically assess the likelihood of the realization of deferred tax assets, and reduce the carrying amount of these deferred tax assets to an amount that is considered to be more-likely-than-not realizable.  Our assessment considers recent cumulative earnings experience, estimated future taxable income and ongoing prudent and feasible tax planning strategies.  Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.

 

We do not recognize a tax benefit for an uncertain tax position unless it is more-likely-than-not that the position will be sustained upon examination based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement.  We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.   Any interest and penalties on uncertain tax positions are included within the tax provision.

 

All tax effects associated with intercompany transfers of assets within our consolidated group are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of operations when the asset is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life. 

 

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which provides a five step approach to be applied to all contracts with customers. ASU No. 2014-09 also requires expanded disclosures about revenue recognition. This

40


 

guidance is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein.  Early adoption is permitted for reporting periods beginning after December 15, 2016.  We are currently analyzing the impact of ASU No. 2014-09 on our results of operations and, at this time, we are unable to determine the impact of the new standard, if any, on our condensed consolidated financial statements.

 

In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements—Going Concern,” to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about our ability to continue as a going concern within one year from the date the financial statements are issued. This guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. We do not believe the pending adoption of ASU No. 2014-15 will have a material impact on our condensed consolidated financial statements.

 

In February 2015, the FASB issued ASU No. 2015-02, “Amendments to the Consolidation Analysis,” which affects reporting entities that are required to evaluate whether they should consolidate certain legal entities.  The amendments place more emphasis in the consolidation evaluation on variable interests other than fee arrangements such as principal investment risk (including debt or equity interests), guarantees of the value of the assets or liabilities of the VIE, written put options on the assets of the VIE, or similar obligations. Additionally, the amendments reduce the extent to which related party arrangements cause an entity to be considered a primary beneficiary. This guidance is to be applied using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The amendments are effective for fiscal years beginning after December 15, 2015, and interim periods therein. We have concluded ASU No. 2015-03 has no impact on our condensed consolidated financial statements. 

 

In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which changes the accounting for certain aspects of share-based payments to employees.  The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled.  In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows.  The standard also clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on the statement of cash flows, and provides an accounting policy election to account for forfeitures as they occur.  The new standard is effective for our calendar year beginning January 1, 2017.  Early adoption is permitted however all of the guidance must be adopted in the same period. 

 

We have elected to early adopt ASU No. 2016-09 as of the first quarter of 2016 which requires us to reflect any adjustments as of January 1, 2016, the beginning of the annual period that includes the interim period of adoption.  The primary impact of adoption was the recognition of $325.6 million of accumulated excess tax benefits as deferred tax assets that under the previous guidance could not be recognized until the benefits were realized through a reduction in cash taxes paid.  This part of the guidance was applied using a modified retrospective method with a cumulative-effect adjustment to the accumulated deficit for the excess tax benefits not previously recognized. However, given the full valuation allowance placed on the additional $325.6 million of deferred tax assets, the recognition upon adoption had no impact to our accumulated deficit as of January 1, 2016.

 

Adoption of the standard also resulted in the recognition of excess tax benefits in our income tax provision rather than as paid-in capital. This guidance is to be applied prospectively and resulted in the recognition of $0.3 million of excess tax benefits in our income tax provision rather than paid-in capital for the three months ended March 31, 2016.  Amendments to the minimum statutory withholding tax requirements had no impact to the accumulated deficit as of January 1, 2016. In addition, we have elected to continue to estimate forfeitures expected to occur when determining the amount of compensation cost to be recognized in each period.

 

We elected to apply the presentation requirements for cash flows related to excess tax benefits prospectively which resulted in classification within operating cash flows of the excess tax benefits recognized during the three months ended March 31, 2016.  This classification is now consistent with all other cash flow impacts from income taxes. In addition, the amendments to the cash flow statement presentation to classify cash payments made on behalf of employees for shares withheld as a financing activity had no impact on our previously reported cash flows, as this requirement is consistent with our previous presentation of these cash flows.

 

Results of Operations

 

We recorded net income of $24.0 million and basic and diluted net income per share of $0.13 and $0.12, respectively, for the three months ended March 31, 2016, as compared to a net loss of $18.4 million and basic and diluted net loss per share of $0.11 in the corresponding period in 2015.

41


 

 

Revenues.

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended,

 

 

 

 

 

March 31,

 

 

 

 

    

2016

    

2015

    

 

 

 

 

(in millions)

 

 

 

Product revenues, net

    

$

183.3

    

$

115.3

 

 

 

Product royalty revenues

 

 

21.9

 

 

15.7

 

 

 

Contract revenues

 

 

58.2

 

 

28.2

 

 

 

Other revenues

 

 

0.1

 

 

0.1

 

 

 

Total revenues

 

$

263.5

 

$

159.3

 

 

 

 

Our product revenues, net from JAKAFI for the three months ended March 31, 2016 and 2015, were $183.3 million and $115.3 million, respectively. The increase in product revenues for the three months ended March 31, 2016 as compared to the corresponding period in 2015 was comprised of a volume increase of $56.9 million and a price increase of $11.1 million.  Product revenues from the sale of JAKAFI are recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance. Our revenue recognition policies require estimates of the aforementioned sales allowances each period.

 

The following table provides a summary of activity with respect to our sales allowances and accruals for the three months ended March 31, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

 

    

 

 

    

Co-Pay

    

 

 

    

 

 

 

 

 

Discounts and

 

Government

 

Assistance

 

 

 

 

 

 

 

 

 

Distribution

 

Rebates and

 

and Other

 

Product

 

 

 

 

Three Months Ended March 31, 2016

    

Fees

    

Chargebacks

    

Discounts

    

Returns

    

Total

 

Balance at January 1, 2016

 

$

3,069

 

$

10,766

 

$

247

 

$

1,815

 

$

15,897

 

Allowances for current period sales

 

 

5,311

 

 

22,263

 

 

1,353

 

 

639

 

 

29,566

 

Allowances for prior period sales

 

 

257

 

 

106

 

 

(5)

 

 

 —

 

 

358

 

Credits/payments for current period sales

 

 

(4,452)

 

 

(8,316)

 

 

(1,224)

 

 

(95)

 

 

(14,087)

 

Credits/payments for prior period sales

 

 

(1,096)

 

 

(5,670)

 

 

(129)

 

 

 —

 

 

(6,895)

 

Balance at March 31, 2016

 

$

3,089

 

$

19,149

 

$

242

 

$

2,359

 

$

24,839

 

 

Government rebates and chargebacks are the most significant component of our sales allowances. Increases in certain government reimbursement rates are limited to a measure of inflation, and when the price of a drug increases faster than this measure of inflation it will result in a penalty adjustment factor that causes a larger sales allowance to those government related entities. We expect government rebates and chargebacks as a percentage of our gross product sales will continue to increase in connection with any future JAKAFI price increases greater than the rate of inflation, and any such increase in these government rebates and chargebacks will have a negative impact on our reported product revenues, net. We adjust our estimates for government rebates and chargebacks based on new information regarding actual rebates as it becomes available.  Claims by third-party payors for rebates and chargebacks are frequently submitted after the period in which the related sales occurred, which may result in adjustments to prior period accrual balances in the period in which the new information becomes available. 

 

We expect our sales allowances to fluctuate from quarter to quarter as a result of the Medicare Part D Coverage Gap, the volume of purchases eligible for government mandated discounts and rebates as well as changes in discount percentages which are impacted by potential future price increases, rate of inflation, and other factors.

 

Product royalty revenues on commercial sales of JAKAVI by Novartis are based on net sales of licensed products in licensed territories as provided by Novartis. Our net product royalty revenues for the three months ended March 31, 2016 and 2015, were $21.9 million and $15.7 million, respectively.

 

Our contract revenues were $58.2 million and $28.2 million for the three months ended March 31, 2016 and 2015, respectively. For the three months ended March 31, 2016 and 2015, contract revenues were derived from the straight line recognition of revenue associated with the Lilly upfront fees over the estimated performance period as well as milestone payments from Lilly and Novartis earned during the periods. During the three months ended March 31, 2016, under the Lilly agreement, we recognized a $35.0 million regulatory milestone payment for the submission of a new drug application to the U.S. Food and Drug Administration for the approval of oral once-daily baricitinib for the

42


 

treatment of moderately-to-severely active rheumatoid arthritis and a $20.0 million regulatory milestone for the submission of a Marketing Authorization Application to the Europe Medicines Agency for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis. During the three months ended March 31, 2015, under the Novartis agreement, we recognized a $25.0 million regulatory milestone triggered by the Committee for Medicinal Products for Human Use of the European Medicines Agency adopting a positive opinion for JAKAVI (ruxolitinib) for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.

 

Cost of Product Revenues.

 

We began capitalizing inventory in mid-November 2011 once the FDA approved JAKAFI as the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to FDA approval of $9.6 million were recorded as research and development expenses in our statements of operations prior to commercialization of JAKAFI. At March 31, 2016, inventory with $1.3 million of product costs incurred prior to FDA approval had not yet been sold. We expect to sell the pre-commercialization inventory over the next 6 to 9 months; however, the time period over which this inventory is consumed will depend on a number of factors, including the amount of future JAKAFI sales, and the ability to utilize inventory prior to its expiration date. As a result, cost of product revenues for the next 6 to 9 months will reflect a lower average per unit cost of materials. Commencing in October 2014, we became obligated to pay tiered, low single digit royalties to Novartis on all sales of JAKAFI in the United States, which is included in cost of product revenues.

 

Cost of product revenues was $6.0 million and $3.0 million for the three months ended March 31, 2016 and 2015, respectively. The increase in cost of product revenues for the three months ended March 31, 2016 as compared to the same periods in 2015 is due primarily to increased JAKAFI sales and our obligation that commenced in October 2014 to pay royalties to Novartis on all JAKAFI sales in the United States. We expect future cost of product revenues to range in the mid-single digits as a percentage of net product sales subsequent to the utilization of all of the remaining pre-launch inventory.

 

Operating Expenses.

 

Research and development expenses.

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended,

 

 

 

 

 

March 31,

 

 

 

 

    

2016

    

2015

    

    

 

 

 

(in millions)

 

 

 

Salary and benefits related

    

$

32.2

    

$

26.2

 

 

 

Stock compensation

 

 

13.0

 

 

10.3

 

 

 

Clinical research and outside services

 

 

100.0

 

 

71.8

 

 

 

Occupancy and all other costs

 

 

11.6

 

 

10.1

 

 

 

Total research and development expenses

 

$

156.8

 

$

118.4

 

 

 

 

We currently account for research and development costs by natural expense line and not costs by project. Salary and benefits related expense increased from the three months ended March 31, 2015 to the three months ended March 31, 2016 due primarily to increased development headcount to sustain our development pipeline. Stock compensation expense may fluctuate from period to period based on the number of awards granted, stock price volatility and expected award lives, as well as expected award forfeiture rates which are used to value equity-based compensation. The increase in clinical research and outside services expense from the three months ended March 31, 2015 to the three months ended March 31, 2016 was primarily the result of increased development costs to advance our clinical pipeline, and the $35.0 million payment to acquire the rights from Lilly to develop ruxolitinib for the treatment of patients with graft-versus-host-disease, as well as an additional $4.1 million of research and development costs incurred under the Agenus  arrangement through March 31, 2016.  Research and development expenses for the three months ended March 31, 2016 and 2015 were net of $2.9 million and $1.2 million, respectively, of costs reimbursed by our collaborative partners. Research and development expenses may fluctuate from period to period depending upon the stage of certain projects and the level of pre-clinical and clinical trial related activities. Many factors can affect the cost and timing of our clinical trials, including requests by regulatory agencies for more information, inconclusive results requiring additional clinical trials, slow patient enrollment, adverse side effects among patients, insufficient supplies for our clinical trials and real or perceived lack of effectiveness or safety of our investigational drugs in our clinical trials. In

43


 

addition, the development of all of our products will be subject to extensive governmental regulation. These factors make it difficult for us to predict the timing and costs of the further development and approval of our products.

 

In July 2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis and we are responsible for funding 30% of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval. Research and development expenses recorded under the Lilly agreement representing 30% of the global development costs for baricitinib for the treatment of rheumatoid arthritis were $5.1 million and $11.6 million for the three months ended March 31, 2016 and 2015, respectively. We expect our share of the global development costs for baricitinib for the treatment of rheumatoid arthritis to decline following submission of the NDA filing by Lilly in January 2016. We have retained certain mechanisms to give us cost protection as baricitinib advances in clinical development. We can defer our portion of co-development study costs by indication if they exceed a predetermined level. This deferment would be credited against future milestones or royalties and we would still be eligible for the full incremental royalties related to the co-development option. In addition, even if we have started co-development funding for any indication, we can at any time opt out, which will stop future co-development cost sharing. If we elect to do this we would still be eligible for our base royalties plus an incremental pro-rated royalty commensurate with our contribution to the total co-development cost for those indications for which we contributed funding.

 

Selling, general and administrative expenses.

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended,

 

 

 

 

 

March 31,

 

 

 

 

    

2016

    

2015

    

 

 

 

 

(in millions)

 

 

 

Salary and benefits related

    

$

16.4

    

$

14.2

 

 

 

Stock compensation

 

 

7.8

 

 

7.3

 

 

 

Other contract services and outside costs

 

 

40.4

 

 

23.4

 

 

 

Total selling, general and administrative expenses

 

$

64.6

 

$

44.9

 

 

 

 

Salary and benefits related expense increased from the three months ended March 31, 2015 to the three months ended March 31, 2016 due to increased headcount. This increased headcount was due primarily to the ongoing commercialization efforts related to JAKAFI for intermediate or high-risk myelofibrosis and for the commercial launch in uncontrolled polycythemia vera which occurred in December 2014. Stock compensation expense may fluctuate from period to period based on the number of awards granted, stock price volatility and expected award lives, as well as expected award forfeiture rates which are used to value equity-based compensation. The increase in other contract services and outside costs was primarily the result of marketing activities for JAKAFI for intermediate or high-risk myelofibrosis and uncontrolled polycythemia vera in addition to an increase in donations to independent non-profit patient assistance organizations in the United States.

 

Other income (expense).

 

Interest and other income, net. Interest and other income, net, for the three months ended March 31, 2016 and 2015 was $1.5 million and $1.6 million, respectively.

 

Interest Expense.  Interest expense for the three months ended March 31, 2016 and 2015 was $10.1 million and $12.7 million, respectively. Included in interest expense for the three months ended March 31, 2016 was $7.8 million of non-cash charges to amortize the discounts on the 2018 Notes and the 2020 Notes. Included in interest expense for the three months ended March 31, 2015 was $9.2 million of non-cash charges to amortize the discounts on the 4.75% convertible senior notes due 2015, the 2018 Notes and the 2020 Notes.

 

Unrealized loss on long term investment. The unrealized loss on our long term investment in Agenus for the three months ended March 31, 2016 was $3.0 million, based on the change in fair value of Agenus’ common stock during the period.

 

Liquidity and Capital Resources

 

We had net losses from inception in 1991 through 1996 and in 1999 through December 31, 2014. Because of those losses, we had an accumulated deficit of $1.8 billion as of March 31, 2016. We have funded our research and development operations through sales of equity securities, the issuance of convertible notes, cash received from customers, and collaborative arrangements. At March 31, 2016, we had available cash, cash equivalents and marketable securities of $810.7 million. Our cash and marketable securities balances are held in a variety of interest-bearing

44


 

instruments, including money market accounts and corporate debt securities. Available cash is invested in accordance with our investment policy’s primary objectives of liquidity, safety of principal and diversity of investments.

 

Net cash provided by operating activities was $97.5 million for the three months ended March 31, 2016, compared to $4.6 million used in operating activities for the three months ended March 31, 2015.  The $102.1 million increase in cash provided by operating activities was due primarily to changes in working capital during the 2016 period.

 

Our investing activities, other than purchases, sales and maturities of marketable securities, have consisted predominantly of capital expenditures and purchases of long term investments.  Net cash provided by investing activities was $28.8 million for the three months ended March 31, 2016, which represented purchases of marketable securities of $16.8 million, capital expenditures of $5.6 million, offset in part by the sale and maturity of marketable securities of $51.1 million.  Net cash used in investing activities was $58.6 million for the three months ended March 31, 2015, which represented purchases of marketable securities of $34.5 million, capital expenditures of $3.6 million, and our long term investment in Agenus of $39.8 million, offset in part by maturities of marketable securities of $19.3 million.  In the future, net cash used by investing activities may fluctuate significantly from period to period due to the timing of strategic equity investments, acquisitions and capital expenditures and maturities/sales and purchases of marketable securities.

 

Net cash provided by financing activities was $9.9 million and $32.7 million for the three months ended March 31, 2016 and 2015, respectively, primarily representing proceeds from the issuance of common stock under our stock plans and employee stock purchase plan.

 

The following summarizes our significant contractual obligations as of March 31, 2016 and the effect those obligations are expected to have on our liquidity and cash flow in future periods (in millions):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

 

    

Less Than

    

Years

    

Years

    

Over

 

 

    

Total

    

1 Year

    

1 - 3

    

4 - 5

    

5 Years

 

Contractual Obligations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Principal on convertible senior debt

 

$

749.8

 

$

 —

 

$

375.0

 

$

374.8

 

$

 —

 

Interest on convertible senior debt

 

 

27.2

 

 

6.1

 

 

12.1

 

 

9.0

 

 

 —

 

Non-cancelable lease obligations

 

 

95.3

 

 

10.7

 

 

18.8

 

 

12.5

 

 

53.3

 

Total contractual obligations

 

$

872.3

 

$

16.8

 

$

405.9

 

$

396.3

 

$

53.3

 

 

We have entered into and may in the future seek to license additional rights relating to technologies or drug development candidates in connection with our drug discovery and development programs. Under these licenses, we may be required to pay upfront fees, milestone payments, and royalties on sales of future products, which are not reflected in the table above.

 

On August 21, 2015, we entered into an Agreement of Sale with Augustine Land II, L.P. (the “Seller”) to purchase the leased land and office building for approximately $79.9 million. We initially made a $4.0 million deposit with a third party escrow agent and a $4.0 million deposit with the Seller during the third quarter of 2015. The escrow agent held the deposit until the building inspection process was completed, and the escrow agent released the $4.0 million to the Seller in October 2015 as an additional deposit.  As of March 31, 2016, the $8.0 million Seller deposit is recorded in other assets, net on the condensed consolidated balance sheets. The table above does not include the additional payments made to the Seller upon closing of the purchase in April 2016. In addition, the lease obligations that remain as of March 31, 2016 under the now terminated leasing arrangement totaling $77.5 million, set forth in the table above, will no longer be paid.

 

As discussed above under “Overview” and in more detail under Item 5(a) of Part II of this Quarterly Report on Form 10-Q, in May 2016 we entered into a share purchase agreement with ARIAD Pharmaceuticals, Inc. under which we agreed to acquire ARIAD’s European operations for an upfront payment of $140.0 million.

 

We believe that our cash, cash equivalents and marketable securities will be adequate to satisfy our capital needs for at least the next twelve months. Our cash requirements depend on numerous factors, including our expenditures in connection with our drug discovery and development programs and commercialization operations; expenditures in connection with litigation or other legal proceedings; competing technological and market developments; the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; costs for future facility requirements; our receipt of any milestone or other payments under any collaborative agreements we may enter into, including the agreements with Novartis and Lilly; the extent to which commercialization of JAKAFI is successful; expenditures in connection with potential exchanges of our outstanding convertible senior notes; and expenditures in connection with strategic relationships and license agreements, including our agreements with Agenus

45


 

and Hengrui, strategic equity investments or potential acquisitions. Changes in our research and development or commercialization plans or other changes affecting our operating expenses may result in changes in the timing and amount of expenditures of our capital resources.

 

Until we can generate a sufficient amount of product revenues to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations. The sale of equity or additional convertible debt securities in the future may be dilutive to our stockholders, and may provide for rights, preferences or privileges senior to those of our holders of common stock. Debt financing arrangements may require us to pledge certain assets or enter into covenants that could restrict our operations or our ability to incur further indebtedness. We do not know whether additional funding will be available on acceptable terms, if at all. If we are not able to secure additional funding when needed, we may have to scale back our operations, delay or eliminate one or more of our research or development programs, or attempt to obtain funds by entering into an agreement with a collaborator or licensee that would result in terms that are not favorable to us or relinquishing our rights in certain of our proprietary technologies or drug candidates.

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet arrangements other than those that are discussed above.

 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

 

Our investments in marketable securities, which are composed primarily of corporate debt securities, are subject to default, changes in credit rating and changes in market value. These investments are also subject to interest rate risk and will decrease in value if market rate interest rates increase. As of March 31, 2016, marketable securities were $153.1 million. Due to the nature of these investments, if market interest rates were to increase immediately and uniformly by 10% from levels as of March 31, 2016, the decline in fair value would not be material.

 

Item 4.   Controls and Procedures

 

Evaluation of disclosure controls and procedures.  We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

 

Changes in internal control over financial reporting. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) for the three months ended March 31, 2016, that materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

46


 

PART II:     OTHER INFORMATION

 

Item 1A.       Risk Factors

 

RISKS RELATING TO COMMERCIALIZATION OF JAKAFI

 

We depend heavily on our lead product, JAKAFI (ruxolitinib), which is marketed as JAKAVI outside the United States. If we are unable to successfully commercialize JAKAFI in its approved indications or to successfully obtain regulatory approval for and commercialize ruxolitinib for the treatment of additional indications, or if we are significantly delayed or limited in doing so, our business may be materially harmed.

 

JAKAFI is our first and, currently, only product approved for sale in the United States. It was approved by the U.S. Food and Drug Administration, or FDA, in November 2011 for the treatment of patients with intermediate or high‑risk myelofibrosis and in December 2014 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, which we refer to as uncontrolled polycythemia vera. Although we have received regulatory approval for these indications, such approval does not guarantee future revenues. The commercial success of JAKAFI and our ability to generate and maintain revenues from the sale of JAKAFI will depend on a number of factors, including:

 

·

the number of patients with intermediate or high‑risk myelofibrosis or uncontrolled polycythemia vera who are diagnosed with the disease and the number of such patients that may be treated with JAKAFI;

 

·

the acceptance of JAKAFI by patients and the healthcare community;

 

·

whether physicians, patients and healthcare payors view JAKAFI as therapeutically effective and safe relative to cost and any alternative therapies;

 

·

the ability to obtain and maintain sufficient coverage or reimbursement by third‑party payors;

 

·

the ability of our third‑party manufacturers to manufacture JAKAFI in sufficient quantities with acceptable quality;

 

·

the ability of our company and our third‑party providers to provide marketing and distribution support for JAKAFI;

 

·

the label and promotional claims allowed by the FDA;

 

·

the maintenance of regulatory approval for the approved indications in the United States; and

 

·

our ability to develop, obtain regulatory approval for and commercialize ruxolitinib in the United States for additional indications.

 

If we are not successful in commercializing JAKAFI in the United States, or are significantly [delayed or] limited in doing so, our business may be materially harmed and we may need to delay other drug discovery and development initiatives or even significantly curtail operations.

 

In addition, our receipt of royalties under our collaboration agreement with Novartis for sales of JAKAVI outside the United States will depend on factors similar to those listed above for jurisdictions outside the United States.

 

If we are unable to obtain, or maintain at anticipated levels, reimbursement for JAKAFI from government health administration authorities, private health insurers and other organizations, our pricing may be affected or our product sales, results of operations or financial condition could be harmed.

 

We may not be able to sell JAKAFI on a profitable basis or our profitability may be reduced if we are required to sell JAKAFI at lower than anticipated prices or reimbursement is unavailable or limited in scope or amount. JAKAFI is expensive and almost all patients will require some form of third party coverage to afford its cost. Our future revenues and profitability will be adversely affected if we cannot depend on government and other third‑party payors to defray the cost of JAKAFI to the patient. Risks related to pricing and reimbursement are described below under “—Other Risks Relating to our Business— Health care reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our drug candidates. Our ability to generate revenues will be diminished if we are unable to obtain an adequate level of reimbursement from private insurers, government insurance programs or other third party payors of health care costs, which could be affected by recent healthcare reform legislation” If government and other third‑party payors refuse to provide coverage and reimbursement with respect to JAKAFI,

47


 

determine to provide a lower level of coverage and reimbursement than anticipated, or reduce previously approved levels of coverage and reimbursement, then our pricing or reimbursement for JAKAFI may be affected and our product sales, results of operations or financial condition could be harmed.

 

We depend upon a limited number of specialty pharmacies and wholesalers for a significant portion of any revenues from JAKAFI, and the loss of, or significant reduction in sales to, any one of these specialty pharmacies or wholesalers could adversely affect our operations and financial condition.

 

We sell JAKAFI primarily to specialty pharmacies and wholesalers. Specialty pharmacies dispense JAKAFI to patients in fulfillment of prescriptions and wholesalers sell JAKAFI to hospitals and physician offices. We do not promote JAKAFI to specialty pharmacies or wholesalers, and they do not set or determine demand for JAKAFI. Our ability to successfully commercialize JAKAFI will depend, in part, on the extent to which we are able to provide adequate distribution of JAKAFI to patients. Although we have contracted with a number of specialty pharmacies and wholesalers, they are expected generally to carry a very limited inventory and may be reluctant to be part of our distribution network in the future if demand for the product does not increase. Further, it is possible that these specialty pharmacies and wholesalers could decide to change their policies or fees, or both, at some time in the future. This could result in their refusal to carry smaller volume products such as JAKAFI, or lower margins or the need to find alternative methods of distributing our product. Although we believe we can find alternative channels to distribute JAKAFI on relatively short notice, our revenue during that period of time may suffer and we may incur additional costs to replace any such specialty pharmacy or wholesaler. The loss of any large specialty pharmacy or wholesaler as part of our distribution network, a significant reduction in sales we make to specialty pharmacies or wholesalers, or any failure to pay for the products we have shipped to them could materially and adversely affect our results of operations and financial condition.

 

If we are unable to establish and maintain effective sales, marketing and distribution capabilities, or to enter into agreements with third parties to do so, we will not be able to successfully commercialize JAKAFI.

 

Prior to our commercialization of JAKAFI, we had no experience selling and marketing drug products and with pricing and obtaining adequate third‑party reimbursement for drug products. Under our collaboration and license agreement with Novartis, we have retained commercialization rights to JAKAFI in the United States. We have established commercial capabilities in the United States, but cannot guarantee that we will be able to enter into and maintain any marketing, distribution or third‑party logistics agreements with third‑party providers on acceptable terms, if at all. We may not be able to correctly judge the size and experience of the sales and marketing force and the scale of distribution capabilities necessary to successfully market and sell JAKAFI. Establishing and maintaining sales, marketing and distribution capabilities are expensive and time‑consuming. Competition for personnel with experience in sales and marketing can be high. Our expenses associated with building and maintaining the sales force and distribution capabilities may be disproportional compared to the revenues we may be able to generate on sales of JAKAFI.

 

If we fail to comply with applicable laws and regulations, we could lose our approval to market JAKAFI or be subject to other governmental enforcement activity.

 

We cannot guarantee that we will be able to maintain regulatory approval to market JAKAFI in the United States. If we do not maintain our regulatory approval to market JAKAFI, our results of operations will be materially harmed. We and our collaborators, third‑party manufacturers and suppliers are subject to rigorous and extensive regulation by the FDA and other federal and state agencies. These regulations continue to apply after product marketing approval, and cover, among other things, testing, manufacturing, quality control, labeling, advertising, promotion, risk mitigation, and adverse event reporting requirements.

 

Our commercialization of JAKAFI is subject to post‑regulatory approval product surveillance, and JAKAFI may have to be withdrawn from the market or subject to restrictions if previously unknown problems occur. Regulatory agencies may also require additional clinical trials or testing for JAKAFI, and JAKAFI may be recalled or may be subject to reformulation, additional studies, changes in labeling, warnings to the public and negative publicity.

 

Failure to comply with the laws and regulations administered by the FDA or other agencies could result in:

 

·

administrative and judicial sanctions, including warning letters;

 

·

fines and other civil penalties;

 

·

withdrawal of regulatory approval to market JAKAFI;

 

·

interruption of production;

 

48


 

·

operating restrictions;

 

·

product recall or seizure;

 

·

injunctions; and

 

·

criminal prosecution.

 

The occurrence of any such event may have a material adverse effect on our business.

 

If the use of JAKAFI harms patients, or is perceived to harm patients even when such harm is unrelated to JAKAFI, our regulatory approval could be revoked or otherwise negatively impacted or we could be subject to costly and damaging product liability claims.

 

The testing of JAKAFI and the manufacturing, marketing and sale of JAKAFI expose us to product liability and other risks. Side effects and other problems experienced by patients from the use of JAKAFI could:

 

·

lessen the frequency with which physicians decide to prescribe JAKAFI;

 

·

encourage physicians to stop prescribing JAKAFI to their patients who previously had been prescribed JAKAFI;

 

·

cause serious harm to patients that may give rise to product liability claims against us; and

 

·

result in our need to withdraw or recall JAKAFI from the marketplace.

 

If JAKAFI is used by a wide patient population, new risks and side effects may be discovered, the rate of known risks or side effects may increase, and risks previously viewed as less significant could be determined to be significant.

 

Previously unknown risks and adverse effects of JAKAFI may also be discovered in connection with unapproved, or off‑label, uses of JAKAFI. We are prohibited by law from promoting or in any way supporting or encouraging the promotion of JAKAFI for off‑label uses, but physicians are permitted to use products for off‑label purposes. In addition, we are studying and expect to continue to study JAKAFI in diseases for potential additional indications in controlled clinical settings, and independent investigators are doing so as well. In the event of any new risks or adverse effects discovered as new patients are treated for intermediate or high‑risk myelofibrosis or uncontrolled polycythemia vera and as JAKAFI is studied in or used by patients for off‑label indications, regulatory authorities may delay or revoke their approvals, we may be required to conduct additional clinical trials, make changes in labeling of JAKAFI, reformulate JAKAFI or make changes and obtain new approvals. We may also experience a significant drop in the sales of JAKAFI, experience harm to our reputation and the reputation of JAKAFI in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent sales of JAKAFI or substantially increase the costs and expenses of commercializing JAKAFI.

 

Patients who have been enrolled in our clinical trials or who may use JAKAFI in the future often have severe and advanced stages of disease and known as well as unknown significant pre‑existing and potentially life‑threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to JAKAFI. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market JAKAFI, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to JAKAFI, the investigation into the circumstance may be time consuming or inconclusive. These investigations may interrupt our sales efforts, impact and limit the type of regulatory approvals JAKAFI receives or maintains, or delay the regulatory approval process for our collaborator Novartis in other countries.

 

Factors similar to those listed above also apply to our collaboration partner Novartis for jurisdictions outside the United States.

 

If we market JAKAFI in a manner that violates various federal and state health care related laws and regulations, we may be subject to civil or criminal penalties.

 

In addition to FDA and related regulatory requirements, we are subject to health care “fraud and abuse” laws, such as the federal False Claims Act, the anti‑kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. Federal and state anti‑kickback laws prohibit, among other things, knowingly and willfully

49


 

offering, paying, soliciting or receiving remuneration to induce, or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid, or other federally‑ or state‑financed health care programs. Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Pharmaceutical companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities.

 

Although physicians are permitted, based on their medical judgment, to prescribe products for indications other than those approved by the FDA, manufacturers are prohibited from promoting their products for such off‑label uses. We market JAKAFI for intermediate or high‑risk myelofibrosis and uncontrolled polycythemia vera and provide promotional materials to physicians regarding the use of JAKAFI for these indications. Although we believe that our promotional materials for physicians do not constitute off‑label promotion of JAKAFI, the FDA or other agencies may disagree. If the FDA or another agency determines that our promotional materials or other activities constitute off‑label promotion of JAKAFI, it could request that we modify our promotional materials or other activities or subject us to regulatory enforcement actions, including the issuance of a warning letter, injunction, seizure, civil fine and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they believe that the alleged improper promotion led to the submission and payment of claims for an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Even if it is later determined we are not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our position and have to divert significant management resources from other matters.

 

The majority of states also have statutes or regulations similar to the federal anti‑kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. In recent years, several states and localities, including California, Connecticut, the District of Columbia, Massachusetts, Minnesota, Nevada, New Mexico, Texas, Vermont, and West Virginia, have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Similar legislation is being considered in other states. Additionally, as part of the Patient Protection and Affordable Care Act, the federal government has enacted the Physician Payment Sunshine provisions. The Sunshine provisions require manufacturers to publicly report certain payments or other transfers of value made to physicians and teaching hospitals. Many of these requirements are new and uncertain, and the penalties for failure to comply with these requirements are unclear. Nonetheless, if we are found not to be in full compliance with these laws, we could face enforcement action and fines and other penalties, and could receive adverse publicity. See also “—Other Risks Relating to our Business—If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business” below.

 

Competition for JAKAFI could harm our business and result in a decrease in our revenue.

 

Present and potential competitors for JAKAFI could include major pharmaceutical and biotechnology companies, as well as specialty pharmaceutical firms.  For example, Gilead Sciences, Inc. has a drug candidate in Phase III clinical trials for the treatment of myelofibrosis. See “—Other Risks Relating to our Business— We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated” for a description of risks relating to this type of competition.  In addition, JAKAFI could face competition from generic products.  As a result of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the United States, generic manufacturers may seek approval of a generic version of an innovative pharmaceutical by filing with the FDA an Abbreviated New Drug Application, or ANDA.  The Hatch-Waxman Act provides significant incentives to generic manufacturers to challenge U.S. patents on successful innovative pharmaceutical products.  In February 2016, we received a notice letter regarding an ANDA that requested approval to market a generic version of JAKAFI and purported to challenge patents covering ruxolitinib phosphate and its use that expire in 2028. There can be no assurance that our patents will be upheld or that any litigation in which we might engage with any such generic manufacturer would be successful in protecting JAKAFI’s exclusivity.  The entry of a generic version of JAKAFI could result in a decrease in JAKAFI sales and materially harm our business, operating results and financial condition.

 

OTHER RISKS RELATING TO OUR BUSINESS

 

We may be unsuccessful in our efforts to discover and develop drug candidates and commercialize drug products.

 

None of our drug candidates, other than JAKAFI/JAKAVI, has received regulatory approval. Our ability to discover and develop drug candidates and to commercialize additional drug products will depend on our ability to:

 

·

hire and retain key employees;

50


 

 

·

identify high quality therapeutic targets;

 

·

identify potential drug candidates;

 

·

develop products internally or license drug candidates from others;

 

·

identify and enroll suitable human subjects, either in the United States or abroad, for our clinical trials;

 

·

complete laboratory testing;

 

·

commence, conduct and complete safe and effective clinical trials on humans;

 

·

obtain and maintain necessary intellectual property rights to our products;

 

·

obtain and maintain necessary regulatory approvals for our products, both in the United States and abroad;

 

·

enter into arrangements with third parties to provide services or to manufacture our products on our behalf;

 

·

deploy sales and marketing resources effectively or enter into arrangements with third parties to provide these functions in compliance with all applicable laws;

 

·

obtain appropriate coverage and reimbursement levels for the cost of our products from governmental authorities, private health insurers and other third‑party payors;

 

·

lease facilities at reasonable rates to support our growth; and

 

·

enter into arrangements with third parties to license and commercialize our products.

 

We have limited experience with many of the activities listed above and may not be successful in discovering, developing, or commercializing additional drug products. Discovery and development of drug candidates are expensive, uncertain and time‑consuming, and we do not know if our efforts will lead to discovery of any drug candidates that can be successfully developed and marketed. Of the compounds or biologics that we identify as potential drug products or that we may in‑license from other companies, including potential products for which we are conducting clinical trials, only a few, if any, are likely to lead to successful drug development programs and commercialized drug products.

 

We depend heavily on the success of our most advanced drug candidates. We might not be able to commercialize any of our drug candidates successfully, and we may spend significant time and money attempting to do so.

 

We have invested significant resources in the development of our most advanced drug candidates. Ruxolitinib had been in Phase III clinical trials for the treatment of advanced or metastatic pancreatic cancer, as well as in other clinical trials. Epacadostat is expected to commence Phase III clinical trials later in 2016.  Further, we have a number of drug candidates in Phase I and Phase II clinical trials. Our ability to generate product revenues will depend on the successful development and eventual commercialization of our most advanced drug candidates. We, or our collaborators or licensees, may decide to discontinue development of any or all of our drug candidates at any time for commercial, scientific or other reasons.  For example, we have recently decided to discontinue the studies of ruxolitinib in pancreatic cancer and solid tumors and INCB 39110 in pancreatic cancer.  If a product is developed but not approved or marketed, we may have spent significant amounts of time and money on it, which could adversely affect our operating results and financial condition as well as our business plans.

 

If we are unable to obtain regulatory approval for our drug candidates in the United States and foreign jurisdictions, we will not be permitted to commercialize products resulting from our research.

 

In order to commercialize drug products in the United States, our drug candidates will have to obtain regulatory approval from the FDA. Satisfaction of regulatory requirements typically takes many years. To obtain regulatory approval, we must first show that our drug candidates are safe and effective for target indications through preclinical testing (animal testing) and clinical trials (human testing). Preclinical testing and clinical development are long, expensive and uncertain processes, and we do not know whether the FDA will allow us to undertake clinical trials of any drug candidates in addition to our compounds currently in clinical trials. If regulatory approval of a product is granted, this approval will be limited to those disease states and conditions for which the product is demonstrated through clinical trials to be safe and effective.

 

51


 

Completion of clinical trials may take several years and failure may occur at any stage of testing. The length of time required varies substantially according to the type, complexity, novelty and intended use of the drug candidate. Interim results of a preclinical test or clinical trial do not necessarily predict final results, and acceptable results in early clinical trials may not be repeated in later clinical trials. For example, a drug candidate that is successful at the preclinical level may cause harmful or dangerous side effects when tested at the clinical level. Our rate of commencement and completion of clinical trials may be delayed, and our existing clinical trials may be stopped, due to many potential factors, including:

 

·

the high degree of risk and uncertainty associated with drug development;

 

·

our inability to formulate or manufacture sufficient quantities of materials for use in clinical trials;

 

·

variability in the number and types of patients available for each study;

 

·

difficulty in maintaining contact with patients after treatment, resulting in incomplete data;

 

·

unforeseen safety issues or side effects;

 

·

poor or unanticipated effectiveness of drug candidates during the clinical trials; or

 

·

government or regulatory delays.

 

Data obtained from clinical trials are susceptible to varying interpretation, which may delay, limit or prevent regulatory approval. Many companies in the pharmaceutical and biopharmaceutical industry, including our company, have suffered significant setbacks in advanced clinical trials, even after achieving promising results in earlier clinical trials. In addition, regulatory authorities may refuse or delay approval as a result of other factors, such as changes in regulatory policy during the period of product development and regulatory agency review. For example, the FDA has in the past required and could in the future require that we conduct additional trials of any of our drug candidates, which would result in delays.

 

Compounds or biologics developed by us or with or by our collaborators and licensees may not prove to be safe and effective in clinical trials and may not meet all of the applicable regulatory requirements needed to receive marketing approval. For example, in January 2016, a Phase II trial that was evaluating ruxolitinib in combination with regorafenib in patients with relapsed or refractory metastatic colorectal cancer and high C-reactive protein was stopped early after a planned analysis of interim efficacy data determined that the likelihood of the trial meeting its efficacy endpoint was insufficient.  In addition, in February 2016, we made a decision to discontinue our JANUS 1 study, our JANUS 2 study, our other studies of ruxolitinib in colorectal, breast and lung cancer, and our study of INCB39110 in pancreatic cancer after a planned analysis of interim efficacy data of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation. If clinical trials of any of our compounds or biologics are stopped for safety, efficacy or other reasons or fail to meet their respective endpoints, our overall development plans, business, prospects, expected operating results and financial condition could be materially harmed and the value of our company could be negatively affected. 

 

Outside the United States, our ability to market a product is contingent upon receiving a marketing authorization from the appropriate regulatory authorities. This foreign regulatory approval process typically includes all of the risks associated with the FDA approval process described above and may also include additional risks. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country and may require us to perform additional testing and expend additional resources. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA.

 

We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business.

 

We have licensed to Novartis rights to ruxolitinib outside of the United States and worldwide rights to our c‑MET inhibitor compounds and licensed to Lilly worldwide rights to baricitinib. We have also licensed to Pfizer our portfolio of CCR2 antagonist compounds. Under the terms of our agreements with these collaborators, we have no or limited control over the further clinical development of these drug candidates and any revenues we may receive if these drug candidates receive regulatory approval and are commercialized will depend primarily on the development and commercialization efforts of others.

 

52


 

Conflicts may arise with our collaborators and licensees if they pursue alternative technologies or develop alternative products either on their own or in collaboration with others as a means for developing treatments for the diseases that we have targeted. Competing products and product opportunities may lead our collaborators and licensees to withdraw their support for our drug candidates. Any failure of our collaborators and licensees to perform their obligations under our agreements with them or otherwise to support our drug candidates could negatively impact the development of our drug candidates, lead to our loss of potential revenues from product sales and milestones and delay our achievement, if any, of profitability. Additionally, conflicts may arise if, among other things, there is a dispute about the achievement and payment of a milestone amount or the ownership of intellectual property that is developed during the course of a collaborative relationship.

 

Our existing collaborative and license agreements can be terminated by our collaborators and licensees for convenience, among other circumstances. If any of our collaborators or licensees terminates its agreement with us, or terminates its rights with respect to certain indications or drug candidates, we may not be able to find a new collaborator for them, and our business could be adversely affected. Should an agreement be terminated before we have realized the benefits of the collaboration or license, our reputation could be harmed, we may not obtain revenues that we anticipated receiving, and our business could be adversely affected.

 

The success of our drug discovery and development efforts may depend on our ability to find suitable collaborators to fully exploit our capabilities. If we are unable to establish collaborations or if these future collaborations are unsuccessful in the development and commercialization of our drug candidates, our research, development and commercialization efforts may be unsuccessful, which could adversely affect our results of operations and financial condition.

 

An important element of our business strategy is to enter into collaborative or license arrangements with other parties, under which we license our drug candidates to those parties for development and commercialization or under which we study our drug candidates in combination with other parties’ compounds or biologics. For example, in addition to our Novartis, Lilly and Pfizer collaborations, we have entered into clinical study relationships with respect to epacadostat and are evaluating strategic relationships with respect to several of our other programs. However, because collaboration and license arrangements are complex to negotiate, we may not be successful in our attempts to establish these arrangements. Also, we may not have drug candidates that are desirable to other parties, or we may be unwilling to license a drug candidate to a particular party because such party interested in it is a competitor or for other reasons. The terms of any such arrangements that we establish may not be favorable to us. Alternatively, potential collaborators may decide against entering into an agreement with us because of our financial, regulatory or intellectual property position or for scientific, commercial or other reasons. If we are not able to establish collaboration or license arrangements, we may not be able to develop and commercialize a drug product, which could adversely affect our business and our revenues.

 

We will likely not be able to control the amount and timing of resources that our collaborators or licensees devote to our programs or drug candidates. If our collaborators or licensees prove difficult to work with, are less skilled than we originally expected, do not devote adequate resources to the program, pursue alternative technologies or develop alternative products, or do not agree with our approach to development or manufacturing of the drug candidate, the relationship could be unsuccessful. If a business combination involving a collaborator or licensee and a third party were to occur, the effect could be to terminate or cause delays in development of a drug candidate.

 

If we fail to enter into additional licensing agreements or if these arrangements are unsuccessful, our business and operations might be adversely affected.

 

In addition to establishing collaborative or license arrangements under which other parties license our drug candidates for development and commercialization or under which we study our drug candidates in combination with such parties’ compounds or biologics, we may explore opportunities to develop our clinical pipeline by in-licensing drug candidates that fit within our focus on oncology, such as our collaborations with Agenus and Jiangsu Hengrui Medicine Co., Ltd. We may be unable to enter into any additional in-licensing agreements because suitable drug candidates that are within our expertise may not be available to us on terms that are acceptable to us or because competitors with greater resources seek to in-license the same drug candidates. Drug candidates that we would like to develop may not be available to us because they are controlled by competitors who are unwilling to license the rights to the drug candidate to us. In addition, we may enter into license agreements that are unsuccessful and our business and operations might be adversely affected by the termination of a drug candidate and termination and winding down of the related license agreement. We may also need to license drug delivery or other technology in order to continue to develop our drug candidates. If we are unable to enter into additional agreements to license drug candidates, drug delivery technology or other technology or if these arrangements are unsuccessful, our research and development efforts could be adversely affected.

 

53


 

Even if a drug candidate that we develop receives regulatory approval, we may decide not to commercialize it if we determine that commercialization of that product would require more money and time than we are willing to invest.

 

Even if any of our drug candidates receives regulatory approval, it could be subject to post‑regulatory surveillance, and may have to be withdrawn from the market or subject to restrictions if previously unknown problems occur. Regulatory agencies may also require additional clinical trials or testing, and the drug product may be recalled or may be subject to reformulation, additional studies, changes in labeling, warnings to the public and negative publicity. As a result, we may not continue to commercialize a product even though it has obtained regulatory approval. Further, we may decide not to continue to commercialize a product if the market does not accept the product because it is too expensive or because third parties such as insurance companies or Medicare have not approved it for substantial reimbursement. In addition, we may decide not to continue to commercialize a product if competitors develop and commercialize similar or superior products or have proprietary rights that preclude us from ultimately marketing our products.

 

Any approved drug product that we bring to the market may not gain market acceptance by physicians, patients, healthcare payors and others in the medical community.

 

Even if we are successful in gaining regulatory approval of any of our drug candidates in addition to JAKAFI, we may not generate significant product revenues and we may not become profitable if these drug products do not achieve an adequate level of acceptance. Physicians may not recommend our drug products until longer‑term clinical data or other factors demonstrate the safety and efficacy of our drug products as compared to other alternative treatments. Even if the clinical safety and efficacy of our drug products is established, physicians may elect not to prescribe these drug products for a variety of reasons, including the reimbursement policies of government and other third‑party payors and the effectiveness of our competitors in marketing their products.

 

Market acceptance of our drug products, if approved for commercial sale, will depend on a number of factors, including:

 

·

the willingness and ability of patients and the healthcare community to use our drug products;

 

·

the ability to manufacture our drug products in sufficient quantities with acceptable quality and to offer our drug products for sale at competitive prices;

 

·

the perception of patients and the healthcare community, including third‑party payors, regarding the safety, efficacy and benefits of our drug products compared to those of competing products or therapies;

 

·

the label and promotional claims allowed by the FDA;

 

·

the pricing and reimbursement of our drug products relative to existing treatments; and

 

·

marketing and distribution support for our drug products.

 

We have limited capacity to conduct preclinical testing and clinical trials, and our resulting dependence on other parties could result in delays in and additional costs for our drug development efforts.

 

We have limited internal resources and capacity to perform preclinical testing and clinical trials. As part of our development strategy, we often hire clinical research organizations, or CROs, to perform preclinical testing and clinical trials for drug candidates. If the CROs that we hire to perform our preclinical testing and clinical trials do not meet deadlines, do not follow proper procedures, or a conflict arises between us and our CROs, our preclinical testing and clinical trials may take longer than expected, may cost more, may be delayed or may be terminated. If we were forced to find a replacement entity to perform any of our preclinical testing or clinical trials, we may not be able to find a suitable entity on favorable terms, or at all. Even if we were able to find another company to perform a preclinical test or clinical trial, the delay in the test or trial may result in significant additional expenditures. Events such as these may result in delays in our obtaining regulatory approval for our drug candidates or our ability to commercialize our products and could result in increased expenditures that would adversely affect our operating results.

 

We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated.

 

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our drug discovery and development efforts may target diseases and conditions that are already subject to existing therapies or that are being developed by our competitors, many of which have substantially greater resources, larger research and development staffs and facilities, more experience in completing preclinical testing and

54


 

clinical trials, and formulation, marketing and manufacturing capabilities. As a result of these resources, our competitors may develop drug products that render our products obsolete or noncompetitive by developing more effective drugs, developing their products more efficiently or pricing their products more competitively. Our ability to develop competitive products would be limited if our competitors succeeded in obtaining regulatory approvals for drug candidates more rapidly than we were able to or in obtaining patent protection or other intellectual property rights that limited our drug development efforts. Any drug products resulting from our research and development efforts, or from our joint efforts with collaborators or licensees, might not be able to compete successfully with our competitors’ existing and future products, or obtain regulatory approval in the United States or elsewhere. The development of products or processes by our competitors with significant advantages over those that we are developing could harm our future revenues and profitability.

 

Our reliance on other parties to manufacture our drug products and drug candidates could result in a short supply of the drugs, delays in clinical trials or drug development, increased costs, and withdrawal or denial of a regulatory authority’s approval.

 

We do not currently operate manufacturing facilities for clinical or commercial production of JAKAFI and our other drug candidates. We currently hire third parties to manufacture the raw materials, active pharmaceutical ingredient, or API, and finished drug product of JAKAFI and our other drug candidates for clinical trials. In addition, we expect to continue to rely on third parties for the manufacture of commercial supplies of raw materials, API and finished drug product for any drugs that we successfully develop. We also hire third parties to package and label the finished product. The FDA requires that the raw materials, API and finished product for JAKAFI and our other drug candidates be manufactured according to its current Good Manufacturing Practices regulations and regulatory authorities in other countries have similar requirements. There are only a limited number of manufacturers that comply with these requirements. Failure to comply with current Good Manufacturing Practices and the applicable regulatory requirements of other countries in the manufacture of our drug candidates and products could result in the FDA or a foreign regulatory authority halting our clinical trials, withdrawing or denying regulatory approval of our drug product, enforcing product recalls or other enforcement actions, which could have a material adverse effect on our business.

 

We may not be able to obtain sufficient quantities of our drug candidates or any drug products we may develop if our designated manufacturers do not have the capacity or capability to manufacture them according to our schedule and specifications. Manufacturers of pharmaceutical products often encounter difficulties in production, especially in scaling up initial production. These problems include difficulties with production costs and yields, quality control and assurance and shortages of qualified personnel.  In addition, we may not be able to arrange for our drug candidates or any drug products that we may develop to be manufactured by one of these parties on reasonable terms, if at all.  We generally have a single source or a limited number of suppliers that are qualified to supply each of the API and finished product of JAKAFI and our other drug candidates and, in the case of JAKAFI, we only have a single source for its raw materials. If any of these suppliers were to become unable or unwilling to supply us with raw materials, API or finished product that complies with applicable regulatory requirements, we could incur significant delays in our clinical trials or interruption of commercial supply that could have a material adverse effect on our business. If we have promised delivery of a drug candidate or drug product and are unable to meet the delivery requirement due to manufacturing difficulties, our development programs could be delayed, we may have to expend additional sums in order to ensure that manufacturing capacity is available when we need it even if we do not use all of the manufacturing capacity, and our business and operating results could be harmed.

 

We may not be able to adequately manage and oversee the manufacturers we choose, they may not perform as agreed or they may terminate their agreements with us. Foreign manufacturing approval processes typically include all of the risks associated with the FDA approval process for manufacturing and may also include additional risks.

 

Two of our collaborations involve the manufacture of antibodies. Under our collaboration with Agenus, Agenus has primary responsibility for manufacturing activities, including selecting and monitoring third‑party manufacturers. Under our collaboration with Hengrui, Hengrui currently has primary responsibility for manufacturing activities, and we are in the process of transferring manufacturing activities to a third party contract manufacturing organization. Manufacturing antibodies and products containing antibodies is a more complex process than manufacturing small molecule drugs and subject to additional risks. The process of manufacturing antibodies and products containing antibodies is highly susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.

 

55


 

If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.

 

Our activities, and the activities of our collaborators, partners and third‑party providers, are subject to extensive government regulation and oversight both in the United States and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. States increasingly have been placing greater restrictions on the marketing practices of healthcare companies. In addition, pharmaceutical and biotechnology companies have been the target of lawsuits and investigations alleging violations of government regulations, including claims asserting submission of incorrect pricing information, impermissible off‑label promotion of pharmaceutical products, payments intended to influence the referral of federal or state healthcare business, submission of false claims for government reimbursement, antitrust violations, violations of the Foreign Corrupt Practices Act and similar anti‑bribery or anti‑corruption laws, or violations related to environmental matters. Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third‑party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.

 

Health care reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our drug candidates. Our ability to generate revenues will be diminished if we are unable to obtain an adequate level of reimbursement from private insurers, government insurance programs or other third‑party payors of health care costs, which could be affected by recent healthcare reform legislation.

 

Our ability to commercialize our drug candidates successfully will depend in part on the extent to which adequate reimbursement levels for the cost of our products and related treatment are obtained from third‑party payors, such as private insurers, government insurance programs, including Medicare and Medicaid, health maintenance organizations (HMOs) and other health care related organizations.

 

In recent years, through legislative and regulatory actions, the federal government has made substantial changes to various payment systems under the Medicare and other federal health care programs. Comprehensive reforms to the U.S. healthcare system were recently enacted, including changes to the methods for, and amounts of, Medicare reimbursement. These reforms could significantly reduce payments from Medicare and Medicaid. Reforms or other changes to these payment systems, may change the availability, methods and rates of reimbursements from Medicare, private insurers and other third‑party payors for our drug candidates. Some of these changes and proposed changes could result in reduced reimbursement rates, which could reduce the price that we or any of our collaborators or licensees receive for any products, if commercialized, in the future, and which would adversely affect our business strategy, operations and financial results. Further federal and state proposals to regulate prices of pharmaceutical products and other health care reforms are possible, which could limit the prices that can be charged for any of our drug candidates and may further limit the commercial viability of our drug candidates. In certain foreign markets, pricing or profitability of prescription pharmaceuticals is subject to government control. If reimbursement for our products, if commercialized, is unavailable, limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed. There may be future changes that result in reductions in current coverage and reimbursement levels for our drug candidates, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.

 

Third‑party payors are increasingly challenging the prices charged for medical products and services. Also, the trend toward managed health care in the United States, the organizations for which could control or significantly influence the purchase of health care services and products, as well as legislative proposals to reform health care or reduce government insurance programs, may all result in lower prices for or rejection of our products. Adoption of our drug candidates by the medical community may be limited without adequate reimbursement for our products. Cost control initiatives may decrease coverage and payment levels for our drug candidates and, in turn, the price that we will be able to charge for any product, if commercialized. Our drug candidates may not be considered cost‑effective, and coverage and reimbursement may not be available or sufficient to allow us to sell our products on a profitable basis. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payors to our drug candidates.

 

The continuing efforts of third‑party payors to contain or reduce the costs of health care, any denial of private or government payor coverage or inadequate reimbursement for our drug candidates could materially and adversely affect

56


 

our business strategy, operations, future revenues and profitability, and the future revenues and profitability of our potential customers, suppliers, collaborators and licensees and the availability of capital.

 

As our drug discovery and development operations are conducted at our headquarters in Wilmington, Delaware, the loss of access to this facility would negatively impact our business.

 

Our facility in Wilmington, Delaware is our headquarters and is also where we conduct all of our drug discovery, research, development and marketing activities. In addition, natural disasters or actions of activists opposed to aspects of pharmaceutical research may disrupt our experiments or our ability to access or use our facility. The loss of access to or use of our Wilmington, Delaware, facility, either on a temporary or permanent basis would result in an interruption of our business and, consequently, would adversely affect our overall business.

 

We depend on key employees in a competitive market for skilled personnel, and the loss of the services of any of our key employees or our inability to attract and retain additional personnel would affect our ability to expand our drug discovery and development programs and achieve our objectives.

 

We are highly dependent on the members of our executive management team and principal members of our commercial, development, medical, operations and scientific staff. We experience intense competition for qualified personnel. Our future success also depends in part on the continued service of our executive management team and key personnel and our ability to recruit, train and retain essential personnel for our drug discovery and development programs, and for our medical affairs and commercialization activities. If we lose the services of any of these people or if we are unable to recruit sufficient qualified personnel, our research and product development goals, and our commercialization efforts could be delayed or curtailed. We do not maintain “key person” insurance on any of our employees.

 

If we fail to manage our growth effectively, our ability to develop and commercialize products could suffer.

 

We expect that if our drug discovery efforts continue to generate drug candidates, our clinical drug candidates continue to progress in development, and we continue to build our development, medical and commercial organizations, we will require significant additional investment in personnel, management and resources. Our ability to achieve our research, development and commercialization objectives depends on our ability to respond effectively to these demands and expand our internal organization, systems, controls and facilities to accommodate additional anticipated growth. If we are unable to manage our growth effectively, our business could be harmed and our ability to execute our business strategy could suffer.

 

We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management’s attention and harm our operating results and prospects.

 

As part of our business strategy, we may pursue additional acquisitions of what we believe to be complementary businesses or assets or seek to enter into joint ventures. We also may pursue strategic alliances in an effort to leverage our existing infrastructure and industry experience to expand our product offerings or distribution, or make investments in other companies. For example, in May 2016, we agreed to acquire the European operations of ARIAD Pharmaceuticals, Inc. and to license European rights to its drug product Iclusig. The success of our acquisitions, joint ventures, strategic alliances and investments will depend on our ability to identify, negotiate, complete and, in the case of acquisitions, integrate those transactions and, if necessary, obtain satisfactory debt or equity financing to fund those transactions.  We may not realize the anticipated benefits of any acquisition, joint venture, strategic alliance or investment. We may not be able to integrate acquisitions successfully into our existing business, maintain the key business relationships of businesses we acquire, or retain key personnel of an acquired business, and we could assume unknown or contingent liabilities or incur unanticipated expenses. Integration of acquired companies or businesses also may require management resources that otherwise would be available for ongoing development of our existing business.  Any acquisitions or investments made by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. For example, we have in the year ended December 31, 2015 and the quarter ended March 31, 2016 recorded unrealized losses related to our investment in Agenus Inc., and we may in the future experience additional losses related to our investments.  In addition, if we choose to issue shares of our stock as consideration for any acquisition, dilution to our stockholders could result.

 

57


 

Risks associated with expanding our operations to Europe could adversely affect our business.

 

We plan to continue to expand our operations and conduct certain development activities in Europe. We have limited experience with conducting activities outside of the United States. International operations and business expansion plans are subject to numerous additional risks, including:

 

·

multiple, conflicting and changing laws and regulations such as tax laws, privacy regulations, export and import restrictions, employment, immigration and labor laws, regulatory requirements, and other governmental approvals, permits and licenses;

 

·

difficulties in staffing and managing foreign operations;

 

·

risks associated with obtaining and maintaining, or the failure to obtain or maintain, regulatory approvals for the sale or use of our products in various countries;

 

·

complexities associated with managing government payor systems, multiple payor‑reimbursement regimes or patient self‑pay systems;

 

·

financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable and exposure to foreign currency exchange rate fluctuations;

 

·

general political and economic conditions in the countries in operate, including terrorism and political unrest, curtailment of trade and other business restrictions;

 

·

regulatory and compliance risks that relate to maintaining accurate information and control over activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions or its anti‑bribery provisions, or similar anti‑bribery or anti‑corruption laws and regulations;

 

Any of these risks, if encountered, could significantly increase our costs of operating internationally, prevent us from operating in certain jurisdictions, or otherwise significantly harm our future international expansion and operations, which could have a material adverse effect on our business, financial condition and results of operations.

 

If product liability lawsuits are brought against us, we could face substantial liabilities and may be required to limit commercialization of our products and our results of operations could be harmed.

 

In addition to the risks described above under “—Risks Relating to Our Lead Product JAKAFI—If the use of JAKAFI harms patients, or is perceived to harm patients even when such harm is unrelated to JAKAFI, our regulatory approval could be revoked or otherwise negatively impacted or we could be subject to costly and damaging product liability claims,” the conduct of clinical trials of medical products that are intended for human use entails an inherent risk of product liability. If any product that we or any of our collaborators or licensees develops causes or is alleged to cause injury during clinical trials or commercialization, we may be held liable. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities, including substantial damages to be paid to the plaintiffs and legal costs, or we may be required to limit further development and commercialization of our products. Additionally, any product liability lawsuit could cause injury to our reputation, participants and investigators to withdraw from clinical trials, and potential collaborators or licensees to seek other partners, any of which could impact our results of operations.

 

Our product liability insurance policy may not fully cover our potential liabilities. In addition, we may determine that we should increase our coverage, and this insurance may be prohibitively expensive to us or our collaborators or licensees and may not fully cover our potential liabilities. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the development or commercialization of our drug candidates and products.

 

Because our activities involve the use of hazardous materials, we may be subject to claims relating to improper handling, storage or disposal of these materials that could be time consuming and costly.

 

We are subject to various environmental, health and safety laws and regulations governing, among other things, the use, handling, storage and disposal of regulated substances and the health and safety of our employees. Our research and development processes involve the controlled use of hazardous and radioactive materials and biological waste resulting in the production of hazardous waste products. We cannot completely eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. If any injury or contamination results from our use or the use by our collaborators or licensees of these materials, we may be sued and our liability may exceed our insurance coverage and our total assets. Further, we may be required to indemnify our collaborators or licensees against

58


 

all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations or licenses. Compliance with the applicable environmental and workplace laws and regulations is expensive. Future changes to environmental, health, workplace and safety laws could cause us to incur additional expense or may restrict our operations or impair our research, development and production efforts.

 

RISKS RELATING TO OUR FINANCIAL RESULTS

 

We expect to incur losses in the future and we may not achieve or maintain profitability in the future.

 

We had net losses from inception in 1991 through 1996 and in 1999 through December 31, 2014. Because of those losses, we had an accumulated deficit of $1.8 billion as of March 31, 2016. We intend to continue to spend significant amounts on our efforts to discover and develop drugs. As a result, we could continue to incur losses in 2016 and in future periods as well.

 

We anticipate that our drug discovery and development efforts and related expenditures will increase as we focus on the studies, including preclinical tests and clinical trials prior to seeking regulatory approval, that are required before we can sell a drug product.

 

The development of drug products will require us to spend significant funds on research, development, testing, obtaining regulatory approvals, manufacturing and marketing. To date, we do not have any drug products that have generated significant revenues other than from sales of JAKAFI and we cannot assure you that we will generate significant revenues from the drug candidates that we license or develop, including JAKAFI, for several years, if ever.

 

We cannot be certain whether or when we will achieve profitability because of the significant uncertainties relating to our ability to generate commercially successful drug products. Even if we are successful in obtaining regulatory approvals for manufacturing and commercializing drug products in addition to JAKAFI, we expect that we will continue to incur losses if our drug products do not generate significant revenues. If we achieve profitability, we may not be able to sustain or increase profitability.

 

We may need additional capital in the future. If we are unable to generate sufficient funds from operations, the capital markets may not permit us to raise additional capital at the time that we require it, which could result in limitations on our research and development or commercialization efforts or the loss of certain of our rights in our technologies or drug candidates.

 

Our future funding requirements will depend on many factors and we anticipate that we may need to raise additional capital to fund our business plan and research and development efforts going‑forward and to repay our indebtedness.

 

Additional factors that may affect our future funding requirements include:

 

·

the amount of revenues generated from our business activities;

 

·

any changes in the breadth of our research and development programs;

 

·

the results of research and development, preclinical testing and clinical trials conducted by us or our current or future collaborators or licensees, if any;

 

·

our exercise of any co‑development options with collaborators that may require us to fund future development;

 

·

the acquisition of businesses, technologies, or drug candidates, or the licensing of technologies or drug candidates, if any;

 

·

costs for future facility requirements;

 

·

our ability to maintain and establish new corporate relationships and research collaborations;

 

·

competing technological and market developments;

 

·

the time and costs involved in filing, prosecuting, defending and enforcing patent and intellectual property claims;

 

59


 

·

the receipt of contingent licensing or milestone fees or royalties on product sales from our current or future collaborative and license arrangements, if established; and

 

·

the timing of regulatory approvals, if any.

 

If we require additional capital at a time when investment in companies such as ours, or in the marketplace generally, is limited due to the then prevailing market or other conditions, we may have to scale back our operations, eliminate one or more of our research or development programs, or attempt to obtain funds by entering into an agreement with a collaborator or licensee that would result in terms that are not favorable to us or relinquishing our rights in certain of our proprietary technologies or drug candidates. If we are unable to raise funds at the time that we desire or at any time thereafter on acceptable terms, we may not be able to continue to develop our drug candidates. The sale of equity or additional convertible debt securities in the future may be dilutive to our stockholders, and debt financing arrangements may require us to pledge certain assets or enter into covenants that could restrict our operations or our ability to incur further indebtedness.

 

We have a large amount of debt and our debt service obligations may prevent us from taking actions that we would otherwise consider to be in our best interests.

 

As of March 31, 2016, the aggregate principal amount of our total consolidated debt was $749.8 million and our stockholders’ equity was $227.7 million. Our substantial leverage could have significant negative consequences for our future operations, including:

 

·

increasing our vulnerability to general adverse economic and industry conditions;

 

·

limiting our ability to obtain additional financing for working capital, capital and research and development expenditures, and general corporate purposes;

 

·

requiring the dedication of a substantial portion of our expected cash flow or our existing cash to service our indebtedness, thereby reducing the amount of our cash available for other purposes, including working capital, capital expenditures and research and development expenditures;

 

·

limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; or

 

·

placing us at a possible competitive disadvantage compared to less leveraged competitors and competitors that have better access to capital resources.

 

We may not generate sufficient cash flow from our operations in the future to enable us to meet our anticipated fixed charges, including our obligations with respect to our outstanding convertible senior notes. As of March 31, 2016, $375.0 million aggregate principal amount of our 0.375% convertible senior notes due 2018 was outstanding and due in November 2018. Annual interest payments for our 0.375% convertible senior notes through 2018, assuming that none of these notes are converted, repurchased or exchanged, are $1.4 million. As of March 31, 2016, $374.8 million aggregate principal amount of our 1.25% convertible senior notes due 2020 was outstanding and due in November 2020. Annual interest payments for our 1.25% convertible senior notes through 2020, assuming that none of these notes are converted, repurchased or exchanged, are $4.7 million. If we are unable to generate cash from our operations or raise additional cash through financings sufficient to meet the remaining obligations under our convertible senior notes, we will need to use existing cash or liquidate marketable securities in order to fund these obligations, which may delay or curtail our research, development and commercialization programs.

 

Our marketable securities and long term investments are subject to risks that could adversely affect our overall financial position.

 

We invest our cash in accordance with an established internal policy and customarily in instruments, corporate bonds and money market funds which historically have been highly liquid and carried relatively low risk. In recent periods, similar types of investments and money market funds have experienced losses in value or liquidity issues that differ from their historical pattern.

 

Should a portion of our cash or marketable securities lose value or have their liquidity impaired, it could adversely affect our overall financial position by imperiling our ability to fund our operations and forcing us to seek additional financing sooner than we would otherwise. Such financing, if available, may not be available on commercially attractive terms.

 

60


 

Any loss in value of our long term investments could adversely affect our financial position on the consolidated balance sheets and consolidated statements of operations.

 

Our current revenues are derived from JAKAFI product sales, JAKAVI product royalties, collaborations and from licensing our intellectual property. If we are unable to achieve milestones, develop products or renew or enter into new collaborations, our revenues may decrease, and future milestone and royalty payments may not contribute significantly to revenues for several years, and may never result in revenues.

 

We derived substantially all of our revenues for the three months ended March 31, 2016 from JAKAFI product revenues, JAKAVI product royalties and our collaborations and licensing our intellectual property to others. Future revenues from research and development collaborations depend upon continuation of the collaborations, the achievement of milestones and royalties we earn from any future products developed from our research. If we are unable to successfully achieve milestones or our collaborators fail to develop successful products, we will not earn the future revenues contemplated under our collaborative agreements.

 

RISKS RELATING TO INTELLECTUAL PROPERTY AND LEGAL MATTERS

 

If we are subject to arbitration, litigation and infringement claims, they could be costly and disrupt our drug discovery and development efforts.

 

The technology that we use to make and develop our drug products, the technology that we incorporate in our products, and the products we are developing may be subject to claims that they infringe the patents or proprietary rights of others. The success of our drug discovery and development efforts will also depend on our ability to develop new compounds, drugs and technologies without infringing or misappropriating the proprietary rights of others. We are aware of patents and patent applications filed in certain countries claiming intellectual property relating to some of our drug discovery targets and drug candidates. While the validity of issued patents, patentability of pending patent applications and applicability of any of them to our programs are uncertain, if any of these patents are asserted against us or if we choose to license any of these patents, our ability to commercialize our products could be harmed or the potential return to us from any product that may be successfully commercialized could be diminished.

 

From time to time we have received, and we may in the future receive, notices from third parties offering licenses to technology or alleging patent, trademark, or copyright infringement, claims regarding trade secrets or other contract claims. Receipt of these notices could result in significant costs as a result of the diversion of the attention of management from our drug discovery and development efforts. Parties sending these notices may have brought and in the future may bring litigation against us or seek arbitration relating to contract claims.

 

We may be involved in future lawsuits or other legal proceedings alleging patent infringement or other intellectual property rights or contract violations. In addition, litigation or other legal proceedings may be necessary to:

 

·

assert claims of infringement;

 

·

enforce our patents or trademarks;

 

·

protect our trade secrets or know‑how; or

 

·

determine the enforceability, scope and validity of the proprietary rights of others.

 

We may be unsuccessful in defending or pursuing these lawsuits, claims or other legal proceedings. Regardless of the outcome, litigation or other legal proceedings can be very costly and can divert management’s efforts. An adverse determination may subject us to significant liabilities or require us or our collaborators or licensees to seek licenses to other parties’ patents or proprietary rights. We or our collaborators or licensees may also be restricted or prevented from manufacturing or selling a drug or other product that we or they develop. Further, we or our future collaborators or licensees may not be able to obtain any necessary licenses on acceptable terms, if at all. If we are unable to develop non‑infringing technology or license technology on a timely basis or on reasonable terms, our business could be harmed.

 

We may be unable to adequately protect or enforce our proprietary information, which may result in its unauthorized use, a loss of revenue under a collaboration agreement or loss of sales to generic versions of our products or otherwise reduce our ability to compete in developing and commercializing products.

 

Our business and competitive position depends in significant part upon our ability to protect our proprietary technology, including any drug products that we create. Despite our efforts to protect this information, unauthorized parties may attempt to obtain and use information that we regard as proprietary. For example, one of our collaborators may disclose proprietary information pertaining to our drug discovery efforts. In addition, while we have filed numerous

61


 

patent applications with respect to ruxolitinib and our drug candidates in the United States and in foreign countries, our patent applications may fail to result in issued patents. In addition, because patent applications can take several years to issue as patents, there may be pending patent applications of others that may later issue as patents that cover some aspect of ruxolitinib and our drug candidates. Our existing patents and any future patents we may obtain may not be broad enough to protect our products or all of the potential uses of our products, or otherwise prevent others from developing competing products or technologies. In addition, our patents may be challenged and invalidated or may fail to provide us with any competitive advantages if, for example, others were first to invent or first to file a patent application for the technologies and products covered by our patents.  As noted above under “—Risks Relating to Commercialization of JAKAFI—Competition for JAKAFI could potentially harm our business and result in a decrease in our revenue,” a potential generic drug company competitor has challenged certain patents relating to JAKAFI.

 

Additionally, when we do not control the prosecution, maintenance and enforcement of certain important intellectual property, such as a drug candidate in‑licensed to us or subject to a collaboration with a third party, the protection of the intellectual property rights may not be in our hands. If we do not control the intellectual property rights in‑licensed to us with respect to a drug candidate and the entity that controls the intellectual property rights does not adequately protect those rights, our rights may be impaired, which may impact our ability to develop, market and commercialize the in‑licensed drug candidate.

 

Our means of protecting our proprietary rights may not be adequate, and our competitors may:

 

·

independently develop substantially equivalent proprietary information, products and techniques;

 

·

otherwise gain access to our proprietary information; or

 

·

design around patents issued to us or our other intellectual property.

 

We pursue a policy of having our employees, consultants and advisors execute proprietary information and invention agreements when they begin working for us. However, these agreements may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure. If we fail to maintain trade secret and patent protection, our potential, future revenues may be decreased.

 

If the effective term of our patents is decreased due to changes in the United States patent laws or if we need to refile some of our patent applications, the value of our patent portfolio and the revenues we derive from it may be decreased.

 

The value of our patents depends in part on their duration. A shorter period of patent protection could lessen the value of our rights under any patents that we obtain and may decrease the revenues we derive from our patents. The United States patent laws were amended in 1995 to change the term of patent protection from 17 years from patent issuance to 20 years from the earliest effective filing date of the application. Because the time from filing to issuance of biotechnology applications may be more than three years depending on the subject matter, a 20‑year patent term from the filing date may result in substantially shorter patent protection.

 

Additionally, United States patent laws were amended in 2011 with the enactment of the America Invents Act and third parties are now able to challenge the validity of issued U.S. patents through various review proceedings; thus rendering the validity of U.S. patents more uncertain. We may be obligated to participate in review proceedings to determine the validity of our U.S. patents. We cannot predict the ultimate outcome of these proceedings, the conduct of which could result in substantial costs and diversion of our efforts and resources. If we are unsuccessful in these proceedings some or all of our claims in the patents may be narrowed or invalidated and the patent protection for our products and drug candidates in the United States could be substantially shortened. Further, if all of the patents covering one of our products are invalidated, the FDA could approve requests to manufacture a generic version of that product prior to the expiration date of those patents.

 

Other changes in the United States patent laws or changes in the interpretation of patent laws could diminish the value of our patents or narrow the scope of our patent protection. For example, the Supreme Court of the United States recently ruled that isolated DNA sequences cannot be patented. Although we no longer receive significant revenues generated from our former information products business, the majority of our gene patent portfolio from that business consists of patents on isolated DNA sequences, and this ruling limits our ability to derive additional revenues from our gene patent portfolio. Additionally, the Supreme Court recently resolved a split among the circuit courts of appeals regarding antitrust challenges to settlements of patent infringement lawsuits under the Hatch‑Waxman Act between brand‑name drug companies and generic drug companies. The Court rejected the “scope of the patent” test and ruled that settlements involving “reverse payments” from brand‑name drug companies to generic drug companies should be analyzed under the rule of reason. This ruling may create uncertainty and make it more difficult to settle patent litigation

62


 

if a company seeking to manufacture a generic version of one of our products challenges the patents covering that product prior to the expiration date of those patents.

 

International patent protection is particularly uncertain and costly, and our involvement in opposition proceedings in foreign countries may result in the expenditure of substantial sums and management resources.

 

Biotechnology and pharmaceutical patent law outside the United States is even more uncertain and costly than in the United States and is currently undergoing review and revision in many countries. Further, the laws of some foreign countries may not protect our intellectual property rights to the same extent as United States laws. For example, certain countries do not grant patent claims that are directed to the treatment of humans. We have participated, and may in the future participate, in opposition proceedings to determine the validity of our foreign patents or our competitors’ foreign patents, which could result in substantial costs and diversion of our efforts. For example, there is a patent opposition proceeding in India against our Indian patent that covers the composition of matter and use of certain Janus Kinase inhibitors, including ruxolitinib phosphate, for the treatment of myeloid proliferative disorders, cancer, immune‑related diseases, skin disorders, and other diseases. Successful challenges to our patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and allow third parties to use our proprietary technologies without a license from us or our collaborators, which may also result in loss of future royalty payments. In addition, successful challenges may jeopardize or delay our ability to enter into new collaborations or commercialize potential products, which could harm our business and results of operations.

 

RISKS RELATING TO INFORMATION TECHNOLOGY

 

Significant disruptions of information technology systems or breaches of data security could adversely affect our business.

 

Our business is increasingly dependent on critical, complex, and interdependent information technology (IT) systems, including Internet-based systems, to support business processes as well as internal and external communications. The size and complexity of our IT systems make us potentially vulnerable to IT system breakdowns, malicious intrusion, and computer viruses, which may result in the impairment of our ability to operate our business effectively.

 

In addition, our systems are potentially vulnerable to data security breaches–whether by employees or others–which may expose sensitive data to unauthorized persons. Such data security breaches could lead to the loss of trade secrets or other intellectual property, or could lead to the public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, customers, business partners and others.

 

Any such disruption or security breach could result in legal proceedings, liability under laws that protect the privacy of personal information, regulatory penalties, disruptions to our operations and collaborations, and damage to our reputation, which could harm our business and results of operations.

 

Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.

 

We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.

 

Item 5.   Other Information

 

(a)On May 9, 2016, Incyte Corporation, as guarantor, our wholly-owned subsidiary Incyte Europe S.a.r.l. (“Incyte Europe”), as purchaser, ARIAD Pharmaceuticals (Cayman) L.P., as seller, and ARIAD Pharmaceuticals, Inc. (“ARIAD”), as guarantor, entered into a Share Purchase Agreement (the “Share Purchase Agreement”) pursuant to which Incyte Europe will acquire all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.a.r.l., the parent company of ARIAD’s European subsidiaries responsible for the development and commercialization of Iclusig® (ponatinib) in the European Union (“EU”) and 22 other countries, including Switzerland, Norway, Turkey, Israel and Russia (the “Territory”), for an upfront payment of $140 million, subject to customary working capital adjustments (the “Upfront Payment”). Iclusig is approved in Europe for the treatment of patients with chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia who are resistant to or intolerant of certain second generation BCR-

63


 

ABL inhibitors and all patients who have the T3151 mutation. We expect to fund the Upfront Payment using available cash on hand. The closing under the Share Purchase Agreement is subject to customary conditions.  Under the Share Purchase Agreement, and subject to certain limitations and exceptions, each party has also agreed to indemnify the other for breaches of representations and warranties and certain other matters to a maximum amount of 10% of the Upfront Payment. The Share Purchase Agreement also includes a standstill provision restricting our ability for a specified period of time to acquire shares of ARIAD’s common stock above a certain percentage or take certain other actions without ARIAD board approval, subject to certain customary exceptions.

 

In connection with the transactions contemplated under the Share Purchase Agreement, the parties have also agreed upon the terms of an Amended and Restated Buy-in License Agreement to be entered into by ARIAD, ARIAD Pharmaceuticals (Europe) S.a.r.l., one of the entities that will be owned by Incyte Europe upon the closing of the Share Purchase Agreement, and Incyte Corporation, as guarantor (the “License Agreement”).  Under the terms of the License Agreement, we will be granted an exclusive license to develop and commercialize Iclusig in the Territory.  ARIAD will be eligible to receive from us tiered royalties of between 32% and 50% on net sales of Iclusig in the Territory. The royalties will be subject to reduction for certain events related to exclusivity and, if necessary, any third-party patent rights.  In addition, ARIAD will be eligible to receive up to $135 million in potential future oncology development and regulatory approval milestone payments for Iclusig in the Territory (the “Milestones”).  We will also be co-funding a portion of the ongoing Iclusig clinical studies OPTIC and OPTIC 2L, which are being conducted by ARIAD, by paying up to $7 million in both 2016 and 2017 (the “Development Costs”). 

 

The terms of the License Agreement also include a limited option for a potential future acquirer of ARIAD to purchase the European development and commercialization rights to Iclusig from us. Under these purchase terms, we would retain all EU infrastructure and be financially compensated.  Our financial compensation would include the repayment of the Upfront Payment and any Milestone or Development Costs payments made by us to ARIAD and an additional payment based upon the last 12 months of Iclusig sales booked by us. We would also be eligible to receive royalties of between 20% to 25% from an ARIAD acquirer on future sales of Iclusig in the EU. The buy-back provision cannot be exercised before two years nor after the sixth year from the effective date of the License Agreement. Following exercise of the buy-back provision, there is a further transition period of up to one year before the provision can be made effective.

 

Unless terminated earlier in accordance with its provisions, our obligations to pay full royalties under the License Agreement will continue to be in effect on a country-by-country basis until the latest to occur of (1) the expiration date of the composition patent in the relevant country, (2) the expiration of any regulatory marketing exclusivity period or other statutory designation that provides similar exclusivity for the commercialization of Iclusig in such country and (3) the seventh anniversary of the first commercial sale of Iclusig in such country.  We will be obligated to pay royalties at a reduced rate for a specified period of time following such full royalty term. The License Agreement may be terminated in its entirety by us for convenience after a certain prescribed period of time.  The License Agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the License Agreement.

 

The closing under the Share Purchase Agreement and effectiveness of the License Agreement is expected to occur on June 1, 2016, pending satisfaction of customary closing conditions.  The closing and effectiveness are not subject to any antitrust waiting periods or notice periods.

 

The foregoing descriptions of the Share Purchase Agreement and the License Agreement do not purport to be complete and are qualified in their entirety by reference to the full agreements, which we expect to file as exhibits to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2016.

 

 

 

64


 

 

Item 6.  Exhibits

 

 

 

 

Exhibit
Number

 

Description of Document

 

 

 

10.1

 

Third Amendment, entered into effective March 31, 2016, to License, Development and Commercialization Agreement entered into as of December 18, 2009, by and between the Company and Eli Lilly and Company

 

 

 

31.1

 

Rule 13a-14(a) Certification of Chief Executive Officer

 

 

 

31.2

 

Rule 13a-14(a) Certification of Chief Financial Officer

 

 

 

32.1*

 

Statement of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

 

 

 

32.2*

 

Statement of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Presentation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Definition Linkbase Document

 


*    In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.

 

Confidential treatment has been requested with respect to certain portions of this agreement.

 

 

65


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

INCYTE CORPORATION

 

 

 

Dated: May 9, 2016

By:

/s/ HERVÉ HOPPENOT

 

 

Hervé Hoppenot

 

 

Chairman, President, and Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

Dated: May 9, 2016

By:

/s/ DAVID W. GRYSKA

 

 

David W. Gryska

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

66


 

INCYTE CORPORATION

 

EXHIBIT INDEX

 

 

 

 

Exhibit
Number

 

Description of Document

 

 

 

10.1

 

Third Amendment, entered into effective March 31, 2016, to License, Development and Commercialization Agreement entered into as of December 18, 2009, by and between the Company and Eli Lilly and Company

 

 

 

31.1

 

Rule 13a-14(a) Certification of Chief Executive Officer

 

 

 

31.2

 

Rule 13a-14(a) Certification of Chief Financial Officer

 

 

 

32.1*

 

Statement of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

 

 

 

32.2*

 

Statement of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Presentation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Definition Linkbase Document

 


*    In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.

 

Confidential treatment has been requested with respect to certain portions of this agreement.

67


EX-10.1 2 incy-20160331ex101940ba3.htm EX-10.1 incy_Ex_10_1

Exhibit 10.1

CONFIDENTIAL TREATMENT MATERIAL

 

CONFIDENTIAL TREATMENT REQUESTED:  Information for which confidential treatment has been requested is omitted and is noted with asterisks.  An unredacted version of this document has been filed separately with the Securities and Exchange Commission (the “Commission”).

 

THIRD AMENDMENT

 

This Third Amendment (“Third Amendment”) is entered into effective March 31, 2016 (the “Third Amendment Effective Date”) by and between Incyte Corporation (“Incyte”), a Delaware corporation having an office at 1801 Augustine Cut-off, Wilmington, DE 19803, and Eli Lilly and Company (“Lilly”), an Indiana corporation having an office at Lilly Corporate Center, Indianapolis, IN 46285.

RECITALS

A.

Incyte and Lilly are parties to (i) a License, Development and Commercialization Agreement, effective December 18, 2009, (ii) an Amendment, effective June 22, 2010, and (iii) a Second Amendment, effective August 1, 2011, pursuant to which Incyte has granted Lilly an exclusive License to develop and commercialize Licensed Compounds and Licensed Products in the Field (such Agreement, as so amended, the “Agreement”).

 

B.

The Parties now desire to further amend the Agreement by excluding Ruxolitinib (as defined below) for use in the Graft-Versus-Host Disease Field (as defined below) from the prohibition in Section 2.6 against Incyte Developing or Commercializing JAK2 Inhibitor Compounds in the Field in exchange for certain payments by Incyte and the waiver by Incyte of its Co-Promotion Option.

 

C.

Unless otherwise defined herein, all capitalized terms appearing in this Third Amendment shall have the meaning set forth in the Agreement.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

1.

“Graft-Versus-Host Disease Field” means the treatment, control, management, mitigation, prevention or cure of all graft-versus-host disease Indications as defined in subsections 279.50 through 279.53 of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) as set forth in Exhibit A to this Third Amendment. [**]

 

2.

“Ruxolitinib” means Incyte’s proprietary JAK2 Inhibitor known as ruxolitinib.

 

3.

Section 2.6(a) (LICENSES; Non-Compete) and Section 2.6(b) (LICENSES; Non-Compete) of the Agreement shall not apply to Development or Commercialization of Ruxolitinib by Incyte, its Affiliates, licensees or sublicensees for use in the Graft-Versus-Host Disease Field.

 


 

Exhibit 10.1

CONFIDENTIAL TREATMENT MATERIAL

 

4.

Incyte shall pay to Lilly the following payments:

 

a.

A one-time, non-creditable, non-refundable payment of $35,000,000 within [**];  

 

b.

A one-time, non-creditable, non-refundable milestone payment of [**]; and

 

c.

A one-time, non-creditable, non-refundable milestone payment of [**].

 

5.

In no event may Lilly hold back any amount of any triggered and owing Lilly milestone or royalty payment under the Agreement as an escrow or otherwise in anticipation of any of the payments due and owing or to become due and owing from Incyte under this Third Amendment.  Similarly, in no event may Incyte hold back any amount of any triggered and owing Incyte upfront or milestone payment under this Third Amendment as an escrow or otherwise in anticipation of any of the payments due and owing or to become due and owing from Lilly under the Agreement. 

 

6.

For clarity, the Parties acknowledge that the Graft-Versus-Host Disease Field is within the Inflammatory Disease Field and the Licensed Field, and that this Third Amendment does not alter this fact or restrict Lilly from Development or Commercialization of any Licensed Compound for use in the Graft-Versus-Host Disease Field.

 

7.

Section 5.4 (COMMERCIALIZATION; Co-Promotion) of the Agreement is hereby deleted and replaced in its entirety with “[RESERVED]”.  The Table of Contents of the Agreement is hereby appropriately revised to reflect such deletion, the reference to “Co-Promotion Option” in the “Additional Definitions” section of the Agreement is deleted, and Section 2.6(g)(iii) (LICENSES; Non-Compete) (relating to termination of the Co-Promotion Option) of the Agreement is hereby deleted.

 

8.

The provision for notices to Incyte in Section 13.5 of the Agreement is hereby amended and restated to read in its entirety as follows:

 

“Notices to Incyte shall be addressed to:

 

Incyte Corporation

1801 Augustine Cut-Off

Wilmington, DE 19803

Attn: President and CEO

Facsimile No.: [**]

 

With a copy to:

 

Incyte Corporation

1801 Augustine Cut-Off

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 


 

Exhibit 10.1

CONFIDENTIAL TREATMENT MATERIAL

 

Wilmington, DE 19803

Attn: General Counsel

Facsimile No.: [**]”

 

9.

All other terms and conditions of the Agreement shall remain in full force and effect.

 

10.

Any disputes regarding this Third Amendment shall be dealt with in accordance the provisions of ARTICLE XII (Dispute Resolution) of the Agreement.  The provisions of ARTICLE XIII (Miscellaneous) of the Agreement shall apply to this Third Amendment as if repeated herein.

 

[remainder of page intentionally left blank]

 

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 


 

Exhibit 10.1

CONFIDENTIAL TREATMENT MATERIAL

 

IN WITNESS WHEREOF, the parties by their respective authorized representatives have executed this Third Amendment as of the Effective Date.

 

 

ELI LILLY AND COMPANY

 

 

By:/s/ David A. Ricks

Name: David A. Ricks

Title: President, Lilly Bio-Medicines

INCYTE CORPORATION

 

 

By:/s/ Hervé Hoppenot 

Name: Hervé Hoppenot

Title: President and Chief Executive Officer

 

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 


 

Exhibit 10.1

CONFIDENTIAL TREATMENT MATERIAL

 

Exhibit A

 

Graft-Versus-Host Disease Field (ICD-9-CM)

 

279.50 Graft-versus-host disease, unspecified (including prophylaxis of Graft-versus-host disease)

279.51 Acute graft-versus-host disease

279.52 Chronic graft-versus-host disease

279.53 Acute on chronic graft-versus-host disease

 

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 


EX-31.1 3 incy-20160331ex3112dcdd4.htm EX-31.1 incy_Ex_31_1

Exhibit 31.1

 

CERTIFICATION

 

I, Hervé Hoppenot, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Incyte Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 9, 2016

 

 

 

 

/s/ HERVÉ HOPPENOT

 

 

 

Hervé Hoppenot

 

Chief Executive Officer

 

 


EX-31.2 4 incy-20160331ex31206fff9.htm EX-31.2 incy_Ex_31_2

Exhibit 31.2

 

CERTIFICATION

 

I, David W. Gryska, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Incyte Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 9, 2016

 

 

/s/ DAVID W. GRYSKA

 

 

 

David W. Gryska

 

Chief Financial Officer

 

 


EX-32.1 5 incy-20160331ex3214c29bd.htm EX-32.1 incy_Ex_32_1

Exhibit 32.1

 

STATEMENT PURSUANT TO

18 U.S.C. SECTION 1350

 

With reference to the Quarterly Report of Incyte Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Hervé Hoppenot, Chief Executive Officer of the Company, certify, for the purposes of 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1)   the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

3

 

 

/s/ HERVÉ HOPPENOT

 

 

 

Hervé Hoppenot

 

Chairman, President, and Chief Executive Officer

 

May 9, 2016

 

 

 


EX-32.2 6 incy-20160331ex322ae28f8.htm EX-32.2 incy_Ex_32_2

Exhibit 32.2

 

STATEMENT PURSUANT TO

18 U.S.C. SECTION 1350

 

With reference to the Quarterly Report of Incyte Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David W. Gryska, Chief Financial Officer of the Company, certify, for the purposes of 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1)   the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

/s/ DAVID W. GRYSKA

 

 

 

David W. Gryska

 

Chief Financial Officer

 

May 9, 2016

 

1


EX-101.INS 7 incy-20160331.xml EX-101.INS 0000879169 us-gaap:EmployeeStockOptionMember 2015-12-31 0000879169 us-gaap:EmployeeStockMember 2016-01-01 2016-03-31 0000879169 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0000879169 us-gaap:EmployeeStockMember 2015-01-01 2015-03-31 0000879169 us-gaap:RestrictedStockUnitsRSUMember incy:PresidentAndChiefExecutiveOfficerMember 2016-03-31 0000879169 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0000879169 us-gaap:RestrictedStockUnitsRSUMember incy:PresidentAndChiefExecutiveOfficerMember 2014-01-01 2014-01-31 0000879169 incy:JakaviMember incy:NovartisMember 2015-01-01 2015-12-31 0000879169 incy:JAKAFIMember incy:NovartisMember 2016-01-01 2016-03-31 0000879169 incy:JAKAFIMember incy:NovartisMember 2015-01-01 2015-03-31 0000879169 incy:GvhdMember incy:EliLillyMember 2016-01-01 2016-03-31 0000879169 incy:AgenusMember us-gaap:AccruedLiabilitiesMember 2016-01-01 2016-03-31 0000879169 incy:HengruiMember 2016-01-01 2016-03-31 0000879169 incy:AgenusMember 2015-01-01 2015-03-31 0000879169 us-gaap:MinimumMember 2016-01-01 2016-03-31 0000879169 us-gaap:MaximumMember 2016-01-01 2016-03-31 0000879169 us-gaap:OfficeEquipmentMember 2016-03-31 0000879169 us-gaap:EquipmentMember 2016-03-31 0000879169 us-gaap:ComputerEquipmentMember 2016-03-31 0000879169 incy:BuildingAndLeaseholdImprovementsMember 2016-03-31 0000879169 us-gaap:OfficeEquipmentMember 2015-12-31 0000879169 us-gaap:EquipmentMember 2015-12-31 0000879169 us-gaap:ComputerEquipmentMember 2015-12-31 0000879169 incy:BuildingAndLeaseholdImprovementsMember 2015-12-31 0000879169 incy:ScenarioPendingAcquisitionMember incy:DefinitivePurchaseAndSaleAgreementMember 2015-08-21 2015-08-21 0000879169 incy:ScenarioPendingAcquisitionMember incy:DefinitivePurchaseAndSaleAgreementMember 2016-01-01 2016-03-31 0000879169 incy:AgenusMember 2015-01-01 2015-12-31 0000879169 incy:AgenusMember incy:StockPurchaseAgreementMember 2015-02-18 0000879169 country:US incy:NovartisMember 2016-01-01 2016-03-31 0000879169 country:US incy:NovartisMember 2015-01-01 2015-03-31 0000879169 us-gaap:RestrictedStockUnitsRSUMember 2016-03-31 0000879169 us-gaap:PerformanceSharesMember 2016-03-31 0000879169 us-gaap:EmployeeStockOptionMember 2016-03-31 0000879169 incy:ScenarioPendingAcquisitionMember incy:DefinitivePurchaseAndSaleAgreementMember 2015-08-21 0000879169 us-gaap:CorporateDebtSecuritiesMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0000879169 us-gaap:CorporateDebtSecuritiesMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0000879169 incy:ConvertibleSeniorNotes1.25PercentDue2020Member 2016-03-31 0000879169 incy:ConvertibleSeniorNotes0.375PercentDue2018Member 2016-03-31 0000879169 incy:ConvertibleSeniorNotes4.75PercentDue2015Member 2015-03-31 0000879169 incy:ConvertibleSeniorNotes1.25PercentDue2020Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0000879169 incy:ConvertibleSeniorNotes1.25PercentDue2020Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0000879169 incy:ConvertibleSeniorNotes0.375PercentDue2018Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0000879169 incy:ConvertibleSeniorNotes0.375PercentDue2018Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0000879169 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0000879169 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0000879169 incy:ConvertibleSeniorNotes1.25PercentDue2020Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0000879169 incy:ConvertibleSeniorNotes1.25PercentDue2020Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0000879169 incy:ConvertibleSeniorNotes0.375PercentDue2018Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0000879169 incy:ConvertibleSeniorNotes0.375PercentDue2018Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0000879169 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0000879169 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0000879169 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember incy:CustomerABCAndDMember 2016-01-01 2016-03-31 0000879169 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember incy:CollaborationPartnerAAndBMember 2016-01-01 2016-03-31 0000879169 incy:SalesRevenueGoodsServicesNetMember us-gaap:CustomerConcentrationRiskMember incy:CustomerDMember 2016-01-01 2016-03-31 0000879169 incy:SalesRevenueGoodsServicesNetMember us-gaap:CustomerConcentrationRiskMember incy:CustomerCMember 2016-01-01 2016-03-31 0000879169 incy:SalesRevenueGoodsServicesNetMember us-gaap:CustomerConcentrationRiskMember incy:CustomerBMember 2016-01-01 2016-03-31 0000879169 incy:SalesRevenueGoodsServicesNetMember us-gaap:CustomerConcentrationRiskMember incy:CustomerAMember 2016-01-01 2016-03-31 0000879169 incy:ContractRevenuesMember us-gaap:CustomerConcentrationRiskMember incy:CollaborationPartnerBMember 2016-01-01 2016-03-31 0000879169 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember incy:CustomerABCAndDMember 2015-01-01 2015-12-31 0000879169 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember incy:CollaborationPartnerAAndBMember 2015-01-01 2015-12-31 0000879169 incy:SalesRevenueGoodsServicesNetMember us-gaap:CustomerConcentrationRiskMember incy:CustomerDMember 2015-01-01 2015-03-31 0000879169 incy:SalesRevenueGoodsServicesNetMember us-gaap:CustomerConcentrationRiskMember incy:CustomerCMember 2015-01-01 2015-03-31 0000879169 incy:SalesRevenueGoodsServicesNetMember us-gaap:CustomerConcentrationRiskMember incy:CustomerBMember 2015-01-01 2015-03-31 0000879169 incy:SalesRevenueGoodsServicesNetMember us-gaap:CustomerConcentrationRiskMember incy:CustomerAMember 2015-01-01 2015-03-31 0000879169 incy:ContractRevenuesMember us-gaap:CustomerConcentrationRiskMember incy:CollaborationPartnerBMember 2015-01-01 2015-03-31 0000879169 incy:ContractRevenuesMember us-gaap:CustomerConcentrationRiskMember incy:CollaborationPartnerAMember 2015-01-01 2015-03-31 0000879169 2015-03-31 0000879169 2013-12-31 0000879169 us-gaap:CorporateDebtSecuritiesMember 2016-03-31 0000879169 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000879169 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000879169 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000879169 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000879169 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000879169 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000879169 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000879169 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000879169 incy:ConvertibleSeniorNotes1.25PercentDue2020Member 2016-01-01 2016-03-31 0000879169 incy:ConvertibleSeniorNotes0.375PercentDue2018Member 2016-01-01 2016-03-31 0000879169 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0000879169 incy:ConvertibleSeniorNotes4.75PercentDue2015Member 2015-01-01 2015-03-31 0000879169 incy:ConvertibleSeniorNotes1.25PercentDue2020Member 2015-01-01 2015-03-31 0000879169 incy:ConvertibleSeniorNotes0.375PercentDue2018Member 2015-01-01 2015-03-31 0000879169 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-03-31 0000879169 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0000879169 us-gaap:PerformanceSharesMember 2016-01-01 2016-03-31 0000879169 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-03-31 0000879169 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0000879169 us-gaap:NewAccountingPronouncementEarlyAdoptionEffectMember 2016-01-01 2016-03-31 0000879169 2013-01-01 2013-12-31 0000879169 us-gaap:PerformanceSharesMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0000879169 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000879169 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0000879169 us-gaap:RestrictedStockUnitsRSUMember incy:PresidentAndChiefExecutiveOfficerMember 2016-01-01 2016-03-31 0000879169 incy:AgenusMember incy:DevelopmentRegulatoryAndCommercializationMilestonesMember 2016-01-01 2016-03-31 0000879169 incy:WhollyOwnedSubsidiaryOfAriadMember us-gaap:SubsequentEventMember incy:StockPurchaseAgreementMember 2016-05-01 2016-05-31 0000879169 incy:AgenusMember incy:StockPurchaseAgreementMember 2015-01-01 2015-01-31 0000879169 incy:AgenusMember us-gaap:MaximumMember incy:StockPurchaseAgreementMember 2015-01-01 2015-01-31 0000879169 incy:AgenusMember incy:DevelopmentRegulatoryAndCommercializationMilestonesMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0000879169 incy:AgenusMember incy:DevelopmentRegulatoryAndCommercializationMilestonesMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0000879169 us-gaap:MaximumMember incy:EliLillyMember 2016-01-01 2016-03-31 0000879169 incy:EliLillyMember 2010-07-01 2010-07-31 0000879169 incy:AgenusMember incy:StockPurchaseAgreementMember 2015-02-18 2015-02-18 0000879169 incy:RegulatoryMilestonesMember us-gaap:MaximumMember incy:EliLillyMember 2009-12-01 2009-12-31 0000879169 incy:PreSpecifiedEventsMember us-gaap:MaximumMember incy:EliLillyMember 2009-12-01 2009-12-31 0000879169 incy:DevelopmentMilestonesMember us-gaap:MaximumMember incy:EliLillyMember 2009-12-01 2009-12-31 0000879169 incy:CommercializationMilestonesMember us-gaap:MaximumMember incy:EliLillyMember 2009-12-01 2009-12-31 0000879169 incy:RegulatoryMilestonesMember us-gaap:MaximumMember incy:NovartisMember 2009-11-01 2009-11-30 0000879169 incy:PreSpecifiedEventsMember us-gaap:MaximumMember incy:NovartisMember 2009-11-01 2009-11-30 0000879169 incy:DevelopmentMilestonesMember us-gaap:MaximumMember incy:NovartisMember 2009-11-01 2009-11-30 0000879169 incy:CommercializationMilestonesMember us-gaap:MaximumMember incy:NovartisMember 2009-11-01 2009-11-30 0000879169 incy:NovartisMember 2009-11-01 2009-11-30 0000879169 incy:HengruiMember 2015-01-01 2015-12-31 0000879169 incy:NovartisMember 2016-01-01 2016-03-31 0000879169 incy:EliLillyMember 2016-01-01 2016-03-31 0000879169 incy:NovartisMember 2015-01-01 2015-03-31 0000879169 incy:EliLillyMember 2015-01-01 2015-03-31 0000879169 incy:NovartisMember 2016-03-31 0000879169 incy:NovartisMember 2015-12-31 0000879169 incy:DevelopmentRegulatoryAndCommercializationMilestonesMember incy:WhollyOwnedSubsidiaryOfAriadMember us-gaap:MaximumMember us-gaap:SubsequentEventMember incy:StockPurchaseAgreementMember 2016-05-31 0000879169 incy:RegulatoryMilestonesMember incy:HengruiMember 2015-09-01 0000879169 incy:CommercializationMilestonesMember incy:HengruiMember 2015-09-01 0000879169 incy:ClinicalSuperiorityMilestonesMember incy:HengruiMember 2015-09-01 0000879169 incy:HengruiMember 2015-09-01 0000879169 incy:EliLillyMember 2009-12-01 2009-12-31 0000879169 incy:NovartisMember 2010-01-01 2010-01-31 0000879169 incy:AgenusMember incy:DevelopmentRegulatoryAndCommercializationMilestonesMember us-gaap:MaximumMember 2016-03-31 0000879169 incy:AgenusMember incy:DevelopmentMilestonesMember us-gaap:MaximumMember 2016-03-31 0000879169 us-gaap:EuropeMember incy:EliLillyMember 2016-01-01 2016-01-31 0000879169 country:US incy:EliLillyMember 2016-01-01 2016-01-31 0000879169 incy:RegulatoryMilestonesMember incy:JakaviMember country:JP incy:NovartisMember 2015-01-01 2015-12-31 0000879169 incy:RegulatoryMilestonesMember incy:JAKAFIMember us-gaap:EuropeMember incy:NovartisMember 2015-01-01 2015-12-31 0000879169 incy:DevelopmentMilestonesMember incy:JAKAFIMember incy:NovartisMember 2015-01-01 2015-12-31 0000879169 incy:CommercializationMilestonesMember incy:JakaviMember incy:NovartisMember 2015-01-01 2015-12-31 0000879169 incy:RegulatoryMilestonesMember incy:JakaviMember us-gaap:EuropeMember incy:NovartisMember 2014-01-01 2014-12-31 0000879169 incy:RegulatoryMilestonesMember incy:JAKAFIMember us-gaap:EuropeMember incy:NovartisMember 2014-01-01 2014-12-31 0000879169 incy:RegulatoryMilestonesMember incy:JAKAFIMember country:JP incy:NovartisMember 2014-01-01 2014-12-31 0000879169 incy:DevelopmentMilestonesMember incy:JAKAFIMember incy:NovartisMember 2014-01-01 2014-12-31 0000879169 incy:DevelopmentMilestonesMember incy:JAKAFIMember incy:NovartisMember 2013-01-01 2013-12-31 0000879169 incy:RegulatoryMilestonesMember incy:JAKAFIMember us-gaap:EuropeMember incy:NovartisMember 2012-01-01 2012-12-31 0000879169 incy:DevelopmentMilestonesMember incy:PhaseThreeMember incy:EliLillyMember 2012-01-01 2012-12-31 0000879169 incy:RegulatoryMilestonesMember incy:JAKAFIMember incy:NovartisMember 2011-01-01 2011-12-31 0000879169 incy:DevelopmentMilestonesMember incy:JAKAFIMember incy:NovartisMember 2011-01-01 2011-12-31 0000879169 incy:DevelopmentMilestonesMember incy:PhaseTwoBMember incy:EliLillyMember 2010-01-01 2010-12-31 0000879169 incy:DevelopmentMilestonesMember incy:PhaseTwoAMember incy:EliLillyMember 2010-01-01 2010-12-31 0000879169 incy:DevelopmentMilestonesMember incy:JAKAFIMember incy:NovartisMember 2010-01-01 2010-12-31 0000879169 incy:RegulatoryMilestonesMember incy:EliLillyMember 2009-12-01 2016-03-31 0000879169 incy:DevelopmentMilestonesMember incy:EliLillyMember 2009-12-01 2016-03-31 0000879169 incy:RegulatoryMilestonesMember incy:NovartisMember 2009-11-01 2016-03-31 0000879169 incy:DevelopmentMilestonesMember incy:NovartisMember 2009-11-01 2016-03-31 0000879169 incy:CommercializationMilestonesMember incy:NovartisMember 2009-11-01 2016-03-31 0000879169 incy:GvhdMember incy:EliLillyMember 2016-03-01 2016-03-31 0000879169 incy:AgenusMember 2016-03-31 0000879169 2015-01-01 2015-03-31 0000879169 incy:NovartisMember 2009-12-31 0000879169 2016-03-31 0000879169 2015-12-31 0000879169 incy:ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member 2016-01-01 2016-03-31 0000879169 incy:AgenusMember 2016-01-01 2016-03-31 0000879169 2016-05-03 0000879169 2016-01-01 2016-03-31 incy:segment utr:sqft incy:item iso4217:USD xbrli:shares iso4217:USD incy:issuer incy:instrument incy:category xbrli:pure xbrli:shares false --12-31 Q1 2016 2016-03-31 10-Q 0000879169 187619384 Yes Large Accelerated Filer INCYTE CORP 0.09 3 1 1 1.30 P20D P5D P30D P5D 0.98 12512000 9297000 10900000 3833000 4.16 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Grant Accounting.</font><font style="display:inline;font-size:10pt;"> &nbsp;Grant amounts received from government agencies for operations are deferred and are amortized into income over the service period of the grant. Grant amounts received for purchases of capital assets are deferred and amortized into interest and other income, net over the useful life of the related capital assets. Such amounts are recorded in other liabilities on the condensed consolidated balance sheets.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> -3237000 -3215000 P36M 19338000 18586000 15000000 40000000 20000000 102000000 175000000 99000000 55000000 50000000 30000000 19000000 15000000 10000000 50000000 40000000 25000000 7000000 25000000 60000000 60000000 20000000 5000000 25000000 15000000 35000000 20000000 20000000 155000000 60000000 2 770000000 150000000 530000000 90000000 135000000 300000 100000 11600000 500000 5100000 300000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;License agreements</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Novartis</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications.&nbsp;&nbsp;Novartis also received worldwide exclusive development and commercialization rights to our c-MET inhibitor compound capmatinib and certain back-up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Under this agreement, we received an upfront payment and immediate milestone payment totaling </font><font style="display:inline;font-size:10pt;">$210.0</font><font style="display:inline;font-size:10pt;">&nbsp;million and were initially eligible to receive up to </font><font style="display:inline;font-size:10pt;">$1.2</font><font style="display:inline;font-size:10pt;">&nbsp;billion in milestone payments across multiple indications upon the achievement of pre-specified events, including up to </font><font style="display:inline;font-size:10pt;">$174.0</font><font style="display:inline;font-size:10pt;">&nbsp;million for the achievement of development milestones, up to </font><font style="display:inline;font-size:10pt;">$495.0</font><font style="display:inline;font-size:10pt;">&nbsp;million for the achievement of regulatory milestones and up to </font><font style="display:inline;font-size:10pt;">$500.0</font><font style="display:inline;font-size:10pt;">&nbsp;million for the achievement of commercialization milestones. Exclusive of the upfront payment of </font><font style="display:inline;font-size:10pt;">$150.0</font><font style="display:inline;font-size:10pt;"> million received in 2009 and the immediate milestone of </font><font style="display:inline;font-size:10pt;">$60.0</font><font style="display:inline;font-size:10pt;"> million earned in 2010, we have recognized and received in the aggregate </font><font style="display:inline;font-size:10pt;">$102.0</font><font style="display:inline;font-size:10pt;"> million for the achievement of development milestones and </font><font style="display:inline;font-size:10pt;">$175.0</font><font style="display:inline;font-size:10pt;"> million for the achievement of regulatory milestones and </font><font style="display:inline;font-size:10pt;">$20.0</font><font style="display:inline;font-size:10pt;"> million for the achievement of sales milestones through March&nbsp;31, 2016.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">During the year ended December 31, 2015, under this agreement, we recognized a </font><font style="display:inline;font-size:10pt;">$5.0</font><font style="display:inline;font-size:10pt;"> million development milestone based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib for a third indication and a </font><font style="display:inline;font-size:10pt;">$25.0</font><font style="display:inline;font-size:10pt;"> million regulatory milestone triggered by the Committee for Medicinal Products for Human Use of the European Medicines Agency adopting a positive opinion for JAKAVI (ruxolitinib) for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea, a </font><font style="display:inline;font-size:10pt;">$15.0</font><font style="display:inline;font-size:10pt;"> million regulatory milestone for the approval of JAKAVI in Japan for the treatment of patients with polycythemia vera, and a </font><font style="display:inline;font-size:10pt;">$20.0</font><font style="display:inline;font-size:10pt;"> million sales milestone for Novartis achieving annual net sales of a JAK licensed product of </font><font style="display:inline;font-size:10pt;">$300.0</font><font style="display:inline;font-size:10pt;"> million. In 2014, we recognized a </font><font style="display:inline;font-size:10pt;">$60.0</font><font style="display:inline;font-size:10pt;"> million regulatory milestone related to reimbursement of JAKAVI (ruxolitinib) in Europe, a </font><font style="display:inline;font-size:10pt;">$25.0</font><font style="display:inline;font-size:10pt;"> million regulatory milestone for the approval of JAKAVI in Japan for the treatment of patients with myelofibrosis and a </font><font style="display:inline;font-size:10pt;">$7.0</font><font style="display:inline;font-size:10pt;">&nbsp;million development milestone based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib in non-small cell lung cancer.&nbsp;&nbsp;In 2013, we recognized a </font><font style="display:inline;font-size:10pt;">$25.0</font><font style="display:inline;font-size:10pt;">&nbsp;million development milestone under this agreement based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib. In 2012, we recognized a </font><font style="display:inline;font-size:10pt;">$40.0</font><font style="display:inline;font-size:10pt;">&nbsp;million regulatory milestone payment under this agreement for the achievement of a predefined milestone for the European Union regulatory approval of JAKAVI. In 2011, we recognized a </font><font style="display:inline;font-size:10pt;">$15.0</font><font style="display:inline;font-size:10pt;">&nbsp;million development milestone under this agreement for the achievement of a predefined milestone in the Phase I dose-escalation trial for capmatinib in patients with solid tumors and a </font><font style="display:inline;font-size:10pt;">$10.0</font><font style="display:inline;font-size:10pt;">&nbsp;million regulatory milestone for the approval of JAKAFI in the United States. In 2010, we recognized </font><font style="display:inline;font-size:10pt;">$50.0</font><font style="display:inline;font-size:10pt;"> million in development milestones for the initiation of the global phase III trial, RESPONSE, in patients with polycythemia vera. We determined that each of these milestones were substantive as their achievement required substantive efforts by us and was at risk until the milestones were ultimately achieved. We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI net sales outside of the United States. Since the achievement of the </font><font style="display:inline;font-size:10pt;">$60.0</font><font style="display:inline;font-size:10pt;"> million regulatory milestone related to reimbursement of JAKAVI in Europe in September 2014, we are obligated to pay to Novartis tiered royalties in the low single digits on future JAKAFI net sales within the United States. During the three months ended March&nbsp;31, 2016 and 2015, such royalties payable to Novartis on net sales within the United States totaled </font><font style="display:inline;font-size:10pt;">$5.2</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$2.5</font><font style="display:inline;font-size:10pt;"> million, respectively, and are reflected in cost of product revenues on the condensed consolidated statements of operations.&nbsp;&nbsp;Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.</font> </p> <p style="margin:0pt;line-height:10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The Novartis agreement will continue on a program-by-program basis until Novartis has </font><font style="display:inline;font-size:10pt;">no</font><font style="display:inline;font-size:10pt;"> royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. Royalties are payable by Novartis on a product-by-product and country-by-country basis until the latest to occur of (1)&nbsp;the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (2)&nbsp;the expiration of regulatory exclusivity for the licensed product in such country and (3)&nbsp;a specified period from first commercial sale in such country of the licensed product by Novartis or its affiliates or sublicensees. The agreement may be terminated in its entirety or on a program-by-program basis by Novartis for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We determined that there were two deliverables under the agreement: (i) the ex U.S. license for ruxolitinib and (ii) our obligations in connection with our participation on the joint development committee for myelofibrosis and polycythemia vera/essential thrombocythemia. We concluded that these deliverables should be accounted for as a single unit of accounting and the $150.0 million upfront payment received in December 2009 and the immediate $60.0 million milestone payment received in January 2010 should be recognized on a straight line basis through December 2013, when we estimated we would complete our obligations in connection with our participation on the joint development committee for myelofibrosis and polycythemia vera, our estimated performance period under the agreement. We completed this substantive performance obligation related to this arrangement in December 2013.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">At December&nbsp;31, 2009, we recorded </font><font style="display:inline;font-size:10pt;">$10.9</font><font style="display:inline;font-size:10pt;">&nbsp;million of reimbursable costs incurred prior to the effective date of the agreement as deferred revenue on the consolidated balance sheet. These costs were recognized on a straight line basis through December 2013 consistent with the aforementioned upfront and milestone payments. Future reimbursable costs incurred after the effective date of the agreement with Novartis are recorded net against the related research and development expenses. At March&nbsp;31, 2016 and December&nbsp;31, 2015, </font><font style="display:inline;font-size:10pt;">$0.1</font><font style="display:inline;font-size:10pt;">&nbsp;million and </font><font style="display:inline;font-size:10pt;">$0.3</font><font style="display:inline;font-size:10pt;">&nbsp;million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets. Research and development expenses for the three months ended March&nbsp;31, 2016 and 2015 were net of </font><font style="display:inline;font-size:10pt;">$0.3</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$0.5</font><font style="display:inline;font-size:10pt;"> million, respectively, of costs reimbursed by Novartis.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Contract revenue under the Novartis agreement was </font><font style="display:inline;font-size:10pt;">$0.0</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$25.0</font><font style="display:inline;font-size:10pt;"> million for the three months ended March&nbsp;31, 2016 and 2015, respectively. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States was </font><font style="display:inline;font-size:10pt;">$21.9</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$15.7</font><font style="display:inline;font-size:10pt;"> million for the three months ended March&nbsp;31, 2016 and 2015, respectively. At March&nbsp;31, 2016 and December&nbsp;31, 2015, </font><font style="display:inline;font-size:10pt;">$21.8</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$23.8</font><font style="display:inline;font-size:10pt;"> million, respectively, of product royalties were included in accounts receivable on the condensed consolidated balance sheets.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Lilly - Baricitinib</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In December&nbsp;2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib, and certain back-up compounds for inflammatory and autoimmune diseases. We received an upfront payment of </font><font style="display:inline;font-size:10pt;">$90.0</font><font style="display:inline;font-size:10pt;">&nbsp;million, and were initially eligible to receive up to </font><font style="display:inline;font-size:10pt;">$665.0</font><font style="display:inline;font-size:10pt;">&nbsp;million in substantive milestone payments across multiple indications upon the achievement of pre-specified events, including up to </font><font style="display:inline;font-size:10pt;">$150.0</font><font style="display:inline;font-size:10pt;">&nbsp;million for the achievement of development milestones, up to </font><font style="display:inline;font-size:10pt;">$365.0</font><font style="display:inline;font-size:10pt;">&nbsp;million for the achievement of regulatory milestones and up to </font><font style="display:inline;font-size:10pt;">$150.0</font><font style="display:inline;font-size:10pt;">&nbsp;million for the achievement of commercialization milestones. Exclusive of the upfront payment of $90.0 million received in 2009, we have recognized and received in the aggregate </font><font style="display:inline;font-size:10pt;">$99.0</font><font style="display:inline;font-size:10pt;"> million for the achievement of development milestones and </font><font style="display:inline;font-size:10pt;">$55.0</font><font style="display:inline;font-size:10pt;"> million for the achievement of regulatory milestones through March&nbsp;31, 2016.&nbsp; </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In January 2016, under this agreement, we recognized a </font><font style="display:inline;font-size:10pt;">$35.0</font><font style="display:inline;font-size:10pt;"> million regulatory milestone for the submission of an NDA to the FDA for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis and a </font><font style="display:inline;font-size:10pt;">$20.0</font><font style="display:inline;font-size:10pt;"> million regulatory milestone for the submission of a Marketing Authorization Application to the Europe Medicines Agency for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis. In 2012, we recognized a </font><font style="display:inline;font-size:10pt;">$50.0</font><font style="display:inline;font-size:10pt;">&nbsp;million development milestone for the achievement of a predefined milestone for the initiation of the rheumatoid arthritis Phase&nbsp;III program for baricitinib. In 2010, we recognized a </font><font style="display:inline;font-size:10pt;">$30.0</font><font style="display:inline;font-size:10pt;">&nbsp;million development milestone based upon the initial three month data in the Phase&nbsp;IIa clinical trial of baricitinib for the treatment of rheumatoid arthritis and a </font><font style="display:inline;font-size:10pt;">$19.0</font><font style="display:inline;font-size:10pt;">&nbsp;million development milestone for the Phase&nbsp;IIb clinical trial initiation of baricitinib for the treatment of rheumatoid arthritis. We determined the 2012 and 2010 milestones to be substantive as their achievement required substantive efforts by us and was at risk until the milestones were ultimately achieved. We also could receive tiered, double-digit royalty payments on future global net sales with rates ranging up to </font><font style="display:inline;font-size:10pt;">20%</font><font style="display:inline;font-size:10pt;"> if the product is successfully commercialized.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We retained options to co-develop our JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis. Lilly is responsible for all costs relating to the development and commercialization of the compounds unless we elect to co-develop any compounds or indications. If we elect to co-develop any compounds and/or indications, we would be responsible for funding </font><font style="display:inline;font-size:10pt;">30%</font><font style="display:inline;font-size:10pt;"> of the associated future global development costs from the initiation of a Phase&nbsp;IIb trial through regulatory approval</font><font style="display:inline;font-size:10pt;">, including post-launch studies required by a regulatory authority</font><font style="display:inline;font-size:10pt;">. We would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global net sales for compounds and/or indications that we elect to co-develop.&nbsp; </font><font style="display:inline;font-size:10pt;">For indications that we elect not to co</font><font style="display:inline;font-size:10pt;">&#8209;develop, we would receive tiered, double</font><font style="display:inline;font-size:10pt;">&#8209;digit royalty payments on future global net sales with rates ranging up to </font><font style="display:inline;font-size:10pt;">20%</font><font style="display:inline;font-size:10pt;"> if the product is successfully commercialized. </font><font style="display:inline;font-size:10pt;"> In July&nbsp;2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis and we are responsible for funding </font><font style="display:inline;font-size:10pt;">30%</font><font style="display:inline;font-size:10pt;"> of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority.&nbsp;&nbsp;We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement.&nbsp; </font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Research and development expenses recorded under the Lilly agreement representing </font><font style="display:inline;font-size:10pt;">30%</font><font style="display:inline;font-size:10pt;"> of the global development costs for baricitinib for the treatment of rheumatoid arthritis were </font><font style="display:inline;font-size:10pt;">$5.1</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$11.6</font><font style="display:inline;font-size:10pt;"> million for the three months ended March&nbsp;31, 2016 and 2015, respectively. We have retained certain mechanisms to give us cost protection as baricitinib advances in clinical development. We can defer our portion of co-development study costs by indication if they exceed a predetermined level. This deferment would be credited against future milestones or royalties and we would still be eligible for the full incremental royalties related to the co-development option. In addition, even if we have started co-development funding for any indication, we can at any time opt out and stop future co-development cost sharing. If we elect to do this we would still be eligible for our base royalties plus an incremental pro-rated royalty commensurate with our contribution to the total co-development cost for those indications for which we co-funded. The Lilly agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. Royalties are payable by Lilly on a product-by-product and country-by-country basis until the latest to occur of (1) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (2) the expiration of regulatory exclusivity for the licensed product in such country and (3) a specified period from first commercial sale in such country of the licensed product by Lilly or its affiliates or sublicensees. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</font> </p> <p style="margin:0pt;line-height:10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We determined that there were </font><font style="display:inline;font-size:10pt;">two</font><font style="display:inline;font-size:10pt;"> deliverables under the agreement: (i)&nbsp;the worldwide license and (ii)&nbsp;our obligations in connection with a co-development option. We concluded that these deliverables should be accounted for as a single unit of accounting and the </font><font style="display:inline;font-size:10pt;">$90.0</font><font style="display:inline;font-size:10pt;">&nbsp;million upfront payment should be recognized on a straight line basis as revenue through December&nbsp;2016, our estimated performance period under the agreement.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Contract revenue under the Lilly agreement was </font><font style="display:inline;font-size:10pt;">$58.2</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$3.2</font><font style="display:inline;font-size:10pt;"> million for the three months ended March&nbsp;31, 2016 and 2015, respectively.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Lilly - Ruxolitinib</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">In March 2016, we entered into an amendment to the agreement with Lilly that amended the non-compete provision of the agreement to allow us to engage in the development and commercialization of ruxolitinib in the graft-versus-host-disease (&#x201C;GVHD&#x201D;) field. We agreed to pay Lilly an upfront payment of </font><font style="display:inline;font-size:10pt;">$35.0</font><font style="display:inline;font-size:10pt;"> million and Lilly is eligible to receive up to </font><font style="display:inline;font-size:10pt;">$40.0</font><font style="display:inline;font-size:10pt;"> million in additional regulatory milestone payments relating to ruxolitinib in the GVHD field. As of March 31, 2016, the </font><font style="display:inline;font-size:10pt;">$35.0</font><font style="display:inline;font-size:10pt;"> million upfront payment was recorded in research and development expense on the condensed consolidated statements of operations and was included in accrued and other current liabilities on the condensed consolidated balance sheet.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Agenus</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly owned subsidiary, 4-Antibody AG, which we collectively refer to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus&#x2019; proprietary antibody discovery platforms. The agreement became effective on February 18, 2015, upon the expiration of the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Under the terms of this agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial four program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, three more targets were added. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we will be responsible for all costs associated with discovery, preclinical activities, clinical development and commercialization activities. The programs relating to GITR and OX40 and two of the undisclosed targets are profit-share programs while the other targets currently under collaboration are royalty-bearing programs. All costs related to the collaboration are subject to a joint research plan.&nbsp;&nbsp;For each royalty-bearing product, Agenus will be eligible to receive up to </font><font style="display:inline;font-size:10pt;">$155.0</font><font style="display:inline;font-size:10pt;"> million in future contingent development, regulatory and commercialization milestones as well as tiered royalties on global net sales ranging from </font><font style="display:inline;font-size:10pt;">6%</font><font style="display:inline;font-size:10pt;"> to </font><font style="display:inline;font-size:10pt;">12%</font><font style="display:inline;font-size:10pt;">. For each profit share product, Agenus will be eligible to receive up to </font><font style="display:inline;font-size:10pt;">$20.0</font><font style="display:inline;font-size:10pt;"> million in future contingent development milestones. Additionally, Agenus retains co-promotion participation rights in the United States on any profit share product. For each royalty bearing product, Agenus has reserved the right to elect to co fund </font><font style="display:inline;font-size:10pt;">30%</font><font style="display:inline;font-size:10pt;"> of development costs for a commensurate increase in royalties. The agreement may be terminated by us for convenience upon 12 months&#x2019; notice and may also be terminated under certain other circumstances, including material breach.&nbsp;&nbsp;We agreed to certain standstill provisions that allow us to acquire up to </font><font style="display:inline;font-size:10pt;">15%</font><font style="display:inline;font-size:10pt;"> of Agenus Inc.&#x2019;s outstanding voting stock, including shares acquired pursuant to the Stock Purchase Agreement described below, solely for investment purposes. </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In January 2015, we also entered into a Stock Purchase Agreement with Agenus Inc. pursuant to which we agreed to purchase approximately </font><font style="display:inline;font-size:10pt;">7.76</font><font style="display:inline;font-size:10pt;"> million shares of Agenus Inc. common stock for an aggregate purchase price of </font><font style="display:inline;font-size:10pt;">$35.0</font><font style="display:inline;font-size:10pt;"> million in cash, or approximately </font><font style="display:inline;font-size:10pt;">$4.51</font><font style="display:inline;font-size:10pt;"> per share. We completed the purchase of the shares on February 18, 2015. On February 18, 2015 the closing price of Agenus Inc. common shares on The NASDAQ Stock Market was </font><font style="display:inline;font-size:10pt;">$5.13</font><font style="display:inline;font-size:10pt;"> per share and, therefore, the value of the </font><font style="display:inline;font-size:10pt;">7.76</font><font style="display:inline;font-size:10pt;"> million shares acquired by us was </font><font style="display:inline;font-size:10pt;">$39.8</font><font style="display:inline;font-size:10pt;"> million. We agreed not to dispose of any of the shares of common stock for a period of </font><font style="display:inline;font-size:10pt;">12</font><font style="display:inline;font-size:10pt;"> months and Agenus Inc. has agreed to certain registration rights with respect to the shares of common stock. </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Upon closing of the Agenus transaction on February 18, 2015, we paid total consideration of </font><font style="display:inline;font-size:10pt;">$60.0</font><font style="display:inline;font-size:10pt;"> million to Agenus Inc.&nbsp;&nbsp;Of the </font><font style="display:inline;font-size:10pt;">$60.0</font><font style="display:inline;font-size:10pt;">&nbsp;</font><font style="display:inline;font-size:10pt;">million, </font><font style="display:inline;font-size:10pt;">$39.8</font><font style="display:inline;font-size:10pt;"> million was allocated to our stock purchase in Agenus Inc. and was recorded as a long term investment on the condensed consolidated balance sheets and </font><font style="display:inline;font-size:10pt;">$20.2</font><font style="display:inline;font-size:10pt;"> million was allocated to research and development expense on the condensed consolidated statement of operations.&nbsp; </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We have concluded Agenus Inc. is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. We own approximately </font><font style="display:inline;font-size:10pt;">9%</font><font style="display:inline;font-size:10pt;"> of the outstanding shares of Agenus Inc. common stock and conclude that we have the ability to exercise significant influence, but not control, over Agenus Inc. based primarily on our ownership interest, the level of intra-entity transactions between us and Agenus related to development expenses, as well as other qualitative factors. We have elected the fair value option to account for our long term investment in Agenus Inc. whereby the investment is marked to market through earnings in each reporting period.&nbsp;&nbsp;We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three months ended </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, we recorded an unrealized loss of </font><font style="display:inline;font-size:10pt;">$3.0</font><font style="display:inline;font-size:10pt;"> million based on the decrease in the market price of Agenus Inc.&#x2019;s common stock from the date of purchase to </font><font style="display:inline;font-size:10pt;">$4.16</font><font style="display:inline;font-size:10pt;"> per share at March 31, 2016. For the three months ended March 31, 2015, there was no gain or loss recorded as the market price of Agenus Inc.&#x2019;s common stock at March 31, 2015 was consistent with the fair value on the acquisition date of the investment. For the year ended December 31, 2015, Agenus Inc. reported total revenues of </font><font style="display:inline;font-size:10pt;">$24.8</font><font style="display:inline;font-size:10pt;"> million and a net loss of </font><font style="display:inline;font-size:10pt;">$87.9</font><font style="display:inline;font-size:10pt;"> million within their consolidated financial statements. </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Research and development expenses for the three months ended March&nbsp;31, 2016 and 2015, included </font><font style="display:inline;font-size:10pt;">$4.1</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$1.8</font><font style="display:inline;font-size:10pt;"> million, respectively, of development costs incurred pursuant to the Agenus arrangement. At </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, a total of </font><font style="display:inline;font-size:10pt;">$10.0</font><font style="display:inline;font-size:10pt;"> million of such costs were included in accrued and other liabilities on the condensed consolidated balance sheet.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Hengrui</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In September 2015,&nbsp;we entered into a License and Collaboration Agreement with Jiangsu Hengrui Medicine Co.,&nbsp;Ltd. (&#x201C;Hengrui&#x201D;). Under the terms of this agreement,&nbsp;we received exclusive development and commercialization rights worldwide, with the exception of Mainland China, Hong Kong, Macau and Taiwan, to INCSHR1210, an investigational PD-1 monoclonal antibody, and certain back-up compounds. INCSHR1210 is currently in clinical development.&nbsp; </font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Under the terms of this agreement, we paid Hengrui an upfront payment of </font><font style="display:inline;font-size:10pt;">$25.0</font><font style="display:inline;font-size:10pt;"> million in 2015 which was recorded in research and development expense on the condensed consolidated statement of operations. Hengrui is also eligible to receive potential milestone payments of up to </font><font style="display:inline;font-size:10pt;">$770.0</font><font style="display:inline;font-size:10pt;"> million, consisting of </font><font style="display:inline;font-size:10pt;">$90.0</font><font style="display:inline;font-size:10pt;"> million for regulatory approval milestones, </font><font style="display:inline;font-size:10pt;">$530.0</font><font style="display:inline;font-size:10pt;"> million for commercial performance milestones, and </font><font style="display:inline;font-size:10pt;">$150.0</font><font style="display:inline;font-size:10pt;"> million for a clinical superiority milestone.&nbsp; Also, Hengrui may be eligible to receive tiered royalties in the high-single digits to mid-double digits based on net sales in our territories. Each company will be responsible for costs relating to the development and commercialization of the PD-1 monoclonal antibody in their respective territories.&nbsp;&nbsp;The agreement will continue on a country-by-country basis until we have no royalty payment obligations with respect to such country or, if earlier, the termination of the agreement in accordance with its terms.&nbsp;&nbsp;The agreement may be terminated in its entirety by us for convenience, and may also be terminated under certain other circumstances, including material breach.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Research and development expenses for the three months ended </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, included </font><font style="display:inline;font-size:10pt;">$0.7</font><font style="display:inline;font-size:10pt;"> million of development costs incurred pursuant to the Hengrui agreement.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 25000000 210000000 500000000 174000000 1200000000 495000000 150000000 150000000 665000000 365000000 150000000 90000000 35000000 P12M 3 P10Y P5Y 0.3 0.3 0.3 0.3 0.5 0.2 0.12 0.06 0.15 0.20 4.51 5.13 7760000 35000000 39800000 140000000 0.30 23800000 21800000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Our inventory balance consists of the following:</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands)</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Work-in-process</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,277 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,555 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Finished goods</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,309 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,783 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,586 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,338 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Inventories-current</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,309 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,783 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Inventories-non-current</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,277 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,555 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">RSU and PSU award activity under the 2010 Stock Plan was as follows:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Subject&nbsp;to</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Available</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Outstanding&nbsp;Awards</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">for&nbsp;Grant</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Grant Date Value</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Balance at December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>834,433 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>565,567 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">RSUs granted </font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(216,711) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>216,711 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88.28 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">PSUs granted </font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">RSUs cancelled </font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,843 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,843) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67.62 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">PSUs cancelled </font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Balance at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>630,565 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>769,435 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We utilized the </font><font style="display:inline;font-size:10pt;">Black-Scholes valuation model</font><font style="display:inline;font-size:10pt;"> for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Employee Stock Options For the Three Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Employee Stock Purchase Plan For the Three Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&#x2002;&#x2002;&#x2002;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&#x2002;&#x2002;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&#x2002;&#x2002;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&#x2002;&#x2002;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Average risk-free interest rates</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.50 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font><font style="display:inline;font-family:Calibri;font-size:10pt;">&#x2002;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.35 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font><font style="display:inline;font-family:Calibri;font-size:10pt;">&#x2002;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.73 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font><font style="display:inline;font-family:Calibri;font-size:10pt;">&#x2002;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.56 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font><font style="display:inline;font-family:Calibri;font-size:10pt;">&#x2002;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Average expected life (in years)</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.00 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.05 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.25 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.25 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Volatility</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Weighted-average fair value (in dollars)</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41.56 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32.59 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26.67 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.56 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Percentage&nbsp;of&nbsp;Total</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Contract&nbsp;Revenues&nbsp;for&nbsp;the</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Collaboration Partner A</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Collaboration Partner B</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Percentage&nbsp;of&nbsp;Total&nbsp;Net</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Product&nbsp;Revenues&nbsp;for&nbsp;the</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Customer A</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Customer B</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Customer C</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Customer D</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 0.167 12843 133333 216711 0.05 1 68324 1412583 1.25 190000 60000000 0 30085000 31899000 114450000 101280000 86531000 133641000 45263000 47481000 -809000 397000 1950764000 1982104000 325600000 17600000 10300000 7300000 20800000 0 13000000 7800000 0 0 39470319 7245263 7245263 10353076 14626717 17138793 7245244 7241284 2652265 1007440000 1103942000 842375000 935581000 743031000 556687000 186344000 842967000 689913000 153054000 186344000 153054000 397000 809000 187153000 152657000 186344000 186344000 153054000 153054000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The following is a summary of our marketable security portfolio as of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> and </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;">, respectively.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Net</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Net</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Amortized</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Estimated</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Cost</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Gains</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Losses</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="11" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Corporate debt securities</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>152,657 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>397 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,054 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Corporate debt securities</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,153 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(809) </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,344 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Basis of presentation</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&nbsp;&nbsp;The condensed consolidated balance sheet as of March 31, 2016 and the condensed consolidated statements of operations, comprehensive income (loss) and cash flows for the three months ended March&nbsp;31, 2016 and 2015, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.&nbsp;&nbsp;The condensed consolidated balance sheet at </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;"> has been derived from audited financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#x201C;U.S. GAAP&#x201D;) have been condensed or omitted pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form&nbsp;10-K for the year ended </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;">.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 452297000 421822000 521439000 657615000 521439000 521439000 657615000 657615000 -30475000 136176000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Cash and Cash Equivalents.</font><font style="display:inline;font-size:10pt;"> &nbsp;Cash and cash equivalents are held in U.S. banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 0.001 0.001 400000000 400000000 186650249 187402129 186650249 187402129 187000 187000 -17916000 25253000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Accumulated Other Comprehensive Income (Loss).</font><font style="display:inline;font-size:10pt;"> &nbsp;Accumulated other comprehensive income (loss) consists of realized and unrealized gains or losses on marketable securities and restricted cash and investments.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Concentrations of Credit Risk.</font><font style="display:inline;font-size:10pt;"> &nbsp;Cash, cash equivalents, marketable securities, trade receivables and restricted investments are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in corporate debt securities and, by policy, limit the amount of credit exposure to any </font><font style="display:inline;font-size:10pt;">one</font><font style="display:inline;font-size:10pt;"> issuer and to any </font><font style="display:inline;font-size:10pt;">one</font><font style="display:inline;font-size:10pt;"> type of investment, other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales of JAKAFI and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash, cash equivalents, marketable securities, trade receivables or restricted investments to date and do not require collateral on receivables.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">4.&nbsp;&nbsp;&nbsp;&nbsp; Concentration of Credit Risk</font> </p> <p style="margin:0pt;line-height:10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In December&nbsp;2009, we entered into a license, development and commercialization agreement with Eli Lilly and Company (&#x201C;Lilly&#x201D;). In November&nbsp;2009, we entered into a collaboration and license agreement with Novartis. The concentration of credit risk related to our collaborative partners is as follows:</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Percentage&nbsp;of&nbsp;Total</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Contract&nbsp;Revenues&nbsp;for&nbsp;the</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Collaboration Partner A</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Collaboration Partner B</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Collaboration Partner A and Collaboration Partner B comprised in the aggregate </font><font style="display:inline;font-size:10pt;">22%</font><font style="display:inline;font-size:10pt;"> and </font><font style="display:inline;font-size:10pt;">39%</font><font style="display:inline;font-size:10pt;"> of the accounts receivable balance as of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> and </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;">, respectively.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In November 2011, we began commercialization and distribution of JAKAFI to a number of customers. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our product revenues is as follows:</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Percentage&nbsp;of&nbsp;Total&nbsp;Net</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Product&nbsp;Revenues&nbsp;for&nbsp;the</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Customer A</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Customer B</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Customer C</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Customer D</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We are exposed to risks associated with extending credit to customers related to the sale of products. Customer A, Customer B, Customer C and Customer D comprised in the aggregate </font><font style="display:inline;font-size:10pt;">48%</font><font style="display:inline;font-size:10pt;"> and </font><font style="display:inline;font-size:10pt;">40%</font><font style="display:inline;font-size:10pt;"> of the accounts receivable balance as of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> and </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;">, respectively.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 0.89 0.11 0.28 0.20 0.13 0.08 0.39 0.40 1.00 0.27 0.18 0.12 0.08 0.22 0.48 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Principles of Consolidation.</font><font style="display:inline;font-size:10pt;"> &nbsp;The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries, including Incyte Holdings Corporation, Incyte International Holdings S.a.r.l. and Incyte Europe S.a.r.l. All inter-company accounts, transactions, and profits have been eliminated in consolidation.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Variable Interest Entities</font><font style="display:inline;font-size:10pt;">. We perform an initial and on-going evaluation of the entities with which we have variable interests, such as equity ownership, in order to</font><font style="display:inline;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display:inline;font-size:10pt;">identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (&#x201C;VIE&#x201D; or &#x201C;VIEs&#x201D;). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE&#x2019;s economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE.&nbsp;&nbsp;As of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, there were </font><font style="display:inline;font-size:10pt;">no</font><font style="display:inline;font-size:10pt;"> entities in which we held a variable interest which we determined to be VIEs.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 28214000 3200000 25000000 58214000 58200000 0 619893000 1623545000 324031000 807422000 295862000 816123000 627642000 1163349000 328173000 574922000 299469000 588427000 619893000 619893000 627642000 627642000 2974000 6005000 166210000 227425000 4000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">9.&nbsp;&nbsp;&nbsp;&nbsp; Debt</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The components of the convertible notes are as follows (in thousands):</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Carrying&nbsp;Amount,</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Interest&nbsp;Rates</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Debt</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Maturities</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">0.375% Convertible Senior Notes due 2018</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.375 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>328,173 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>324,031 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">1.25% Convertible Senior Notes due 2020</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.25 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2020 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>299,469 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>295,862 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>627,642 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>619,893 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Less current portion</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>627,642 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>619,893 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The carrying amount and fair value of our convertible notes are as follows (in thousands):</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Carrying</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Carrying</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">0.375% Convertible Senior Notes due 2018</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>328,173 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>574,922 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>324,031 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>807,422 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">1.25% Convertible Senior Notes due 2020</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>299,469 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>588,427 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>295,862 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>816,123 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>627,642 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,163,349 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>619,893 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,623,545 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The fair values of the </font><font style="display:inline;font-size:10pt;">0.375%</font><font style="display:inline;font-size:10pt;"> Convertible Senior Notes due 2018 (the &#x201C;2018 Notes&#x201D;) and the </font><font style="display:inline;font-size:10pt;">1.25%</font><font style="display:inline;font-size:10pt;"> Convertible Senior Notes due 2020 (the &#x201C;2020 Notes&#x201D;) are based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments, and, therefore, these convertible senior notes are classified within Level 2 in the fair value hierarchy. </font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Prior to May 14, 2014, the 2018 and 2020 Notes were not convertible except in connection with a make whole fundamental change, as defined in the respective indentures. Beginning on, and including, May 15, 2014, the 2018 and 2020 Notes are convertible prior to the close of business on the business day immediately preceding May 15, 2018, in the case of the 2018 Notes, and May 15, 2020, in the case of the 2020 Notes, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for at least </font><font style="display:inline;font-size:10pt;">20</font><font style="display:inline;font-size:10pt;"> trading days (whether or not consecutive) during a period of </font><font style="display:inline;font-size:10pt;">30</font><font style="display:inline;font-size:10pt;"> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to </font><font style="display:inline;font-size:10pt;">130%</font><font style="display:inline;font-size:10pt;"> of the conversion price for the 2018 Notes or 2020 Notes, as applicable, on each applicable trading day; (2) during the </font><font style="display:inline;font-size:10pt;">five</font><font style="display:inline;font-size:10pt;"> business day period after any </font><font style="display:inline;font-size:10pt;">five</font><font style="display:inline;font-size:10pt;"> consecutive trading day period (the &#x201C;measurement period&#x201D;) in which the trading price per </font><font style="display:inline;font-size:10pt;">$1,000</font><font style="display:inline;font-size:10pt;"> principal amount of 2018 Notes or 2020 Notes, as applicable, for each trading day of the measurement period was less than </font><font style="display:inline;font-size:10pt;">98%</font><font style="display:inline;font-size:10pt;"> of the product of the last reported sale price of our common stock and the conversion rate for the 2018 Notes or 2020 Notes, as applicable, on each such trading day; or (3) upon the occurrence of specified corporate events. On or after May 15, 2018, in the case of the 2018 Notes, and May 15, 2020, in the case of the 2020 Notes, until the close of business on the second scheduled trading day immediately preceding the relevant maturity date, the Notes are convertible at any time, regardless of the foregoing circumstances. Upon conversion we will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at our election.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">On </font><font style="display:inline;font-size:10pt;">April 1, 2016</font><font style="display:inline;font-size:10pt;">, the 2018 Notes and 2020 Notes became convertible through at least </font><font style="display:inline;font-size:10pt;">June 30, 2016</font><font style="display:inline;font-size:10pt;">, based on meeting the conversion criteria related to the sale price of our common stock during the calendar quarter ended </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> as described in (1) above. Management&#x2019;s intent is to settle any conversions of 2018 Notes or 2020 Notes during this period in shares of our common stock and, therefore, the 2018 Notes and 2020 Notes are reflected in long term liabilities on the condensed consolidated balance sheet at </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">. &nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 1000 0.0475 0.00375 0.0125 P18M P12M <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Financing Costs Related to Long-term Debt.</font><font style="display:inline;font-size:10pt;"> &nbsp;Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the consolidated balance sheets.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 11835000 11058000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">8.&nbsp;&nbsp;&nbsp;&nbsp; Stock compensation</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We recorded </font><font style="display:inline;font-size:10pt;">$20.8</font><font style="display:inline;font-size:10pt;">&nbsp;million and </font><font style="display:inline;font-size:10pt;">$17.6</font><font style="display:inline;font-size:10pt;"> million of stock compensation expense on our condensed consolidated statements of operations for the three months ended March&nbsp;31, 2016 and 2015, respectively. Stock compensation expense included within our condensed consolidated statements of operations included research and development expense of </font><font style="display:inline;font-size:10pt;">$13.0</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$10.3</font><font style="display:inline;font-size:10pt;"> million for the three months ended March&nbsp;31, 2016 and 2015, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included selling, general and administrative expense of </font><font style="display:inline;font-size:10pt;">$7.8</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$7.3</font><font style="display:inline;font-size:10pt;"> million for the three months ended March&nbsp;31, 2016 and 2015, respectively. </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We utilized the </font><font style="display:inline;font-size:10pt;">Black-Scholes valuation model</font><font style="display:inline;font-size:10pt;"> for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Employee Stock Options For the Three Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Employee Stock Purchase Plan For the Three Months&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&#x2002;&#x2002;&#x2002;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&#x2002;&#x2002;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&#x2002;&#x2002;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&#x2002;&#x2002;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Average risk-free interest rates</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.50 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font><font style="display:inline;font-family:Calibri;font-size:10pt;">&#x2002;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.35 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font><font style="display:inline;font-family:Calibri;font-size:10pt;">&#x2002;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.73 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font><font style="display:inline;font-family:Calibri;font-size:10pt;">&#x2002;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.56 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font><font style="display:inline;font-family:Calibri;font-size:10pt;">&#x2002;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Average expected life (in years)</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.00 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.05 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.25 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.25 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Volatility</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Weighted-average fair value (in dollars)</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41.56 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32.59 </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26.67 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.56 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The risk-free interest rate is derived from the U.S. Federal Reserve rate in effect at the time of grant. The expected life calculation is based on the observed and expected time to the exercise of options by our employees based on historical exercise patterns for similar type options. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the options. A dividend yield of </font><font style="display:inline;font-size:10pt;">zero</font><font style="display:inline;font-size:10pt;"> is assumed based on the fact that we have never paid cash dividends and have </font><font style="display:inline;font-size:10pt;">no</font><font style="display:inline;font-size:10pt;"> present intention to pay cash dividends.</font> </p> <p style="margin:0pt;line-height:10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Option activity under the 2010 Stock Plan was as follows:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Subject&nbsp;to</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Outstanding&nbsp;Options</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Available</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Weighted&nbsp;Average</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">for&nbsp;Grant</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Balance at December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,846,717 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,052,279 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33.55 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Options granted</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,412,583) </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,412,583 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94.69 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Options exercised</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(751,784) </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14.06 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Options cancelled</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,324 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(68,324) </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73.24 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Options expired</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,834) </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.11 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Balance at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,502,458 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,642,920 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42.00 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">RSU and PSU award activity under the 2010 Stock Plan was as follows:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Subject&nbsp;to</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Available</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Outstanding&nbsp;Awards</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">for&nbsp;Grant</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Grant Date Value</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Balance at December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>834,433 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>565,567 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">RSUs granted </font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(216,711) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>216,711 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88.28 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">PSUs granted </font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">RSUs cancelled </font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,843 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,843) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67.62 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">PSUs cancelled </font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:61.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Balance at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>630,565 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>769,435 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> <font style="display:inline;font-size:10pt;">In January&nbsp;2014, we began granting RSUs and PSUs to our employees at the share price on the date of grant.&nbsp;&nbsp;&nbsp;Each RSU represents the right to acquire </font><font style="display:inline;font-size:10pt;">one</font><font style="display:inline;font-size:10pt;"> share of our common stock. We granted a total of </font><font style="display:inline;font-size:10pt;">216,711</font><font style="display:inline;font-size:10pt;"> RSUs during the three months ended </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> which will cliff vest in </font><font style="display:inline;font-size:10pt;">three</font><font style="display:inline;font-size:10pt;"> years and will be recognized as stock compensation expense over this period.&nbsp;&nbsp;Also, in January&nbsp;2014, Herv&#xE9; Hoppenot, our President and Chief Executive Officer, was granted a one-time grant of </font><font style="display:inline;font-size:10pt;">400,000</font><font style="display:inline;font-size:10pt;"> RSUs outside of our 2010 Stock Incentive Plan. Vesting of the RSUs will be subject to Mr.&nbsp;Hoppenot&#x2019;s continued employment on the applicable vesting dates, with </font><font style="display:inline;font-size:10pt;">one</font><font style="display:inline;font-size:10pt;">-sixth of the RSUs vesting at the end of each of the calendar years 2014 through 2019, subject to earlier acceleration of vesting upon the occurrence of certain events in accordance with the terms of his employment agreement.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-size:10pt;">As of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, a total of </font><font style="display:inline;font-size:10pt;">133,333</font><font style="display:inline;font-size:10pt;"> RSUs granted to Mr. Hoppenot vested and were released leaving </font><font style="display:inline;font-size:10pt;">266,667</font><font style="display:inline;font-size:10pt;"> RSUs outstanding. </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">At </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, we have only recognized stock compensation expense relating to performance conditions of the outstanding PSUs that are deemed probable of achievement at that date. For PSUs containing performance conditions which have not been deemed probable of achievement at </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, &nbsp;</font><font style="display:inline;font-size:10pt;">no</font><font style="display:inline;font-size:10pt;"> stock compensation expense has been recognized for these awards. The actual number of shares of our common stock into which each PSU may convert are subject to a multiplier of up to </font><font style="display:inline;font-size:10pt;">125%</font><font style="display:inline;font-size:10pt;"> based on the level at which the performance conditions are achieved.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Based on our historical experience of employee turnover, we have assumed an annualized forfeiture rate of </font><font style="display:inline;font-size:10pt;">5%</font><font style="display:inline;font-size:10pt;"> for our options, </font><font style="display:inline;font-size:10pt;">PSU</font><font style="display:inline;font-size:10pt;">s and </font><font style="display:inline;font-size:10pt;">RSU</font><font style="display:inline;font-size:10pt;">s.&nbsp;&nbsp;Under the true-up provisions of the stock compensation guidance, we will record additional expense if the actual forfeiture rate is lower than we estimated, and will record a recovery of prior expense if the actual forfeiture is higher than we estimated.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Total compensation cost of options granted but not yet vested, as of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, was </font><font style="display:inline;font-size:10pt;">$68.7</font><font style="display:inline;font-size:10pt;"> million, which is expected to be recognized over the weighted average period of </font><font style="display:inline;font-size:10pt;">3.0</font><font style="display:inline;font-size:10pt;"> years. Total compensation cost of RSUs granted but not yet vested, as of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, was </font><font style="display:inline;font-size:10pt;">$35.4</font><font style="display:inline;font-size:10pt;"> million, which is expected to be recognized over the weighted average period of </font><font style="display:inline;font-size:10pt;">3.0</font><font style="display:inline;font-size:10pt;"> years. Total compensation cost of PSUs granted but not yet vested, as of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, was </font><font style="display:inline;font-size:10pt;">$0.7</font><font style="display:inline;font-size:10pt;"> million, which is expected to be recognized over the weighted average period of </font><font style="display:inline;font-size:10pt;">3.0</font><font style="display:inline;font-size:10pt;"> years, should the underlying performance conditions be deemed probable of achievement.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 4000000 -0.11 0.13 -0.11 0.12 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Net Income (Loss) Per Share.</font><font style="display:inline;font-size:10pt;"> &nbsp;Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) per share</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Net income (loss) per share was calculated as follows for the periods indicated:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months&nbsp;Ended</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;"> <font style="display:inline;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands, except per share data)</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Basic Net Income (Loss) Per Share</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Basic net income (loss)</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,047 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,359) </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Weighted average common shares outstanding</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,184 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>172,070 </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Basic net income (loss) per share</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.13 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.11) </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Diluted Net Income (Loss) Per Share</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Diluted net income (loss)</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,047 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,359) </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Weighted average common shares outstanding</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,184 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>172,070 </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Dilutive stock options and RSU&#x2019;s</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,441 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Weighted average shares used to compute diluted net income (loss) per share </font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>192,625 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>172,070 </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Diluted net income (loss) per share</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.12 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.11) </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"></font><font style="display:inline;font-size:10pt;">The following potential common shares were excluded from the calculations as their effect would be anti-dilutive:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months&nbsp;Ended</font></p> </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Outstanding stock options and awards</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,652,265 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,626,717 </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Common shares issuable upon conversion of the </font><font style="display:inline;font-size:10pt;">4.75%</font><font style="display:inline;font-size:10pt;"> Convertible Senior Notes due 2015</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,353,076 </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Common shares issuable upon conversion of the 2018 Notes</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,245,244 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,245,263 </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Common shares issuable upon conversion of the 2020 Notes</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,241,284 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,245,263 </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Total potential common shares excluded from diluted net loss per share computation</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,138,793 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,470,319 </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 38117000 23197000 68700000 700000 35400000 P3Y P3Y P3Y <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Equity Method Investments.</font><font style="display:inline;font-size:10pt;"> &nbsp;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option under U.S. GAAP.&nbsp;&nbsp;&nbsp;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Under the equity method of accounting, we record within our results of operations our share of income or loss of the investee company.&nbsp;&nbsp;Under the fair value option, our investment is carried at fair value on our condensed consolidated balance sheets as a long term investment and all changes in fair value are reported in our condensed consolidated statements of operations as an unrealized gain (loss) on long term investment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 4000000 3833000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">3.&nbsp;&nbsp;&nbsp;&nbsp; Fair value of financial instruments</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (&#x201C;the exit price&#x201D;) in an orderly transaction between market participants at the measurement date. The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Level&nbsp;1&#x2014;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</font> </p> <p style="margin:0pt;line-height:10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Level&nbsp;2&#x2014;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Level&nbsp;3&#x2014;Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Our marketable securities consist of investments in corporate debt securities that are classified as available-for-sale. </font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">At </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> and December&nbsp;31, 2015, our Level 2 corporate debt securities were valued using readily available pricing sources which utilize market observable inputs, including the current interest rate and other characteristics for similar types of investments. </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at fair value on a recurring basis as of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> (in thousands):</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value&nbsp;Measurement&nbsp;at&nbsp;Reporting&nbsp;Date&nbsp;Using:</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices&nbsp;in</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;Other</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Significant</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Active&nbsp;Markets&nbsp;for</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Observable</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unobservable</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Identical&nbsp;Assets</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Balance&nbsp;as&nbsp;of</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Cash and cash equivalents</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>657,615 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>657,615 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Corporate debt securities</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,054 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,054 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Long term investment (Note 7)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,298 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,298 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Total assets</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>689,913 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,054 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>842,967 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis as of </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;"> (in thousands):</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value&nbsp;Measurement&nbsp;at&nbsp;Reporting&nbsp;Date&nbsp;Using:</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices&nbsp;in</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;Other</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Significant</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Active&nbsp;Markets&nbsp;for</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Observable</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unobservable</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Identical&nbsp;Assets</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Balance&nbsp;as&nbsp;of</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Cash and cash equivalents</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>521,439 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>521,439 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Corporate debt securities</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,344 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,344 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Long term investment (Note 7)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,248 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,248 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Total assets</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>556,687 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,344 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>743,031 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The following is a summary of our marketable security portfolio as of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> and </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;">, respectively.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Net</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Net</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Amortized</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unrealized</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Estimated</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Cost</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Gains</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Losses</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td colspan="11" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Corporate debt securities</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>152,657 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>397 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,054 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Corporate debt securities</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,153 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(809) </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,344 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Our corporate debt securities generally have contractual maturity dates of between </font><font style="display:inline;font-size:10pt;">12</font><font style="display:inline;font-size:10pt;"> to </font><font style="display:inline;font-size:10pt;">18</font><font style="display:inline;font-size:10pt;">&nbsp;months. </font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 12279000 12298000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Foreign Currency Translation</font><font style="display:inline;font-size:10pt;">. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month, which approximates the results that would be obtained using actual currency rates on the dates of individual transactions. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into the U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in interest and other income, net in the condensed consolidated statements of operations. To date, both the translation gains or losses in other comprehensive income (loss) and the transaction gains or losses in interest and other income, net have been immaterial.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> -17992000 24447000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">10.</font><font style="display:inline;font-weight:bold;font-size:10pt;"> &nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;font-size:10pt;">Income taxes</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In January 2015, we licensed certain intellectual property rights related to our non-partnered clinical programs to our wholly-owned subsidiary in Switzerland. Although the license of intellectual property rights did not result in any gain or loss in the condensed consolidated statements of operations, the transaction generated a taxable gain in the U.S, and we are utilizing available federal and state net operating loss carryforwards to offset the majority of this gain. Any taxes incurred related to intercompany transactions are treated as prepaid tax in our condensed consolidated balance sheets and amortized to income tax expense over the life of the intellectual property.&nbsp;&nbsp;&nbsp;Any cash taxes anticipated to be paid related to this intercompany transaction are immaterial.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In January 2016, the Delaware Competes Act (the &#x201C;Act&#x201D;) was enacted by the State of Delaware, which changes the corporate income tax apportionment formula to a single sales factor apportionment formula by 2020.&nbsp;&nbsp;As a qualified Delaware headquarter company under the Act, we may elect to use either a three-factor apportionment or single sales factor starting in 2017.&nbsp;&nbsp;We are currently evaluating the impact of the law change and the apportionment election available to us starting in 2017.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 13000 14000 367000 400000 -300000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Income Taxes.</font><font style="display:inline;font-size:10pt;"> &nbsp;We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. In addition, we follow the guidance related to accounting for uncertainty in income taxes. This guidance creates a single model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before it is recognized in the financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 2124000 1814000 11671000 -13170000 1190000 29679000 -1000 -752000 194000 3667000 2500000 5200000 5441000 12687000 10134000 839000 846000 762000 2285000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">5.</font><font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;font-size:10pt;"> Inventory</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Our inventory balance consists of the following:</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands)</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Work-in-process</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,277 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,555 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Finished goods</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,309 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,783 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,586 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,338 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Inventories-current</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,309 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,783 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Inventories-non-current</font></p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,277 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,555 </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Inventories, stated at the lower of cost or market, consist of work in process and finished goods. At </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, &nbsp;</font><font style="display:inline;font-size:10pt;">$</font><font style="display:inline;font-size:10pt;">1.3</font><font style="display:inline;font-size:10pt;"> million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, &nbsp;</font><font style="display:inline;font-size:10pt;">$</font><font style="display:inline;font-size:10pt;">17.3</font><font style="display:inline;font-size:10pt;"> million of inventory was classified as non-current on the condensed consolidated balance sheet as we did not expect this inventory to be consumed for commercial use within the next twelve months.&nbsp;&nbsp;We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The raw materials and work-in-process inventory is not subject to expiration and the shelf life for finished goods inventory is </font><font style="display:inline;font-size:10pt;">36</font><font style="display:inline;font-size:10pt;">&nbsp;months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 1783000 1309000 1783000 1309000 17555000 17277000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Inventory.</font><font style="display:inline;font-size:10pt;"> &nbsp;Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. We began capitalizing inventory in mid-November 2011 once the U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) approved JAKAFI as the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to approval of JAKAFI have been recorded as research and development expense in our statements of operations. As a result, cost of product revenues for the next </font><font style="display:inline;font-size:10pt;">6</font><font style="display:inline;font-size:10pt;"> to </font><font style="display:inline;font-size:10pt;">9</font><font style="display:inline;font-size:10pt;"> months will reflect a lower average per unit cost of materials.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The raw materials and work-in-process inventory is not subject to expiration and the shelf life for finished goods inventory is </font><font style="display:inline;font-size:10pt;">36</font><font style="display:inline;font-size:10pt;">&nbsp;months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 17555000 17277000 1630000 1492000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Lease Accounting.</font><font style="display:inline;font-size:10pt;"> &nbsp;We account for operating leases by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date we gain possession of leased property. We include tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Capital leases are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets under capital leases are recorded in property and equipment, net on the condensed consolidated balance sheets and depreciated in a manner similar to other property and equipment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Certain construction projects may be accounted for as direct financing arrangements, whereby we record, over the construction period, the full cost of the asset in property and equipment, net on the condensed consolidated balance sheets. A corresponding liability is also recorded, net of leasehold improvements paid for by us, and is amortized over the expected lease term through monthly rental payments using the effective interest method.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="text-indent:0pt;margin-left:0pt; padding-right:8.5pt;"><font style="display:inline;font-weight:bold;font-size:10pt;">12.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display:inline;font-weight:bold;font-size:10pt;">Contingencies</font></font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="text-indent:0pt;margin-left:0pt; padding-right:20.5pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display:inline;font-weight:bold;font-size:10pt;"></font><font style="display:inline;font-size:10pt;">In February 2016, we received a Paragraph IV certification notice (the &#x201C;Notice Letter&#x201D;) regarding an Abbreviated New Drug Application submitted to the U.S. Food and Drug Administration requesting approval to market a generic version of Jakafi (ruxolitinib).&nbsp;&nbsp;The Notice Letter purports to challenge patents covering ruxolitinib phosphate and its use that expire in 2028.&nbsp;&nbsp;The Notice Letter does not challenge the ruxolitinib composition of matter patent, which expires on December 24, 2027.&nbsp;&nbsp;We do not believe there is any kind of loss that is probable or estimable related to this matter at this time.</font></font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> P15Y 836285000 876194000 1007440000 1103942000 168007000 200319000 39800000 35248000 35248000 35248000 32298000 32298000 32298000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Marketable Securities&#x2014;Available-for-Sale.</font><font style="display:inline;font-size:10pt;"> &nbsp;All marketable securities are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders&#x2019; equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in &#x201C;Interest and other income, net.&#x201D; The cost of securities sold is based on the specific identification method.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 186344000 153054000 32686000 9884000 -58575000 28757000 -4586000 97535000 -87900000 -18359000 24047000 -18359000 24047000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">Recent Accounting Pronouncements</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) No. 2014-09, &#x201C;Revenue from Contracts with Customers,&#x201D; which provides a five step approach to be applied to all contracts with customers. ASU No. 2014-09 also requires expanded disclosures about revenue recognition. This guidance is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein.&nbsp;&nbsp;Early adoption is permitted for reporting periods beginning after December 15, 2016.&nbsp;&nbsp;We are currently analyzing the impact of ASU No. 2014-09 on our results of operations and, at this time, we are unable to determine the impact of the new standard, if any, on our condensed consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15, &#x201C;Presentation of Financial Statements&#x2014;Going Concern,&#x201D; to provide guidance on management&#x2019;s responsibility in evaluating whether there is substantial doubt about a company&#x2019;s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about our ability to continue as a going concern within one year from the date the financial statements are issued. This guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. We do not believe the pending adoption of ASU No. 2014-15 will have a material impact on our condensed consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In February 2015, the FASB issued ASU No. 2015-02, &#x201C;Amendments to the Consolidation Analysis,&#x201D; which affects reporting entities that are required to evaluate whether they should consolidate certain legal entities.&nbsp;&nbsp;The amendments place more emphasis in the consolidation evaluation on variable interests other than fee arrangements such as principal investment risk (including debt or equity interests), guarantees of the value of the assets or liabilities of the variable interest entity (&#x201C;VIE&#x201D;), written put options on the assets of the VIE, or similar obligations. Additionally, the amendments reduce the extent to which related party arrangements cause an entity to be considered a primary beneficiary. This guidance is to be applied using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The amendments are effective for fiscal years beginning after December 15, 2015, and interim periods therein. We have concluded ASU No. 2015-02 has no impact on our condensed consolidated financial statements.&nbsp; </font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, &#x201C;Improvements to Employee Share-Based Payment Accounting,&#x201D; which changes the accounting for certain aspects of share-based payments to employees.&nbsp;&nbsp;The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled.&nbsp;&nbsp;In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows.&nbsp;&nbsp;The standard also clarifies that all cash payments made on an employee&#x2019;s behalf for withheld shares should be presented as a financing activity on the statement of cash flows, and provides an accounting policy election to account for forfeitures as they occur.&nbsp;&nbsp;The new standard is effective for our calendar year beginning January 1, 2017.&nbsp;&nbsp;Early adoption is permitted however all of the guidance must be adopted in the same period.&nbsp; </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We have elected to early adopt ASU No. 2016-09 as of the first quarter of 2016 which requires us to reflect any adjustments as of January 1, 2016, the beginning of the annual period that includes the interim period of adoption.&nbsp;&nbsp;The primary impact of adoption was the recognition of </font><font style="display:inline;font-size:10pt;">$325.6</font><font style="display:inline;font-size:10pt;"> million of accumulated excess tax benefits as deferred tax assets that under the previous guidance could not be recognized until the benefits were realized through a reduction in cash taxes paid.&nbsp;&nbsp;This part of the guidance was applied using a modified retrospective method with a cumulative-effect adjustment to the accumulated deficit for the excess tax benefits not previously recognized. However, given the full valuation allowance placed on the additional </font><font style="display:inline;font-size:10pt;">$325.6</font><font style="display:inline;font-size:10pt;"> million of deferred tax assets, the recognition upon adoption had no impact to our accumulated deficit as of January 1, 2016.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Adoption of the standard also resulted in the recognition of excess tax benefits in our income tax provision rather than as paid-in capital. This guidance is to be applied prospectively and resulted in the recognition of </font><font style="display:inline;font-size:10pt;">$0.3</font><font style="display:inline;font-size:10pt;"> million of excess tax benefits in our income tax provision rather than paid-in capital for the three months ended March 31, 2016.&nbsp;&nbsp;Amendments to the minimum statutory withholding tax requirements had no impact to the accumulated deficit as of January 1, 2016. In addition, we have elected to continue to estimate forfeitures expected to occur when determining the amount of compensation cost to be recognized in each period.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We elected to apply the presentation requirements for cash flows related to excess tax benefits prospectively </font><font style="display:inline;font-size:10pt;">which resulted in classification within operating cash flows of the excess tax benefits recognized during the three months ended March 31, 2016.&nbsp;&nbsp;This classification is now consistent with all other cash flow impacts from income taxes. In addition, the amendments to the cash flow statement presentation to classify cash payments made on behalf of employees for shares withheld as a financing activity had no impact on our previously reported cash flows, as this requirement is consistent with our previous presentation of these cash flows. </font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 1 -6935000 36039000 500000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">1.&nbsp;&nbsp;&nbsp;&nbsp; Organization and business</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Incyte Corporation (&#x201C;Incyte,&#x201D; &#x201C;we,&#x201D; &#x201C;us,&#x201D; or &#x201C;our&#x201D;) is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. Our pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI&#xAE; (ruxolitinib). Our operations are treated as </font><font style="display:inline;font-size:10pt;">one</font><font style="display:inline;font-size:10pt;"> operating segment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 443000 1206000 -178000 443000 1028000 48385000 48233000 178000 58000 80000 39829000 34467000 16795000 3553000 5562000 8000000 79900000 0.001 0.001 5000000 5000000 0 0 0 0 17843000 21806000 125000 110000 19274000 51114000 29180000 10219000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;Property and Equipment</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Property and equipment consists of the following:</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands)</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Office equipment</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,115 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,753 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Laboratory equipment</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,263 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,296 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Computer equipment</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,186 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,491 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Building and leasehold improvements</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,539 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,729 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140,103 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131,269 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Less accumulated depreciation and amortization</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(47,481) </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(45,263) </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>92,622 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86,006 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In 2013, we entered into a lease agreement for a new corporate headquarters, which consists of approximately </font><font style="display:inline;font-size:10pt;">190,000</font><font style="display:inline;font-size:10pt;"> square feet of laboratory and office space located in Wilmington, Delaware. The term of this lease is </font><font style="display:inline;font-size:10pt;">15</font><font style="display:inline;font-size:10pt;">&nbsp;years from the date of commencement. The construction of the facility was completed and the lease commenced on October 1, 2014 with a monthly lease rate of </font><font style="display:inline;font-size:10pt;">$0.5</font><font style="display:inline;font-size:10pt;">&nbsp;million for the first </font><font style="display:inline;font-size:10pt;">10</font><font style="display:inline;font-size:10pt;">&nbsp;years of the lease and with the monthly lease rate increasing annually during the last </font><font style="display:inline;font-size:10pt;">five</font><font style="display:inline;font-size:10pt;">&nbsp;years of the lease.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We are accounting for the lease as a direct financing arrangement whereby over the construction period, we recorded the value of the facility (consisting of the estimated fair value of the existing shell, plus construction costs incurred) as a capital asset, with a corresponding lease liability, net of build out costs paid for by us during the construction period. The lease liability will be amortized over the term of the lease using the effective interest method. In addition, we have posted a </font><font style="display:inline;font-size:10pt;">$15.0</font><font style="display:inline;font-size:10pt;">&nbsp;million letter of credit for the facility lease for the benefit of the landlord, which is collateralized by a restricted investments account for the same amount. This amount was recorded as restricted cash and investments on the condensed consolidated balance sheets and will be reduced over a period of time during the duration of the lease. The letter of credit could be subject to accelerated reductions if we meet certain pre-defined financial targets and will be cancelled as a condition of closing of the purchase as described in the paragraph below. Restricted investments related to this direct financing lease on the condensed consolidated balance sheets at </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> and </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;"> were </font><font style="display:inline;font-size:10pt;">$</font><font style="display:inline;font-size:10pt;">13.9</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$14.0</font><font style="display:inline;font-size:10pt;"> million, respectively.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">On August 21, 2015, we entered into an Agreement of Sale with Augustine Land II, L.P. (the &#x201C;Seller&#x201D;) to purchase the leased land and office building for approximately </font><font style="display:inline;font-size:10pt;">$79.9</font><font style="display:inline;font-size:10pt;"> million.&nbsp;&nbsp;Pursuant to the terms of the Agreement of Sale, we initially made a </font><font style="display:inline;font-size:10pt;">$4.0</font><font style="display:inline;font-size:10pt;"> million deposit with a third party escrow agent and a </font><font style="display:inline;font-size:10pt;">$4.0</font><font style="display:inline;font-size:10pt;"> million deposit with the Seller. The escrow agent held the deposit until the building inspection process was completed, and the escrow agent released the </font><font style="display:inline;font-size:10pt;">$4.0</font><font style="display:inline;font-size:10pt;"> million to the Seller in October 2015 as an additional deposit. As of March 31, 2016, the </font><font style="display:inline;font-size:10pt;">$8.0</font><font style="display:inline;font-size:10pt;"> million Seller deposit is recorded in other assets, net on the condensed consolidated balance sheets. </font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 131269000 70729000 22491000 31296000 6753000 140103000 72539000 26186000 33263000 8115000 86006000 92622000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Property and Equipment.</font><font style="display:inline;font-size:10pt;"> &nbsp;Property and equipment is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets (generally </font><font style="display:inline;font-size:10pt;">three</font><font style="display:inline;font-size:10pt;"> to </font><font style="display:inline;font-size:10pt;">five</font><font style="display:inline;font-size:10pt;"> years). Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Management continually reviews the estimated useful lives of technologically sensitive equipment and believes that those estimates appropriately reflect the current useful life of our assets. In the event that a currently unknown significantly advanced technology became commercially available, we would re-evaluate the value and estimated useful lives of our existing equipment, possibly having a material impact on the financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Property and equipment consists of the following:</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands)</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Office equipment</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,115 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,753 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Laboratory equipment</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,263 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,296 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Computer equipment</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,186 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,491 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Building and leasehold improvements</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,539 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,729 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140,103 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131,269 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Less accumulated depreciation and amortization</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(47,481) </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(45,263) </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>92,622 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86,006 </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> P5Y P3Y 452000 445000 118365000 1800000 20200000 156824000 4100000 700000 10000000 35000000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Research and Development Costs.</font><font style="display:inline;font-size:10pt;"> &nbsp;Our policy is to expense research and development costs as incurred. We often contract with clinical research organizations (&#x201C;CROs&#x201D;) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period. </font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 14000000 13900000 516000 517000 13977000 13866000 -1778987000 -1754940000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Revenue Recognition.</font><font style="display:inline;font-size:10pt;"> &nbsp;Revenues are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured. Revenues are deferred for fees received before earned or until no further obligations exist. We exercise judgment in determining that collectability is reasonably assured or that services have been delivered in accordance with the arrangement. We assess whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. We assess collectability based primarily on the customer&#x2019;s payment history and on the creditworthiness of the customer.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;text-decoration:underline;">Product Revenues</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Our product revenues consist of U.S. sales of JAKAFI and are recognized once we meet all four revenue recognition criteria described above. In November 2011, we began shipping JAKAFI to our customers, which include specialty pharmacies and wholesalers.&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and Medicare Part D coverage gap reimbursements. Product shipping and handling costs are included in cost of product revenues.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Customer Credits:</font><font style="display:inline;font-size:10pt;"> &nbsp;Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Rebates:</font><font style="display:inline;font-size:10pt;"> &nbsp;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launch. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-style:italic;font-size:10pt;">Chargebacks:&nbsp; </font><font style="display:inline;font-size:10pt;">Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received, we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel.&nbsp;&nbsp;If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Medicare Part&nbsp;D Coverage Gap:</font><font style="display:inline;font-size:10pt;"> &nbsp;Medicare Part&nbsp;D prescription drug benefit mandates manufacturers to fund </font><font style="display:inline;font-size:10pt;">50%</font><font style="display:inline;font-size:10pt;"> of the Medicare Part&nbsp;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part&nbsp;D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Co-payment Assistance:</font><font style="display:inline;font-size:10pt;"> &nbsp;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;text-decoration:underline;">Product Royalty Revenues</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI</font><font style="display:inline;font-size:6.5pt;">&#xAE;</font><font style="display:inline;font-size:10pt;"> outside the United States) by Novartis Pharmaceutical International&nbsp;Ltd. (&#x201C;Novartis&#x201D;) are based on net sales of licensed products in licensed territories as provided by Novartis. We recognize royalty revenues in the period the sales occur.</font> </p> <p style="margin:0pt;line-height:10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;text-decoration:underline;">Cost of Product Revenues</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Cost of product revenues includes all JAKAFI related costs that are recoverable through the commercialization of the product. Beginning in October 2014, we became obligated to pay tiered, low single digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States which are included in cost of product revenues.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;text-decoration:underline;">Contract and License Revenues</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Under agreements involving multiple deliverables, services and/or rights to use assets that we entered into prior to January 1, 2011, the multiple elements are divided into separate units of accounting when certain criteria are met, including whether the delivered items have stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered items. When separate units of accounting exist, consideration is allocated among the separate elements based on their respective fair values. The determination of fair value of each element is based on objective evidence from historical sales of the individual elements by us to other customers. If such evidence of fair value for each undelivered element of the arrangement does not exist, all revenue from the arrangement is deferred until such time that evidence of fair value for each undelivered element does exist or until all elements of the arrangement are delivered. When elements are specifically tied to a separate earnings process, revenue is recognized when the specific performance obligation tied to the element is completed. When revenues for an element are not specifically tied to a separate earnings process, they are recognized ratably over the term of the agreement. We assess whether a substantive milestone exists at the inception of our agreements. For all milestones within our arrangements that are considered substantive, we recognize revenue upon the achievement of the associated milestone. If a milestone is not considered substantive, we would recognize the applicable milestone payment over the remaining period of performance under the arrangement. As of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, all remaining potential milestones under our collaborative arrangements are considered substantive.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">On January&nbsp;1, 2011, updated guidance on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements we may enter into on or after January&nbsp;1, 2011. This updated guidance (i)&nbsp;relates to whether multiple deliverables exist, how the deliverables in a revenue arrangement should be separated and how the consideration should be allocated; (ii)&nbsp;requires companies to allocate revenues in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (iii)&nbsp;eliminates the use of the residual method and requires companies to allocate revenues using the relative selling price method. During the three months ended March&nbsp;31, 2016 and 2015, we did not enter into any agreements that are subject to this updated guidance. If we enter into an agreement with multiple deliverables after January&nbsp;1, 2011 or amend existing agreements, this updated guidance could have a material effect on our financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events. These </font><font style="display:inline;font-size:10pt;">three</font><font style="display:inline;font-size:10pt;"> categories of milestone events reflect </font><font style="display:inline;font-size:10pt;">the </font><font style="display:inline;font-size:10pt;">three</font><font style="display:inline;font-size:10pt;">&nbsp;</font><font style="display:inline;font-size:10pt;">stages of the life-cycle of our drugs, which we describe in more detail in the following paragraphs.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the FDA requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate&#x2019;s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (&#x201C;IND&#x201D;), which must be reviewed by the FDA.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (&#x201C;NDA&#x201D;) or biologics license application (&#x201C;BLA&#x201D;) to the FDA for review and FDA approval of the NDA or BLA.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.</font> </p> <p style="margin:0pt;line-height:10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase&nbsp;I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase&nbsp;II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase&nbsp;III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase&nbsp;I, Phase&nbsp;II or Phase&nbsp;III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 159275000 24800000 263464000 15673000 15700000 21903000 21900000 115330000 183267000 300000000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">The following potential common shares were excluded from the calculations as their effect would be anti-dilutive:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months&nbsp;Ended</font></p> </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Outstanding stock options and awards</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,652,265 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,626,717 </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Common shares issuable upon conversion of the </font><font style="display:inline;font-size:10pt;">4.75%</font><font style="display:inline;font-size:10pt;"> Convertible Senior Notes due 2015</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,353,076 </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Common shares issuable upon conversion of the 2018 Notes</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,245,244 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,245,263 </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Common shares issuable upon conversion of the 2020 Notes</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,241,284 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,245,263 </td> </tr> <tr> <td valign="bottom" style="width:62.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Total potential common shares excluded from diluted net loss per share computation</font></p> </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,138,793 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,470,319 </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The carrying amount and fair value of our convertible notes are as follows (in thousands):</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Carrying</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Carrying</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">0.375% Convertible Senior Notes due 2018</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>328,173 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>574,922 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>324,031 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>807,422 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">1.25% Convertible Senior Notes due 2020</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>299,469 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>588,427 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>295,862 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>816,123 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>627,642 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,163,349 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>619,893 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,623,545 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The components of the convertible notes are as follows (in thousands):</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Carrying&nbsp;Amount,</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Interest&nbsp;Rates</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31, </font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Debt</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Maturities</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">0.375% Convertible Senior Notes due 2018</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.375 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>328,173 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>324,031 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">1.25% Convertible Senior Notes due 2020</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.25 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2020 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>299,469 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>295,862 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>627,642 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>619,893 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Less current portion</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:60.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>627,642 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>619,893 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Net income (loss) per share was calculated as follows for the periods indicated:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months&nbsp;Ended</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;"> <font style="display:inline;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, </font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands, except per share data)</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Basic Net Income (Loss) Per Share</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Basic net income (loss)</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,047 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,359) </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Weighted average common shares outstanding</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,184 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>172,070 </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Basic net income (loss) per share</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.13 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.11) </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Diluted Net Income (Loss) Per Share</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Diluted net income (loss)</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,047 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,359) </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Weighted average common shares outstanding</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,184 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>172,070 </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Dilutive stock options and RSU&#x2019;s</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,441 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Weighted average shares used to compute diluted net income (loss) per share </font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>192,625 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>172,070 </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Diluted net income (loss) per share</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.12 </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:07.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.11) </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"></font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at fair value on a recurring basis as of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> (in thousands):</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value&nbsp;Measurement&nbsp;at&nbsp;Reporting&nbsp;Date&nbsp;Using:</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices&nbsp;in</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;Other</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Significant</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Active&nbsp;Markets&nbsp;for</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Observable</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unobservable</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Identical&nbsp;Assets</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Balance&nbsp;as&nbsp;of</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Cash and cash equivalents</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>657,615 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>657,615 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Corporate debt securities</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,054 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,054 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Long term investment (Note 7)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,298 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,298 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Total assets</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>689,913 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,054 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>842,967 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis as of </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;"> (in thousands):</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value&nbsp;Measurement&nbsp;at&nbsp;Reporting&nbsp;Date&nbsp;Using:</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices&nbsp;in</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;Other</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Significant</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Active&nbsp;Markets&nbsp;for</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Observable</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Unobservable</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Identical&nbsp;Assets</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Balance&nbsp;as&nbsp;of</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Cash and cash equivalents</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>521,439 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>521,439 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Corporate debt securities</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,344 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,344 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Long term investment (Note 7)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,248 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,248 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Total assets</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>556,687 </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,344 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>743,031 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Option activity under the 2010 Stock Plan was as follows:</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Subject&nbsp;to</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Outstanding&nbsp;Options</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Available</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Weighted&nbsp;Average</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">for&nbsp;Grant</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Balance at December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,846,717 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,052,279 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33.55 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Options granted</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,412,583) </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,412,583 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94.69 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Options exercised</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(751,784) </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14.06 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Options cancelled</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,324 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(68,324) </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73.24 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Options expired</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,834) </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.11 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Balance at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,502,458 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,642,920 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42.00 </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 44871000 64596000 17558000 20769000 P3Y 12843 67.62 400000 216711 88.28 834433 630565 266667 0.00 P3M P5Y18D P3M P5Y 0.38 0.50 0.61 0.49 Black-Scholes valuation model 0.0056 0.0135 0.0073 0.0150 565567 769435 3846717 2502458 1834 68324 1412583 9.56 32.59 26.67 41.56 11052279 11642920 33.55 42.00 14.06 3.11 73.24 94.69 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Stock Compensation</font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">.</font><font style="display:inline;font-size:10pt;"> &nbsp;Share-based payment transactions with employees, which include stock options, restricted stock units (&#x201C;RSUs&#x201D;) and performance shares (&#x201C;PSUs&#x201D;), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates.&nbsp;&nbsp;The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting.&nbsp;&nbsp;The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method.&nbsp;&nbsp;The fair value of RSUs, which are generally subject to cliff vesting, are recognized as compensation expense over the requisite service period using the straight line attribution method.&nbsp;&nbsp;The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, over the remaining requisite service period. We recorded </font><font style="display:inline;font-size:10pt;">$20.8</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$17.6</font><font style="display:inline;font-size:10pt;"> million of stock compensation expense on our condensed consolidated statements of operations for the three months ended </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016 and 2015</font><font style="display:inline;font-size:10pt;">, respectively.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">2.&nbsp;&nbsp;&nbsp;&nbsp; Summary of significant accounting policies</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Basis of presentation</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&nbsp;&nbsp;The condensed consolidated balance sheet as of March 31, 2016 and the condensed consolidated statements of operations, comprehensive income (loss) and cash flows for the three months ended March&nbsp;31, 2016 and 2015, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.&nbsp;&nbsp;The condensed consolidated balance sheet at </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;"> has been derived from audited financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#x201C;U.S. GAAP&#x201D;) have been condensed or omitted pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form&nbsp;10-K for the year ended </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;">.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Principles of Consolidation.</font><font style="display:inline;font-size:10pt;"> &nbsp;The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries, including Incyte Holdings Corporation, Incyte International Holdings S.a.r.l. and Incyte Europe S.a.r.l. All inter-company accounts, transactions, and profits have been eliminated in consolidation.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Foreign Currency Translation</font><font style="display:inline;font-size:10pt;">. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month, which approximates the results that would be obtained using actual currency rates on the dates of individual transactions. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into the U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in interest and other income, net in the condensed consolidated statements of operations. To date, both the translation gains or losses in other comprehensive income (loss) and the transaction gains or losses in interest and other income, net have been immaterial.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Use of Estimates.</font><font style="display:inline;font-size:10pt;"> &nbsp;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Concentrations of Credit Risk.</font><font style="display:inline;font-size:10pt;"> &nbsp;Cash, cash equivalents, marketable securities, trade receivables and restricted investments are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in corporate debt securities and, by policy, limit the amount of credit exposure to any </font><font style="display:inline;font-size:10pt;">one</font><font style="display:inline;font-size:10pt;"> issuer and to any </font><font style="display:inline;font-size:10pt;">one</font><font style="display:inline;font-size:10pt;"> type of investment, other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales of JAKAFI and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash, cash equivalents, marketable securities, trade receivables or restricted investments to date and do not require collateral on receivables.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Cash and Cash Equivalents.</font><font style="display:inline;font-size:10pt;"> &nbsp;Cash and cash equivalents are held in U.S. banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Marketable Securities&#x2014;Available-for-Sale.</font><font style="display:inline;font-size:10pt;"> &nbsp;All marketable securities are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders&#x2019; equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in &#x201C;Interest and other income, net.&#x201D; The cost of securities sold is based on the specific identification method.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Accounts Receivable.</font><font style="display:inline;font-size:10pt;"> &nbsp;As of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> and </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;">, we had </font><font style="display:inline;font-size:10pt;">no</font><font style="display:inline;font-size:10pt;"> allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Inventory.</font><font style="display:inline;font-size:10pt;"> &nbsp;Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. We began capitalizing inventory in mid-November 2011 once the U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) approved JAKAFI as the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to approval of JAKAFI have been recorded as research and development expense in our statements of operations. As a result, cost of product revenues for the next </font><font style="display:inline;font-size:10pt;">6</font><font style="display:inline;font-size:10pt;"> to </font><font style="display:inline;font-size:10pt;">9</font><font style="display:inline;font-size:10pt;"> months will reflect a lower average per unit cost of materials.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The raw materials and work-in-process inventory is not subject to expiration and the shelf life for finished goods inventory is </font><font style="display:inline;font-size:10pt;">36</font><font style="display:inline;font-size:10pt;">&nbsp;months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Variable Interest Entities</font><font style="display:inline;font-size:10pt;">. We perform an initial and on-going evaluation of the entities with which we have variable interests, such as equity ownership, in order to</font><font style="display:inline;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display:inline;font-size:10pt;">identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (&#x201C;VIE&#x201D; or &#x201C;VIEs&#x201D;). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE&#x2019;s economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE.&nbsp;&nbsp;As of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, there were </font><font style="display:inline;font-size:10pt;">no</font><font style="display:inline;font-size:10pt;"> entities in which we held a variable interest which we determined to be VIEs.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Equity Method Investments.</font><font style="display:inline;font-size:10pt;"> &nbsp;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option under U.S. GAAP.&nbsp;&nbsp;&nbsp;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Under the equity method of accounting, we record within our results of operations our share of income or loss of the investee company.&nbsp;&nbsp;Under the fair value option, our investment is carried at fair value on our condensed consolidated balance sheets as a long term investment and all changes in fair value are reported in our condensed consolidated statements of operations as an unrealized gain (loss) on long term investment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Property and Equipment.</font><font style="display:inline;font-size:10pt;"> &nbsp;Property and equipment is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets (generally </font><font style="display:inline;font-size:10pt;">three</font><font style="display:inline;font-size:10pt;"> to </font><font style="display:inline;font-size:10pt;">five</font><font style="display:inline;font-size:10pt;"> years). Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Management continually reviews the estimated useful lives of technologically sensitive equipment and believes that those estimates appropriately reflect the current useful life of our assets. In the event that a currently unknown significantly advanced technology became commercially available, we would re-evaluate the value and estimated useful lives of our existing equipment, possibly having a material impact on the financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Lease Accounting.</font><font style="display:inline;font-size:10pt;"> &nbsp;We account for operating leases by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date we gain possession of leased property. We include tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Capital leases are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets under capital leases are recorded in property and equipment, net on the condensed consolidated balance sheets and depreciated in a manner similar to other property and equipment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Certain construction projects may be accounted for as direct financing arrangements, whereby we record, over the construction period, the full cost of the asset in property and equipment, net on the condensed consolidated balance sheets. A corresponding liability is also recorded, net of leasehold improvements paid for by us, and is amortized over the expected lease term through monthly rental payments using the effective interest method.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Income Taxes.</font><font style="display:inline;font-size:10pt;"> &nbsp;We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. In addition, we follow the guidance related to accounting for uncertainty in income taxes. This guidance creates a single model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before it is recognized in the financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Financing Costs Related to Long-term Debt.</font><font style="display:inline;font-size:10pt;"> &nbsp;Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the consolidated balance sheets.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Grant Accounting.</font><font style="display:inline;font-size:10pt;"> &nbsp;Grant amounts received from government agencies for operations are deferred and are amortized into income over the service period of the grant. Grant amounts received for purchases of capital assets are deferred and amortized into interest and other income, net over the useful life of the related capital assets. Such amounts are recorded in other liabilities on the condensed consolidated balance sheets.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Net Income (Loss) Per Share.</font><font style="display:inline;font-size:10pt;"> &nbsp;Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Accumulated Other Comprehensive Income (Loss).</font><font style="display:inline;font-size:10pt;"> &nbsp;Accumulated other comprehensive income (loss) consists of realized and unrealized gains or losses on marketable securities and restricted cash and investments.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Revenue Recognition.</font><font style="display:inline;font-size:10pt;"> &nbsp;Revenues are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured. Revenues are deferred for fees received before earned or until no further obligations exist. We exercise judgment in determining that collectability is reasonably assured or that services have been delivered in accordance with the arrangement. We assess whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. We assess collectability based primarily on the customer&#x2019;s payment history and on the creditworthiness of the customer.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;text-decoration:underline;">Product Revenues</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Our product revenues consist of U.S. sales of JAKAFI and are recognized once we meet all four revenue recognition criteria described above. In November 2011, we began shipping JAKAFI to our customers, which include specialty pharmacies and wholesalers.&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and Medicare Part D coverage gap reimbursements. Product shipping and handling costs are included in cost of product revenues.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Customer Credits:</font><font style="display:inline;font-size:10pt;"> &nbsp;Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Rebates:</font><font style="display:inline;font-size:10pt;"> &nbsp;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launch. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-style:italic;font-size:10pt;">Chargebacks:&nbsp; </font><font style="display:inline;font-size:10pt;">Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received, we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel.&nbsp;&nbsp;If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Medicare Part&nbsp;D Coverage Gap:</font><font style="display:inline;font-size:10pt;"> &nbsp;Medicare Part&nbsp;D prescription drug benefit mandates manufacturers to fund </font><font style="display:inline;font-size:10pt;">50%</font><font style="display:inline;font-size:10pt;"> of the Medicare Part&nbsp;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part&nbsp;D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Co-payment Assistance:</font><font style="display:inline;font-size:10pt;"> &nbsp;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;text-decoration:underline;">Product Royalty Revenues</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI</font><font style="display:inline;font-size:6.5pt;">&#xAE;</font><font style="display:inline;font-size:10pt;"> outside the United States) by Novartis Pharmaceutical International&nbsp;Ltd. (&#x201C;Novartis&#x201D;) are based on net sales of licensed products in licensed territories as provided by Novartis. We recognize royalty revenues in the period the sales occur.</font> </p> <p style="margin:0pt;line-height:10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;text-decoration:underline;">Cost of Product Revenues</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Cost of product revenues includes all JAKAFI related costs that are recoverable through the commercialization of the product. Beginning in October 2014, we became obligated to pay tiered, low single digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States which are included in cost of product revenues.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;text-decoration:underline;">Contract and License Revenues</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Under agreements involving multiple deliverables, services and/or rights to use assets that we entered into prior to January 1, 2011, the multiple elements are divided into separate units of accounting when certain criteria are met, including whether the delivered items have stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered items. When separate units of accounting exist, consideration is allocated among the separate elements based on their respective fair values. The determination of fair value of each element is based on objective evidence from historical sales of the individual elements by us to other customers. If such evidence of fair value for each undelivered element of the arrangement does not exist, all revenue from the arrangement is deferred until such time that evidence of fair value for each undelivered element does exist or until all elements of the arrangement are delivered. When elements are specifically tied to a separate earnings process, revenue is recognized when the specific performance obligation tied to the element is completed. When revenues for an element are not specifically tied to a separate earnings process, they are recognized ratably over the term of the agreement. We assess whether a substantive milestone exists at the inception of our agreements. For all milestones within our arrangements that are considered substantive, we recognize revenue upon the achievement of the associated milestone. If a milestone is not considered substantive, we would recognize the applicable milestone payment over the remaining period of performance under the arrangement. As of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;">, all remaining potential milestones under our collaborative arrangements are considered substantive.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">On January&nbsp;1, 2011, updated guidance on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements we may enter into on or after January&nbsp;1, 2011. This updated guidance (i)&nbsp;relates to whether multiple deliverables exist, how the deliverables in a revenue arrangement should be separated and how the consideration should be allocated; (ii)&nbsp;requires companies to allocate revenues in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (iii)&nbsp;eliminates the use of the residual method and requires companies to allocate revenues using the relative selling price method. During the three months ended March&nbsp;31, 2016 and 2015, we did not enter into any agreements that are subject to this updated guidance. If we enter into an agreement with multiple deliverables after January&nbsp;1, 2011 or amend existing agreements, this updated guidance could have a material effect on our financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events. These </font><font style="display:inline;font-size:10pt;">three</font><font style="display:inline;font-size:10pt;"> categories of milestone events reflect </font><font style="display:inline;font-size:10pt;">the </font><font style="display:inline;font-size:10pt;">three</font><font style="display:inline;font-size:10pt;">&nbsp;</font><font style="display:inline;font-size:10pt;">stages of the life-cycle of our drugs, which we describe in more detail in the following paragraphs.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the FDA requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate&#x2019;s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (&#x201C;IND&#x201D;), which must be reviewed by the FDA.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (&#x201C;NDA&#x201D;) or biologics license application (&#x201C;BLA&#x201D;) to the FDA for review and FDA approval of the NDA or BLA.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.</font> </p> <p style="margin:0pt;line-height:10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase&nbsp;I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase&nbsp;II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase&nbsp;III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase&nbsp;I, Phase&nbsp;II or Phase&nbsp;III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Research and Development Costs.</font><font style="display:inline;font-size:10pt;"> &nbsp;Our policy is to expense research and development costs as incurred. We often contract with clinical research organizations (&#x201C;CROs&#x201D;) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period. </font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Stock Compensation</font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">.</font><font style="display:inline;font-size:10pt;"> &nbsp;Share-based payment transactions with employees, which include stock options, restricted stock units (&#x201C;RSUs&#x201D;) and performance shares (&#x201C;PSUs&#x201D;), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates.&nbsp;&nbsp;The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting.&nbsp;&nbsp;The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method.&nbsp;&nbsp;The fair value of RSUs, which are generally subject to cliff vesting, are recognized as compensation expense over the requisite service period using the straight line attribution method.&nbsp;&nbsp;The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, over the remaining requisite service period. We recorded </font><font style="display:inline;font-size:10pt;">$20.8</font><font style="display:inline;font-size:10pt;"> million and </font><font style="display:inline;font-size:10pt;">$17.6</font><font style="display:inline;font-size:10pt;"> million of stock compensation expense on our condensed consolidated statements of operations for the three months ended </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016 and 2015</font><font style="display:inline;font-size:10pt;">, respectively.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">Recent Accounting Pronouncements</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) No. 2014-09, &#x201C;Revenue from Contracts with Customers,&#x201D; which provides a five step approach to be applied to all contracts with customers. ASU No. 2014-09 also requires expanded disclosures about revenue recognition. This guidance is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein.&nbsp;&nbsp;Early adoption is permitted for reporting periods beginning after December 15, 2016.&nbsp;&nbsp;We are currently analyzing the impact of ASU No. 2014-09 on our results of operations and, at this time, we are unable to determine the impact of the new standard, if any, on our condensed consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15, &#x201C;Presentation of Financial Statements&#x2014;Going Concern,&#x201D; to provide guidance on management&#x2019;s responsibility in evaluating whether there is substantial doubt about a company&#x2019;s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about our ability to continue as a going concern within one year from the date the financial statements are issued. This guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. We do not believe the pending adoption of ASU No. 2014-15 will have a material impact on our condensed consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In February 2015, the FASB issued ASU No. 2015-02, &#x201C;Amendments to the Consolidation Analysis,&#x201D; which affects reporting entities that are required to evaluate whether they should consolidate certain legal entities.&nbsp;&nbsp;The amendments place more emphasis in the consolidation evaluation on variable interests other than fee arrangements such as principal investment risk (including debt or equity interests), guarantees of the value of the assets or liabilities of the variable interest entity (&#x201C;VIE&#x201D;), written put options on the assets of the VIE, or similar obligations. Additionally, the amendments reduce the extent to which related party arrangements cause an entity to be considered a primary beneficiary. This guidance is to be applied using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The amendments are effective for fiscal years beginning after December 15, 2015, and interim periods therein. We have concluded ASU No. 2015-02 has no impact on our condensed consolidated financial statements.&nbsp; </font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, &#x201C;Improvements to Employee Share-Based Payment Accounting,&#x201D; which changes the accounting for certain aspects of share-based payments to employees.&nbsp;&nbsp;The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled.&nbsp;&nbsp;In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows.&nbsp;&nbsp;The standard also clarifies that all cash payments made on an employee&#x2019;s behalf for withheld shares should be presented as a financing activity on the statement of cash flows, and provides an accounting policy election to account for forfeitures as they occur.&nbsp;&nbsp;The new standard is effective for our calendar year beginning January 1, 2017.&nbsp;&nbsp;Early adoption is permitted however all of the guidance must be adopted in the same period.&nbsp; </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We have elected to early adopt ASU No. 2016-09 as of the first quarter of 2016 which requires us to reflect any adjustments as of January 1, 2016, the beginning of the annual period that includes the interim period of adoption.&nbsp;&nbsp;The primary impact of adoption was the recognition of </font><font style="display:inline;font-size:10pt;">$325.6</font><font style="display:inline;font-size:10pt;"> million of accumulated excess tax benefits as deferred tax assets that under the previous guidance could not be recognized until the benefits were realized through a reduction in cash taxes paid.&nbsp;&nbsp;This part of the guidance was applied using a modified retrospective method with a cumulative-effect adjustment to the accumulated deficit for the excess tax benefits not previously recognized. However, given the full valuation allowance placed on the additional </font><font style="display:inline;font-size:10pt;">$325.6</font><font style="display:inline;font-size:10pt;"> million of deferred tax assets, the recognition upon adoption had no impact to our accumulated deficit as of January 1, 2016.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">Adoption of the standard also resulted in the recognition of excess tax benefits in our income tax provision rather than as paid-in capital. This guidance is to be applied prospectively and resulted in the recognition of </font><font style="display:inline;font-size:10pt;">$0.3</font><font style="display:inline;font-size:10pt;"> million of excess tax benefits in our income tax provision rather than paid-in capital for the three months ended March 31, 2016.&nbsp;&nbsp;Amendments to the minimum statutory withholding tax requirements had no impact to the accumulated deficit as of January 1, 2016. In addition, we have elected to continue to estimate forfeitures expected to occur when determining the amount of compensation cost to be recognized in each period.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">We elected to apply the presentation requirements for cash flows related to excess tax benefits prospectively </font><font style="display:inline;font-size:10pt;">which resulted in classification within operating cash flows of the excess tax benefits recognized during the three months ended March 31, 2016.&nbsp;&nbsp;This classification is now consistent with all other cash flow impacts from income taxes. In addition, the amendments to the cash flow statement presentation to classify cash payments made on behalf of employees for shares withheld as a financing activity had no impact on our previously reported cash flows, as this requirement is consistent with our previous presentation of these cash flows. </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 171155000 227748000 751784 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-size:10pt;">13.&nbsp;&nbsp;&nbsp;&nbsp;Subsequent event </font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-weight:bold;font-size:10pt;"></font><font style="display:inline;font-size:10pt;">In April 2016, we entered into an amendment to the agreement with Novartis under which Novartis received exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in the GVHD field.&nbsp;&nbsp;We are eligible to receive future additional payments from Novartis if defined development and regulatory milestones relating to ruxolitinib for GVHD outside of the United States are achieved. In addition, we remain eligible to receive potential milestone payments and royalties on total sales of ruxolitinib (including GVHD) by Novartis outside of the United States.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In April 2016, we closed on the agreement of sale with Augustine Land II, L.P. for the purchase of the previously leased land and office building.&nbsp; </font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">In May 2016, we entered into a share purchase agreement with ARIAD Pharmaceuticals, Inc. (&#x201C;ARIAD&#x201D;) and a wholly-owned subsidiary of ARIAD pursuant to which we will acquire all of the outstanding shares of a wholly-owned subsidiary of ARIAD that is the parent company of ARIAD&#x2019;s European subsidiaries responsible for the development and commercialization of Iclusig&#xAE; (ponatinib) in the European Union and 22 other countries (the &#x201C;Territory&#x201D;) for an upfront payment of </font><font style="display:inline;font-size:10pt;">$140.0</font><font style="display:inline;font-size:10pt;"> million. &nbsp;In addition, we agreed upon the terms of a license agreement to be entered into by ARIAD and us, pursuant to which we will be granted an exclusive license to develop and commercialize Iclusig in the Territory.&nbsp; ARIAD will be eligible to receive from us tiered royalties on net sales of Iclusig in the Territory and up to </font><font style="display:inline;font-size:10pt;">$135.0</font><font style="display:inline;font-size:10pt;"> million in potential future oncology development and regulatory approval milestone payments.&nbsp; The closing under the share purchase agreement and effectiveness of the license agreement is expected to occur on June 1, 2016, pending satisfaction of customary closing conditions.&nbsp; We believe that the transaction will be accounted for as a business combination.&nbsp;&nbsp;Please see Item 5(a) of Part II of this Quarterly Report on Form 10-Q for a more detailed description of the share purchase agreement and license agreement.</font> </p> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Accounts Receivable.</font><font style="display:inline;font-size:10pt;"> &nbsp;As of </font><font style="display:inline;font-size:10pt;">March&nbsp;31, 2016</font><font style="display:inline;font-size:10pt;"> and </font><font style="display:inline;font-size:10pt;">December&nbsp;31, 2015</font><font style="display:inline;font-size:10pt;">, we had </font><font style="display:inline;font-size:10pt;">no</font><font style="display:inline;font-size:10pt;"> allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> -2950000 -3000000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;font-size:10pt;">Use of Estimates.</font><font style="display:inline;font-size:10pt;"> &nbsp;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font> </p> <p style="margin:0pt;line-height:10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-size:10pt;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 172070 192625 172070 187184 The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date. EX-101.SCH 8 incy-20160331.xsd EX-101.SCH 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair value of financial instruments (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Fair value of financial instruments (Details 2) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Inventory (Details) Calc2 link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00405 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Concentration of Credit Risk link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock compensation link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Net income (loss) per share link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair value of financial instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Concentration of Credit Risk (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Stock compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Net loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and business (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of significant accounting policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Property and Equipment (Details 2) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - License agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - License agreements (Details 2) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - License agreements (Details 3) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Stock Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Stock Compensation (Details 3) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Net income (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 incy-20160331_cal.xml EX-101.CAL EX-101.DEF 10 incy-20160331_def.xml EX-101.DEF EX-101.LAB 11 incy-20160331_lab.xml EX-101.LAB EX-101.PRE 12 incy-20160331_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2016
May. 03, 2016
Document and Entity Information    
Entity Registrant Name INCYTE CORP  
Entity Central Index Key 0000879169  
Document Type 10-Q  
Document Period End Date Mar. 31, 2016  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   187,619,384
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q1  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
[1]
Current assets:    
Cash and cash equivalents $ 657,615 $ 521,439
Marketable securities-available-for-sale 153,054 186,344
Restricted cash and investments 517 516
Accounts receivable 101,280 114,450
Inventory 1,309 1,783
Prepaid expenses and other current assets 21,806 17,843
Total current assets 935,581 842,375
Restricted cash and investments 13,866 13,977
Long term investment 32,298 35,248
Inventory 17,277 17,555
Property and equipment, net 92,622 86,006
Other assets, net 12,298 12,279
Total assets 1,103,942 1,007,440
Current liabilities:    
Accounts payable 31,899 30,085
Accrued compensation 23,197 38,117
Interest payable 2,285 762
Accrued and other current liabilities 133,641 86,531
Deferred revenue-collaborative agreements 9,297 12,512
Total current liabilities 200,319 168,007
Convertible senior notes 627,642 619,893
Other liabilities 48,233 48,385
Total liabilities $ 876,194 $ 836,285
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding as of March 31, 2016 and December 31, 2015
Common stock, $0.001 par value; 400,000,000 shares authorized; 187,402,129 and 186,650,249 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively $ 187 $ 187
Additional paid-in capital 1,982,104 1,950,764
Accumulated other comprehensive income (loss) 397 (809)
Accumulated deficit (1,754,940) (1,778,987)
Total stockholders' equity (deficit) 227,748 171,155
Total liabilities and stockholders' equity (deficit) $ 1,103,942 $ 1,007,440
[1] The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date.
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2016
Dec. 31, 2015
CONDENSED CONSOLIDATED BALANCE SHEETS    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 400,000,000 400,000,000
Common stock, shares issued 187,402,129 186,650,249
Common stock, shares outstanding 187,402,129 186,650,249
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenues:    
Product revenues, net $ 183,267 $ 115,330
Product royalty revenues 21,903 15,673
Contract revenues 58,214 28,214
Other revenues 80 58
Total revenues 263,464 159,275
Costs and expenses:    
Cost of product revenues 6,005 2,974
Research and development 156,824 118,365
Selling, general and administrative 64,596 44,871
Total costs and expenses 227,425 166,210
Income (loss) from operations 36,039 (6,935)
Interest and other income, net 1,492 1,630
Interest expense (10,134) (12,687)
Unrealized loss on long term investment (2,950)  
Income (loss) before provision for income taxes 24,447 (17,992)
Provision for income taxes 400 367
Net income (loss) $ 24,047 $ (18,359)
Net income (loss) per share:    
Basic $ 0.13 $ (0.11)
Diluted $ 0.12 $ (0.11)
Shares used in computing net income (loss) per share:    
Basic 187,184 172,070
Diluted 192,625 172,070
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)    
Net income (loss) $ 24,047 $ (18,359)
Other comprehensive income:    
Unrealized gain on restricted investments and marketable securities, net of tax 1,028 443
Reclassification adjustment for realized gains on marketable securities 178  
Other comprehensive income 1,206 443
Comprehensive income (loss) $ 25,253 $ (17,916)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities:    
Net income (loss) $ 24,047 $ (18,359)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization of debt discounts 11,058 11,835
Stock-based compensation 20,769 17,558
Other, net 178  
Unrealized loss on long term investment 2,950  
Excess tax benefit from stock based compensation   (3,833)
Changes in operating assets and liabilities:    
Accounts receivable 13,170 (11,671)
Prepaid expenses and other assets (3,667) (194)
Inventory 752 1
Accounts payable 1,814 2,124
Accrued and other liabilities 29,679 1,190
Deferred revenue - collaborative agreements (3,215) (3,237)
Net cash provided by (used in) operating activities 97,535 (4,586)
Cash flows from investing activities:    
Long term investment   (39,829)
Capital expenditures (5,562) (3,553)
Purchases of marketable securities (16,795) (34,467)
Sale and maturities of marketable securities 51,114 19,274
Net cash provided by (used in) investing activities 28,757 (58,575)
Cash flows from financing activities:    
Restricted investments, net 110 125
Proceeds from issuance of common stock under stock plans 10,219 29,180
Direct financing arrangement repayments (445) (452)
Excess tax benefit from stock based compensation   3,833
Net cash provided by financing activities 9,884 32,686
Net increase in cash and cash equivalents 136,176 (30,475)
Cash and cash equivalents at beginning of period [1] 521,439  
Cash and cash equivalents at end of period 657,615 421,822
Supplemental Schedule of Cash Flow Information    
Interest paid 846 839
Incomes taxes paid 14 $ 13
Reclassification to common stock and additional paid in capital in connection with conversions of 1.25% convertible senior notes due 2020 $ 4  
[1] The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date.
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)
Mar. 31, 2016
1.25% Convertible Senior Notes due 2020  
Interest rate of debt (as a percent) 1.25%
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
Organization and business
3 Months Ended
Mar. 31, 2016
Organization and business  
Organization and Summary of Significant Accounting Policies

1.     Organization and business

 

Incyte Corporation (“Incyte,” “we,” “us,” or “our”) is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. Our pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI® (ruxolitinib). Our operations are treated as one operating segment.

 

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of significant accounting policies
3 Months Ended
Mar. 31, 2016
Summary of significant accounting policies  
Summary of significant accounting policies

2.     Summary of significant accounting policies

 

Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  The condensed consolidated balance sheet as of March 31, 2016 and the condensed consolidated statements of operations, comprehensive income (loss) and cash flows for the three months ended March 31, 2016 and 2015, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.  The condensed consolidated balance sheet at December 31, 2015 has been derived from audited financial statements.

 

Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission.

 

Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.

 

Principles of Consolidation.  The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries, including Incyte Holdings Corporation, Incyte International Holdings S.a.r.l. and Incyte Europe S.a.r.l. All inter-company accounts, transactions, and profits have been eliminated in consolidation.

 

Foreign Currency Translation. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month, which approximates the results that would be obtained using actual currency rates on the dates of individual transactions. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into the U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in interest and other income, net in the condensed consolidated statements of operations. To date, both the translation gains or losses in other comprehensive income (loss) and the transaction gains or losses in interest and other income, net have been immaterial.

 

Use of Estimates.  The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

 

Concentrations of Credit Risk.  Cash, cash equivalents, marketable securities, trade receivables and restricted investments are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in corporate debt securities and, by policy, limit the amount of credit exposure to any one issuer and to any one type of investment, other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales of JAKAFI and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash, cash equivalents, marketable securities, trade receivables or restricted investments to date and do not require collateral on receivables.

 

Cash and Cash Equivalents.  Cash and cash equivalents are held in U.S. banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.

 

Marketable Securities—Available-for-Sale.  All marketable securities are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders’ equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in “Interest and other income, net.” The cost of securities sold is based on the specific identification method.

 

Accounts Receivable.  As of March 31, 2016 and December 31, 2015, we had no allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.

 

Inventory.  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. We began capitalizing inventory in mid-November 2011 once the U.S. Food and Drug Administration (“FDA”) approved JAKAFI as the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to approval of JAKAFI have been recorded as research and development expense in our statements of operations. As a result, cost of product revenues for the next 6 to 9 months will reflect a lower average per unit cost of materials.

 

The raw materials and work-in-process inventory is not subject to expiration and the shelf life for finished goods inventory is 36 months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.

 

Variable Interest Entities. We perform an initial and on-going evaluation of the entities with which we have variable interests, such as equity ownership, in order to identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (“VIE” or “VIEs”). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE’s economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE.  As of March 31, 2016, there were no entities in which we held a variable interest which we determined to be VIEs.

 

Equity Method Investments.  In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option under U.S. GAAP.   In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Under the equity method of accounting, we record within our results of operations our share of income or loss of the investee company.  Under the fair value option, our investment is carried at fair value on our condensed consolidated balance sheets as a long term investment and all changes in fair value are reported in our condensed consolidated statements of operations as an unrealized gain (loss) on long term investment.

 

Property and Equipment.  Property and equipment is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets (generally three to five years). Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.

 

Management continually reviews the estimated useful lives of technologically sensitive equipment and believes that those estimates appropriately reflect the current useful life of our assets. In the event that a currently unknown significantly advanced technology became commercially available, we would re-evaluate the value and estimated useful lives of our existing equipment, possibly having a material impact on the financial statements.

 

Lease Accounting.  We account for operating leases by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date we gain possession of leased property. We include tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease.

 

Capital leases are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets under capital leases are recorded in property and equipment, net on the condensed consolidated balance sheets and depreciated in a manner similar to other property and equipment.

 

Certain construction projects may be accounted for as direct financing arrangements, whereby we record, over the construction period, the full cost of the asset in property and equipment, net on the condensed consolidated balance sheets. A corresponding liability is also recorded, net of leasehold improvements paid for by us, and is amortized over the expected lease term through monthly rental payments using the effective interest method.

 

Income Taxes.  We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. In addition, we follow the guidance related to accounting for uncertainty in income taxes. This guidance creates a single model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before it is recognized in the financial statements.

 

Financing Costs Related to Long-term Debt.  Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the consolidated balance sheets.

 

Grant Accounting.  Grant amounts received from government agencies for operations are deferred and are amortized into income over the service period of the grant. Grant amounts received for purchases of capital assets are deferred and amortized into interest and other income, net over the useful life of the related capital assets. Such amounts are recorded in other liabilities on the condensed consolidated balance sheets.

 

Net Income (Loss) Per Share.  Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.

 

Accumulated Other Comprehensive Income (Loss).  Accumulated other comprehensive income (loss) consists of realized and unrealized gains or losses on marketable securities and restricted cash and investments.

 

Revenue Recognition.  Revenues are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured. Revenues are deferred for fees received before earned or until no further obligations exist. We exercise judgment in determining that collectability is reasonably assured or that services have been delivered in accordance with the arrangement. We assess whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. We assess collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.

 

Product Revenues

 

Our product revenues consist of U.S. sales of JAKAFI and are recognized once we meet all four revenue recognition criteria described above. In November 2011, we began shipping JAKAFI to our customers, which include specialty pharmacies and wholesalers. 

 

We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and Medicare Part D coverage gap reimbursements. Product shipping and handling costs are included in cost of product revenues.

 

Customer Credits:  Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.

 

Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launch. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Chargebacks:  Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received, we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel.  If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Medicare Part D Coverage Gap:  Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Co-payment Assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.

 

Product Royalty Revenues

 

Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI® outside the United States) by Novartis Pharmaceutical International Ltd. (“Novartis”) are based on net sales of licensed products in licensed territories as provided by Novartis. We recognize royalty revenues in the period the sales occur.

 

Cost of Product Revenues

 

Cost of product revenues includes all JAKAFI related costs that are recoverable through the commercialization of the product. Beginning in October 2014, we became obligated to pay tiered, low single digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States which are included in cost of product revenues.

 

Contract and License Revenues

 

Under agreements involving multiple deliverables, services and/or rights to use assets that we entered into prior to January 1, 2011, the multiple elements are divided into separate units of accounting when certain criteria are met, including whether the delivered items have stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered items. When separate units of accounting exist, consideration is allocated among the separate elements based on their respective fair values. The determination of fair value of each element is based on objective evidence from historical sales of the individual elements by us to other customers. If such evidence of fair value for each undelivered element of the arrangement does not exist, all revenue from the arrangement is deferred until such time that evidence of fair value for each undelivered element does exist or until all elements of the arrangement are delivered. When elements are specifically tied to a separate earnings process, revenue is recognized when the specific performance obligation tied to the element is completed. When revenues for an element are not specifically tied to a separate earnings process, they are recognized ratably over the term of the agreement. We assess whether a substantive milestone exists at the inception of our agreements. For all milestones within our arrangements that are considered substantive, we recognize revenue upon the achievement of the associated milestone. If a milestone is not considered substantive, we would recognize the applicable milestone payment over the remaining period of performance under the arrangement. As of March 31, 2016, all remaining potential milestones under our collaborative arrangements are considered substantive.

 

On January 1, 2011, updated guidance on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements we may enter into on or after January 1, 2011. This updated guidance (i) relates to whether multiple deliverables exist, how the deliverables in a revenue arrangement should be separated and how the consideration should be allocated; (ii) requires companies to allocate revenues in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (iii) eliminates the use of the residual method and requires companies to allocate revenues using the relative selling price method. During the three months ended March 31, 2016 and 2015, we did not enter into any agreements that are subject to this updated guidance. If we enter into an agreement with multiple deliverables after January 1, 2011 or amend existing agreements, this updated guidance could have a material effect on our financial statements.

 

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events. These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraphs.

 

The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the FDA requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate’s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (“IND”), which must be reviewed by the FDA.

 

The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (“NDA”) or biologics license application (“BLA”) to the FDA for review and FDA approval of the NDA or BLA.

 

Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.

 

Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase I, Phase II or Phase III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.

 

Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.

 

Research and Development Costs.  Our policy is to expense research and development costs as incurred. We often contract with clinical research organizations (“CROs”) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract.

 

These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period.

 

Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred.

 

Stock Compensation.  Share-based payment transactions with employees, which include stock options, restricted stock units (“RSUs”) and performance shares (“PSUs”), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates.  The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting.  The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method.  The fair value of RSUs, which are generally subject to cliff vesting, are recognized as compensation expense over the requisite service period using the straight line attribution method.  The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, over the remaining requisite service period. We recorded $20.8 million and $17.6 million of stock compensation expense on our condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015, respectively.

 

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which provides a five step approach to be applied to all contracts with customers. ASU No. 2014-09 also requires expanded disclosures about revenue recognition. This guidance is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein.  Early adoption is permitted for reporting periods beginning after December 15, 2016.  We are currently analyzing the impact of ASU No. 2014-09 on our results of operations and, at this time, we are unable to determine the impact of the new standard, if any, on our condensed consolidated financial statements.

 

In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements—Going Concern,” to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about our ability to continue as a going concern within one year from the date the financial statements are issued. This guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. We do not believe the pending adoption of ASU No. 2014-15 will have a material impact on our condensed consolidated financial statements.

 

In February 2015, the FASB issued ASU No. 2015-02, “Amendments to the Consolidation Analysis,” which affects reporting entities that are required to evaluate whether they should consolidate certain legal entities.  The amendments place more emphasis in the consolidation evaluation on variable interests other than fee arrangements such as principal investment risk (including debt or equity interests), guarantees of the value of the assets or liabilities of the variable interest entity (“VIE”), written put options on the assets of the VIE, or similar obligations. Additionally, the amendments reduce the extent to which related party arrangements cause an entity to be considered a primary beneficiary. This guidance is to be applied using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The amendments are effective for fiscal years beginning after December 15, 2015, and interim periods therein. We have concluded ASU No. 2015-02 has no impact on our condensed consolidated financial statements. 

 

In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which changes the accounting for certain aspects of share-based payments to employees.  The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled.  In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows.  The standard also clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on the statement of cash flows, and provides an accounting policy election to account for forfeitures as they occur.  The new standard is effective for our calendar year beginning January 1, 2017.  Early adoption is permitted however all of the guidance must be adopted in the same period. 

 

We have elected to early adopt ASU No. 2016-09 as of the first quarter of 2016 which requires us to reflect any adjustments as of January 1, 2016, the beginning of the annual period that includes the interim period of adoption.  The primary impact of adoption was the recognition of $325.6 million of accumulated excess tax benefits as deferred tax assets that under the previous guidance could not be recognized until the benefits were realized through a reduction in cash taxes paid.  This part of the guidance was applied using a modified retrospective method with a cumulative-effect adjustment to the accumulated deficit for the excess tax benefits not previously recognized. However, given the full valuation allowance placed on the additional $325.6 million of deferred tax assets, the recognition upon adoption had no impact to our accumulated deficit as of January 1, 2016.

 

Adoption of the standard also resulted in the recognition of excess tax benefits in our income tax provision rather than as paid-in capital. This guidance is to be applied prospectively and resulted in the recognition of $0.3 million of excess tax benefits in our income tax provision rather than paid-in capital for the three months ended March 31, 2016.  Amendments to the minimum statutory withholding tax requirements had no impact to the accumulated deficit as of January 1, 2016. In addition, we have elected to continue to estimate forfeitures expected to occur when determining the amount of compensation cost to be recognized in each period.

 

We elected to apply the presentation requirements for cash flows related to excess tax benefits prospectively which resulted in classification within operating cash flows of the excess tax benefits recognized during the three months ended March 31, 2016.  This classification is now consistent with all other cash flow impacts from income taxes. In addition, the amendments to the cash flow statement presentation to classify cash payments made on behalf of employees for shares withheld as a financing activity had no impact on our previously reported cash flows, as this requirement is consistent with our previous presentation of these cash flows.

 

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair Value of Financial Instruments
3 Months Ended
Mar. 31, 2016
Fair value of financial instruments.  
Fair value of financial instruments

3.     Fair value of financial instruments

 

FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (“the exit price”) in an orderly transaction between market participants at the measurement date. The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

 

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

 

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

 

Level 3—Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.

 

Our marketable securities consist of investments in corporate debt securities that are classified as available-for-sale.

 

At March 31, 2016 and December 31, 2015, our Level 2 corporate debt securities were valued using readily available pricing sources which utilize market observable inputs, including the current interest rate and other characteristics for similar types of investments.

 

The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurement at Reporting Date Using:

 

 

 

 

 

 

Quoted Prices in

 

Significant Other

 

Significant

 

 

 

 

 

 

Active Markets for

 

Observable

 

Unobservable

 

 

 

 

 

 

Identical Assets

 

Inputs

 

Inputs

 

Balance as of

 

 

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

March 31, 2016

 

Cash and cash equivalents

 

$

657,615

 

$

 —

 

$

 —

 

$

657,615

 

Corporate debt securities

 

 

 —

 

 

153,054

 

 

 —

 

 

153,054

 

Long term investment (Note 7)

 

 

32,298

 

 

 —

 

 

 —

 

 

32,298

 

Total assets

 

$

689,913

 

$

153,054

 

$

 —

 

$

842,967

 

 

The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis as of December 31, 2015 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurement at Reporting Date Using:

 

 

 

 

 

 

Quoted Prices in

 

Significant Other

 

Significant

 

 

 

 

 

 

Active Markets for

 

Observable

 

Unobservable

 

 

 

 

 

 

Identical Assets

 

Inputs

 

Inputs

 

Balance as of

 

 

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

December 31, 2015

 

Cash and cash equivalents

 

$

521,439

 

$

 —

 

$

 —

 

$

521,439

 

Corporate debt securities

 

 

 —

 

 

186,344

 

 

 —

 

 

186,344

 

Long term investment (Note 7)

 

 

35,248

 

 

 —

 

 

 —

 

 

35,248

 

Total assets

 

$

556,687

 

$

186,344

 

$

 —

 

$

743,031

 

 

The following is a summary of our marketable security portfolio as of March 31, 2016 and December 31, 2015, respectively.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net

 

Net

 

 

 

 

 

 

Amortized

 

Unrealized

 

Unrealized

 

Estimated

 

 

    

Cost

    

Gains

    

Losses

    

Fair Value

 

 

 

(in thousands)

 

March 31, 2016

    

 

 

    

 

 

    

 

 

    

 

 

 

Corporate debt securities

 

$

152,657

 

$

397

 

$

 —

 

$

153,054

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

187,153

 

$

 —

 

$

(809)

 

$

186,344

 

 

Our corporate debt securities generally have contractual maturity dates of between 12 to 18 months.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
Concentration of Credit Risk
3 Months Ended
Mar. 31, 2016
Concentration of Credit Risk  
Concentrations of Credit Risk

4.     Concentration of Credit Risk

 

In December 2009, we entered into a license, development and commercialization agreement with Eli Lilly and Company (“Lilly”). In November 2009, we entered into a collaboration and license agreement with Novartis. The concentration of credit risk related to our collaborative partners is as follows:

 

 

 

 

 

 

 

 

 

 

Percentage of Total

 

 

 

Contract Revenues for the

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2016

    

2015

    

 

Collaboration Partner A

    

 —

%  

89

%  

 

Collaboration Partner B

 

100

%  

11

%  

 

 

Collaboration Partner A and Collaboration Partner B comprised in the aggregate 22% and 39% of the accounts receivable balance as of March 31, 2016 and December 31, 2015, respectively.

 

In November 2011, we began commercialization and distribution of JAKAFI to a number of customers. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our product revenues is as follows:

 

 

 

 

 

 

 

 

 

 

Percentage of Total Net

 

 

 

Product Revenues for the

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2016

    

2015

    

 

Customer A

    

27

%  

28

%  

 

Customer B

 

18

%  

20

%  

 

Customer C

 

12

%  

13

%  

 

Customer D

 

8

%  

8

%  

 

 

We are exposed to risks associated with extending credit to customers related to the sale of products. Customer A, Customer B, Customer C and Customer D comprised in the aggregate 48% and 40% of the accounts receivable balance as of March 31, 2016 and December 31, 2015, respectively.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventory
3 Months Ended
Mar. 31, 2016
Inventory  
Inventory

5.     Inventory

 

Our inventory balance consists of the following:

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

December 31,

 

 

    

2016

    

2015

 

 

 

(in thousands)

 

 

    

 

 

  

 

 

  

Work-in-process

 

$

17,277

 

$

17,555

 

Finished goods

 

 

1,309

 

 

1,783

 

 

 

 

18,586

 

 

19,338

 

Inventories-current

 

 

1,309

 

 

1,783

 

Inventories-non-current

 

$

17,277

 

$

17,555

 

 

Inventories, stated at the lower of cost or market, consist of work in process and finished goods. At March 31, 2016,  $1.3 million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At March 31, 2016,  $17.3 million of inventory was classified as non-current on the condensed consolidated balance sheet as we did not expect this inventory to be consumed for commercial use within the next twelve months.  We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.

 

The raw materials and work-in-process inventory is not subject to expiration and the shelf life for finished goods inventory is 36 months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
Property and Equipment
3 Months Ended
Mar. 31, 2016
Property and Equipment  
Property and Equipment

6.    Property and Equipment

 

Property and equipment consists of the following:

 

 

 

 

 

 

 

 

 

 

 

 

March 31,

December 31,

 

 

 

    

2016

    

2015

 

 

 

 

(in thousands)

 

 

Office equipment

    

$

8,115

 

$

6,753

    

 

Laboratory equipment

 

 

33,263

    

 

31,296

 

 

Computer equipment

 

 

26,186

 

 

22,491

 

 

Building and leasehold improvements

 

 

72,539

 

 

70,729

 

 

 

 

 

140,103

 

 

131,269

 

 

Less accumulated depreciation and amortization

 

 

(47,481)

 

 

(45,263)

 

 

 

 

$

92,622

 

$

86,006

 

 

 

In 2013, we entered into a lease agreement for a new corporate headquarters, which consists of approximately 190,000 square feet of laboratory and office space located in Wilmington, Delaware. The term of this lease is 15 years from the date of commencement. The construction of the facility was completed and the lease commenced on October 1, 2014 with a monthly lease rate of $0.5 million for the first 10 years of the lease and with the monthly lease rate increasing annually during the last five years of the lease.

 

We are accounting for the lease as a direct financing arrangement whereby over the construction period, we recorded the value of the facility (consisting of the estimated fair value of the existing shell, plus construction costs incurred) as a capital asset, with a corresponding lease liability, net of build out costs paid for by us during the construction period. The lease liability will be amortized over the term of the lease using the effective interest method. In addition, we have posted a $15.0 million letter of credit for the facility lease for the benefit of the landlord, which is collateralized by a restricted investments account for the same amount. This amount was recorded as restricted cash and investments on the condensed consolidated balance sheets and will be reduced over a period of time during the duration of the lease. The letter of credit could be subject to accelerated reductions if we meet certain pre-defined financial targets and will be cancelled as a condition of closing of the purchase as described in the paragraph below. Restricted investments related to this direct financing lease on the condensed consolidated balance sheets at March 31, 2016 and December 31, 2015 were $13.9 million and $14.0 million, respectively.

 

On August 21, 2015, we entered into an Agreement of Sale with Augustine Land II, L.P. (the “Seller”) to purchase the leased land and office building for approximately $79.9 million.  Pursuant to the terms of the Agreement of Sale, we initially made a $4.0 million deposit with a third party escrow agent and a $4.0 million deposit with the Seller. The escrow agent held the deposit until the building inspection process was completed, and the escrow agent released the $4.0 million to the Seller in October 2015 as an additional deposit. As of March 31, 2016, the $8.0 million Seller deposit is recorded in other assets, net on the condensed consolidated balance sheets.

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
License Agreements
3 Months Ended
Mar. 31, 2016
License agreements  
License Agreements

7.    License agreements

 

Novartis

 

In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications.  Novartis also received worldwide exclusive development and commercialization rights to our c-MET inhibitor compound capmatinib and certain back-up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States.

 

Under this agreement, we received an upfront payment and immediate milestone payment totaling $210.0 million and were initially eligible to receive up to $1.2 billion in milestone payments across multiple indications upon the achievement of pre-specified events, including up to $174.0 million for the achievement of development milestones, up to $495.0 million for the achievement of regulatory milestones and up to $500.0 million for the achievement of commercialization milestones. Exclusive of the upfront payment of $150.0 million received in 2009 and the immediate milestone of $60.0 million earned in 2010, we have recognized and received in the aggregate $102.0 million for the achievement of development milestones and $175.0 million for the achievement of regulatory milestones and $20.0 million for the achievement of sales milestones through March 31, 2016.

 

During the year ended December 31, 2015, under this agreement, we recognized a $5.0 million development milestone based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib for a third indication and a $25.0 million regulatory milestone triggered by the Committee for Medicinal Products for Human Use of the European Medicines Agency adopting a positive opinion for JAKAVI (ruxolitinib) for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea, a $15.0 million regulatory milestone for the approval of JAKAVI in Japan for the treatment of patients with polycythemia vera, and a $20.0 million sales milestone for Novartis achieving annual net sales of a JAK licensed product of $300.0 million. In 2014, we recognized a $60.0 million regulatory milestone related to reimbursement of JAKAVI (ruxolitinib) in Europe, a $25.0 million regulatory milestone for the approval of JAKAVI in Japan for the treatment of patients with myelofibrosis and a $7.0 million development milestone based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib in non-small cell lung cancer.  In 2013, we recognized a $25.0 million development milestone under this agreement based on the formal initiation by Novartis of a Phase II clinical trial evaluating capmatinib. In 2012, we recognized a $40.0 million regulatory milestone payment under this agreement for the achievement of a predefined milestone for the European Union regulatory approval of JAKAVI. In 2011, we recognized a $15.0 million development milestone under this agreement for the achievement of a predefined milestone in the Phase I dose-escalation trial for capmatinib in patients with solid tumors and a $10.0 million regulatory milestone for the approval of JAKAFI in the United States. In 2010, we recognized $50.0 million in development milestones for the initiation of the global phase III trial, RESPONSE, in patients with polycythemia vera. We determined that each of these milestones were substantive as their achievement required substantive efforts by us and was at risk until the milestones were ultimately achieved. We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI net sales outside of the United States. Since the achievement of the $60.0 million regulatory milestone related to reimbursement of JAKAVI in Europe in September 2014, we are obligated to pay to Novartis tiered royalties in the low single digits on future JAKAFI net sales within the United States. During the three months ended March 31, 2016 and 2015, such royalties payable to Novartis on net sales within the United States totaled $5.2 million and $2.5 million, respectively, and are reflected in cost of product revenues on the condensed consolidated statements of operations.  Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.

 

The Novartis agreement will continue on a program-by-program basis until Novartis has no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. Royalties are payable by Novartis on a product-by-product and country-by-country basis until the latest to occur of (1) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (2) the expiration of regulatory exclusivity for the licensed product in such country and (3) a specified period from first commercial sale in such country of the licensed product by Novartis or its affiliates or sublicensees. The agreement may be terminated in its entirety or on a program-by-program basis by Novartis for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach.

 

We determined that there were two deliverables under the agreement: (i) the ex U.S. license for ruxolitinib and (ii) our obligations in connection with our participation on the joint development committee for myelofibrosis and polycythemia vera/essential thrombocythemia. We concluded that these deliverables should be accounted for as a single unit of accounting and the $150.0 million upfront payment received in December 2009 and the immediate $60.0 million milestone payment received in January 2010 should be recognized on a straight line basis through December 2013, when we estimated we would complete our obligations in connection with our participation on the joint development committee for myelofibrosis and polycythemia vera, our estimated performance period under the agreement. We completed this substantive performance obligation related to this arrangement in December 2013.

 

At December 31, 2009, we recorded $10.9 million of reimbursable costs incurred prior to the effective date of the agreement as deferred revenue on the consolidated balance sheet. These costs were recognized on a straight line basis through December 2013 consistent with the aforementioned upfront and milestone payments. Future reimbursable costs incurred after the effective date of the agreement with Novartis are recorded net against the related research and development expenses. At March 31, 2016 and December 31, 2015, $0.1 million and $0.3 million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets. Research and development expenses for the three months ended March 31, 2016 and 2015 were net of $0.3 million and $0.5 million, respectively, of costs reimbursed by Novartis.

 

Contract revenue under the Novartis agreement was $0.0 million and $25.0 million for the three months ended March 31, 2016 and 2015, respectively. Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States was $21.9 million and $15.7 million for the three months ended March 31, 2016 and 2015, respectively. At March 31, 2016 and December 31, 2015, $21.8 million and $23.8 million, respectively, of product royalties were included in accounts receivable on the condensed consolidated balance sheets.

 

Lilly - Baricitinib

 

In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib, and certain back-up compounds for inflammatory and autoimmune diseases. We received an upfront payment of $90.0 million, and were initially eligible to receive up to $665.0 million in substantive milestone payments across multiple indications upon the achievement of pre-specified events, including up to $150.0 million for the achievement of development milestones, up to $365.0 million for the achievement of regulatory milestones and up to $150.0 million for the achievement of commercialization milestones. Exclusive of the upfront payment of $90.0 million received in 2009, we have recognized and received in the aggregate $99.0 million for the achievement of development milestones and $55.0 million for the achievement of regulatory milestones through March 31, 2016. 

 

In January 2016, under this agreement, we recognized a $35.0 million regulatory milestone for the submission of an NDA to the FDA for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis and a $20.0 million regulatory milestone for the submission of a Marketing Authorization Application to the Europe Medicines Agency for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis. In 2012, we recognized a $50.0 million development milestone for the achievement of a predefined milestone for the initiation of the rheumatoid arthritis Phase III program for baricitinib. In 2010, we recognized a $30.0 million development milestone based upon the initial three month data in the Phase IIa clinical trial of baricitinib for the treatment of rheumatoid arthritis and a $19.0 million development milestone for the Phase IIb clinical trial initiation of baricitinib for the treatment of rheumatoid arthritis. We determined the 2012 and 2010 milestones to be substantive as their achievement required substantive efforts by us and was at risk until the milestones were ultimately achieved. We also could receive tiered, double-digit royalty payments on future global net sales with rates ranging up to 20% if the product is successfully commercialized.

 

We retained options to co-develop our JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis. Lilly is responsible for all costs relating to the development and commercialization of the compounds unless we elect to co-develop any compounds or indications. If we elect to co-develop any compounds and/or indications, we would be responsible for funding 30% of the associated future global development costs from the initiation of a Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. We would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global net sales for compounds and/or indications that we elect to co-develop.  For indications that we elect not to co‑develop, we would receive tiered, double‑digit royalty payments on future global net sales with rates ranging up to 20% if the product is successfully commercialized. In July 2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis and we are responsible for funding 30% of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority.  We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement. 

 

Research and development expenses recorded under the Lilly agreement representing 30% of the global development costs for baricitinib for the treatment of rheumatoid arthritis were $5.1 million and $11.6 million for the three months ended March 31, 2016 and 2015, respectively. We have retained certain mechanisms to give us cost protection as baricitinib advances in clinical development. We can defer our portion of co-development study costs by indication if they exceed a predetermined level. This deferment would be credited against future milestones or royalties and we would still be eligible for the full incremental royalties related to the co-development option. In addition, even if we have started co-development funding for any indication, we can at any time opt out and stop future co-development cost sharing. If we elect to do this we would still be eligible for our base royalties plus an incremental pro-rated royalty commensurate with our contribution to the total co-development cost for those indications for which we co-funded. The Lilly agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. Royalties are payable by Lilly on a product-by-product and country-by-country basis until the latest to occur of (1) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (2) the expiration of regulatory exclusivity for the licensed product in such country and (3) a specified period from first commercial sale in such country of the licensed product by Lilly or its affiliates or sublicensees. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.

 

We determined that there were two deliverables under the agreement: (i) the worldwide license and (ii) our obligations in connection with a co-development option. We concluded that these deliverables should be accounted for as a single unit of accounting and the $90.0 million upfront payment should be recognized on a straight line basis as revenue through December 2016, our estimated performance period under the agreement.

 

Contract revenue under the Lilly agreement was $58.2 million and $3.2 million for the three months ended March 31, 2016 and 2015, respectively.

 

Lilly - Ruxolitinib

 

In March 2016, we entered into an amendment to the agreement with Lilly that amended the non-compete provision of the agreement to allow us to engage in the development and commercialization of ruxolitinib in the graft-versus-host-disease (“GVHD”) field. We agreed to pay Lilly an upfront payment of $35.0 million and Lilly is eligible to receive up to $40.0 million in additional regulatory milestone payments relating to ruxolitinib in the GVHD field. As of March 31, 2016, the $35.0 million upfront payment was recorded in research and development expense on the condensed consolidated statements of operations and was included in accrued and other current liabilities on the condensed consolidated balance sheet.

 

Agenus

 

In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly owned subsidiary, 4-Antibody AG, which we collectively refer to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus’ proprietary antibody discovery platforms. The agreement became effective on February 18, 2015, upon the expiration of the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976.

 

Under the terms of this agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial four program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, three more targets were added. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we will be responsible for all costs associated with discovery, preclinical activities, clinical development and commercialization activities. The programs relating to GITR and OX40 and two of the undisclosed targets are profit-share programs while the other targets currently under collaboration are royalty-bearing programs. All costs related to the collaboration are subject to a joint research plan.  For each royalty-bearing product, Agenus will be eligible to receive up to $155.0 million in future contingent development, regulatory and commercialization milestones as well as tiered royalties on global net sales ranging from 6% to 12%. For each profit share product, Agenus will be eligible to receive up to $20.0 million in future contingent development milestones. Additionally, Agenus retains co-promotion participation rights in the United States on any profit share product. For each royalty bearing product, Agenus has reserved the right to elect to co fund 30% of development costs for a commensurate increase in royalties. The agreement may be terminated by us for convenience upon 12 months’ notice and may also be terminated under certain other circumstances, including material breach.  We agreed to certain standstill provisions that allow us to acquire up to 15% of Agenus Inc.’s outstanding voting stock, including shares acquired pursuant to the Stock Purchase Agreement described below, solely for investment purposes.

 

In January 2015, we also entered into a Stock Purchase Agreement with Agenus Inc. pursuant to which we agreed to purchase approximately 7.76 million shares of Agenus Inc. common stock for an aggregate purchase price of $35.0 million in cash, or approximately $4.51 per share. We completed the purchase of the shares on February 18, 2015. On February 18, 2015 the closing price of Agenus Inc. common shares on The NASDAQ Stock Market was $5.13 per share and, therefore, the value of the 7.76 million shares acquired by us was $39.8 million. We agreed not to dispose of any of the shares of common stock for a period of 12 months and Agenus Inc. has agreed to certain registration rights with respect to the shares of common stock.

 

Upon closing of the Agenus transaction on February 18, 2015, we paid total consideration of $60.0 million to Agenus Inc.  Of the $60.0 million, $39.8 million was allocated to our stock purchase in Agenus Inc. and was recorded as a long term investment on the condensed consolidated balance sheets and $20.2 million was allocated to research and development expense on the condensed consolidated statement of operations. 

 

We have concluded Agenus Inc. is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. We own approximately 9% of the outstanding shares of Agenus Inc. common stock and conclude that we have the ability to exercise significant influence, but not control, over Agenus Inc. based primarily on our ownership interest, the level of intra-entity transactions between us and Agenus related to development expenses, as well as other qualitative factors. We have elected the fair value option to account for our long term investment in Agenus Inc. whereby the investment is marked to market through earnings in each reporting period.  We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three months ended March 31, 2016, we recorded an unrealized loss of $3.0 million based on the decrease in the market price of Agenus Inc.’s common stock from the date of purchase to $4.16 per share at March 31, 2016. For the three months ended March 31, 2015, there was no gain or loss recorded as the market price of Agenus Inc.’s common stock at March 31, 2015 was consistent with the fair value on the acquisition date of the investment. For the year ended December 31, 2015, Agenus Inc. reported total revenues of $24.8 million and a net loss of $87.9 million within their consolidated financial statements.

 

Research and development expenses for the three months ended March 31, 2016 and 2015, included $4.1 million and $1.8 million, respectively, of development costs incurred pursuant to the Agenus arrangement. At March 31, 2016, a total of $10.0 million of such costs were included in accrued and other liabilities on the condensed consolidated balance sheet.

 

Hengrui

 

In September 2015, we entered into a License and Collaboration Agreement with Jiangsu Hengrui Medicine Co., Ltd. (“Hengrui”). Under the terms of this agreement, we received exclusive development and commercialization rights worldwide, with the exception of Mainland China, Hong Kong, Macau and Taiwan, to INCSHR1210, an investigational PD-1 monoclonal antibody, and certain back-up compounds. INCSHR1210 is currently in clinical development. 

 

Under the terms of this agreement, we paid Hengrui an upfront payment of $25.0 million in 2015 which was recorded in research and development expense on the condensed consolidated statement of operations. Hengrui is also eligible to receive potential milestone payments of up to $770.0 million, consisting of $90.0 million for regulatory approval milestones, $530.0 million for commercial performance milestones, and $150.0 million for a clinical superiority milestone.  Also, Hengrui may be eligible to receive tiered royalties in the high-single digits to mid-double digits based on net sales in our territories. Each company will be responsible for costs relating to the development and commercialization of the PD-1 monoclonal antibody in their respective territories.  The agreement will continue on a country-by-country basis until we have no royalty payment obligations with respect to such country or, if earlier, the termination of the agreement in accordance with its terms.  The agreement may be terminated in its entirety by us for convenience, and may also be terminated under certain other circumstances, including material breach.

 

Research and development expenses for the three months ended March 31, 2016, included $0.7 million of development costs incurred pursuant to the Hengrui agreement.

 

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock compensation
3 Months Ended
Mar. 31, 2016
Stock compensation  
Stock Compensation

8.     Stock compensation

 

We recorded $20.8 million and $17.6 million of stock compensation expense on our condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015, respectively. Stock compensation expense included within our condensed consolidated statements of operations included research and development expense of $13.0 million and $10.3 million for the three months ended March 31, 2016 and 2015, respectively. Stock compensation expense included within our condensed consolidated statements of operations also included selling, general and administrative expense of $7.8 million and $7.3 million for the three months ended March 31, 2016 and 2015, respectively.

 

We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee Stock Options For the Three Months Ended

 

Employee Stock Purchase Plan For the Three Months Ended

 

 

 

March 31,

 

March 31,

 

 

 

2016

       

2015

      

 

2016

      

2015

      

 

 

Average risk-free interest rates

1.50

%  

1.35

%  

 

0.73

%  

0.56

%  

 

 

Average expected life (in years)

5.00

 

5.05

 

 

0.25

 

0.25

 

 

 

Volatility

49

%  

50

%  

 

61

%  

38

%  

 

 

Weighted-average fair value (in dollars)

41.56

 

32.59

 

 

26.67

 

9.56

 

 

 

 

The risk-free interest rate is derived from the U.S. Federal Reserve rate in effect at the time of grant. The expected life calculation is based on the observed and expected time to the exercise of options by our employees based on historical exercise patterns for similar type options. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the options. A dividend yield of zero is assumed based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends.

 

Option activity under the 2010 Stock Plan was as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares Subject to

 

 

 

 

 

Outstanding Options

 

 

 

Shares Available

 

 

 

Weighted Average

 

 

    

for Grant

    

Shares

    

Exercise Price

 

Balance at December 31, 2015

 

3,846,717

 

11,052,279

 

$

33.55

 

Options granted

 

(1,412,583)

 

1,412,583

 

$

94.69

 

Options exercised

 

 —

 

(751,784)

 

$

14.06

 

Options cancelled

 

68,324

 

(68,324)

 

$

73.24

 

Options expired

 

 —

 

(1,834)

 

$

3.11

 

Balance at March 31, 2016

 

2,502,458

 

11,642,920

 

$

42.00

 

 

RSU and PSU award activity under the 2010 Stock Plan was as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares Subject to

 

 

 

Shares Available

 

Outstanding Awards

 

 

    

for Grant

    

Shares

    

Grant Date Value

 

Balance at December 31, 2015

    

834,433

    

565,567

    

 

 —

 

RSUs granted

 

(216,711)

 

216,711

 

$

88.28

 

PSUs granted

 

 —

 

 —

 

 

 —

 

RSUs cancelled

 

12,843

 

(12,843)

 

$

67.62

 

PSUs cancelled

 

 —

 

 —

 

 

 —

 

Balance at March 31, 2016

 

630,565

 

769,435

 

 

 —

 

 

In January 2014, we began granting RSUs and PSUs to our employees at the share price on the date of grant.   Each RSU represents the right to acquire one share of our common stock. We granted a total of 216,711 RSUs during the three months ended March 31, 2016 which will cliff vest in three years and will be recognized as stock compensation expense over this period.  Also, in January 2014, Hervé Hoppenot, our President and Chief Executive Officer, was granted a one-time grant of 400,000 RSUs outside of our 2010 Stock Incentive Plan. Vesting of the RSUs will be subject to Mr. Hoppenot’s continued employment on the applicable vesting dates, with one-sixth of the RSUs vesting at the end of each of the calendar years 2014 through 2019, subject to earlier acceleration of vesting upon the occurrence of certain events in accordance with the terms of his employment agreement. As of March 31, 2016, a total of 133,333 RSUs granted to Mr. Hoppenot vested and were released leaving 266,667 RSUs outstanding.

 

At March 31, 2016, we have only recognized stock compensation expense relating to performance conditions of the outstanding PSUs that are deemed probable of achievement at that date. For PSUs containing performance conditions which have not been deemed probable of achievement at March 31, 2016,  no stock compensation expense has been recognized for these awards. The actual number of shares of our common stock into which each PSU may convert are subject to a multiplier of up to 125% based on the level at which the performance conditions are achieved.

 

Based on our historical experience of employee turnover, we have assumed an annualized forfeiture rate of 5% for our options, PSUs and RSUs.  Under the true-up provisions of the stock compensation guidance, we will record additional expense if the actual forfeiture rate is lower than we estimated, and will record a recovery of prior expense if the actual forfeiture is higher than we estimated.

 

Total compensation cost of options granted but not yet vested, as of March 31, 2016, was $68.7 million, which is expected to be recognized over the weighted average period of 3.0 years. Total compensation cost of RSUs granted but not yet vested, as of March 31, 2016, was $35.4 million, which is expected to be recognized over the weighted average period of 3.0 years. Total compensation cost of PSUs granted but not yet vested, as of March 31, 2016, was $0.7 million, which is expected to be recognized over the weighted average period of 3.0 years, should the underlying performance conditions be deemed probable of achievement.

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
Debt
3 Months Ended
Mar. 31, 2016
Debt  
Debt

9.     Debt

 

The components of the convertible notes are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Carrying Amount,

 

 

 

Interest Rates

 

 

 

March 31,

 

December 31,

 

Debt

    

March 31, 2016

    

Maturities

    

2016

    

2015

 

0.375% Convertible Senior Notes due 2018

 

0.375

%  

2018

 

$

328,173

 

 

324,031

 

1.25% Convertible Senior Notes due 2020

 

1.25

%  

2020

 

 

299,469

 

 

295,862

 

 

 

 

 

 

 

 

627,642

 

 

619,893

 

Less current portion

 

 

 

 

 

 

 —

 

 

 —

 

 

 

 

 

 

 

$

627,642

 

$

619,893

 

 

The carrying amount and fair value of our convertible notes are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2016

 

December 31, 2015

 

 

    

Carrying

    

 

 

    

Carrying

    

 

 

 

 

 

Amount

 

Fair Value

 

Amount

 

Fair Value

 

0.375% Convertible Senior Notes due 2018

 

 

328,173

 

 

574,922

 

 

324,031

 

 

807,422

 

1.25% Convertible Senior Notes due 2020

 

 

299,469

 

 

588,427

 

 

295,862

 

 

816,123

 

 

 

$

627,642

 

$

1,163,349

 

$

619,893

 

$

1,623,545

 

 

The fair values of the 0.375% Convertible Senior Notes due 2018 (the “2018 Notes”) and the 1.25% Convertible Senior Notes due 2020 (the “2020 Notes”) are based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments, and, therefore, these convertible senior notes are classified within Level 2 in the fair value hierarchy.

 

Prior to May 14, 2014, the 2018 and 2020 Notes were not convertible except in connection with a make whole fundamental change, as defined in the respective indentures. Beginning on, and including, May 15, 2014, the 2018 and 2020 Notes are convertible prior to the close of business on the business day immediately preceding May 15, 2018, in the case of the 2018 Notes, and May 15, 2020, in the case of the 2020 Notes, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2018 Notes or 2020 Notes, as applicable, on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of 2018 Notes or 2020 Notes, as applicable, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the 2018 Notes or 2020 Notes, as applicable, on each such trading day; or (3) upon the occurrence of specified corporate events. On or after May 15, 2018, in the case of the 2018 Notes, and May 15, 2020, in the case of the 2020 Notes, until the close of business on the second scheduled trading day immediately preceding the relevant maturity date, the Notes are convertible at any time, regardless of the foregoing circumstances. Upon conversion we will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at our election.

 

On April 1, 2016, the 2018 Notes and 2020 Notes became convertible through at least June 30, 2016, based on meeting the conversion criteria related to the sale price of our common stock during the calendar quarter ended March 31, 2016 as described in (1) above. Management’s intent is to settle any conversions of 2018 Notes or 2020 Notes during this period in shares of our common stock and, therefore, the 2018 Notes and 2020 Notes are reflected in long term liabilities on the condensed consolidated balance sheet at March 31, 2016.  

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
Income taxes
3 Months Ended
Mar. 31, 2016
Income taxes  
Income taxes

10.     Income taxes

 

In January 2015, we licensed certain intellectual property rights related to our non-partnered clinical programs to our wholly-owned subsidiary in Switzerland. Although the license of intellectual property rights did not result in any gain or loss in the condensed consolidated statements of operations, the transaction generated a taxable gain in the U.S, and we are utilizing available federal and state net operating loss carryforwards to offset the majority of this gain. Any taxes incurred related to intercompany transactions are treated as prepaid tax in our condensed consolidated balance sheets and amortized to income tax expense over the life of the intellectual property.   Any cash taxes anticipated to be paid related to this intercompany transaction are immaterial.

 

In January 2016, the Delaware Competes Act (the “Act”) was enacted by the State of Delaware, which changes the corporate income tax apportionment formula to a single sales factor apportionment formula by 2020.  As a qualified Delaware headquarter company under the Act, we may elect to use either a three-factor apportionment or single sales factor starting in 2017.  We are currently evaluating the impact of the law change and the apportionment election available to us starting in 2017.

 

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
Net income (loss) per share
3 Months Ended
Mar. 31, 2016
Net income (loss) per share  
Net income (loss) per share

11.    Net income (loss) per share

 

Net income (loss) per share was calculated as follows for the periods indicated:

 

 

 

 

 

 

 

 

  

Three Months Ended

 

 

March 31,

(in thousands, except per share data)

    

 

2016

    

2015

Basic Net Income (Loss) Per Share

  

 

 

  

 

 

Basic net income (loss)

 

$

24,047

 

$

(18,359)

Weighted average common shares outstanding

 

 

187,184

 

 

172,070

 

  

 

 

  

 

 

Basic net income (loss) per share

  

$

0.13

  

$

(0.11)

 

  

 

 

  

 

 

Diluted Net Income (Loss) Per Share

  

 

 

  

 

 

Diluted net income (loss)

 

$

24,047

  

$

(18,359)

Weighted average common shares outstanding

 

 

187,184

 

 

172,070

 

 

 

 

 

 

 

Dilutive stock options and RSU’s

 

 

5,441

 

 

 —

 

 

 

 

 

 

 

Weighted average shares used to compute diluted net income (loss) per share

  

 

192,625

 

 

172,070

 

 

 

 

 

 

 

Diluted net income (loss) per share

  

$

0.12

  

$

(0.11)

 

The following potential common shares were excluded from the calculations as their effect would be anti-dilutive:

 

 

 

 

 

 

 

Three Months Ended

 

 

March 31,

 

    

2016

    

2015

Outstanding stock options and awards

 

2,652,265

 

14,626,717

Common shares issuable upon conversion of the 4.75% Convertible Senior Notes due 2015

 

 —

 

10,353,076

Common shares issuable upon conversion of the 2018 Notes

 

7,245,244

 

7,245,263

Common shares issuable upon conversion of the 2020 Notes

 

7,241,284

 

7,245,263

Total potential common shares excluded from diluted net loss per share computation

 

17,138,793

 

39,470,319

 

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.4.0.3
Contingencies
3 Months Ended
Mar. 31, 2016
Contingencies  
Contingencies

12.Contingencies

 

In February 2016, we received a Paragraph IV certification notice (the “Notice Letter”) regarding an Abbreviated New Drug Application submitted to the U.S. Food and Drug Administration requesting approval to market a generic version of Jakafi (ruxolitinib).  The Notice Letter purports to challenge patents covering ruxolitinib phosphate and its use that expire in 2028.  The Notice Letter does not challenge the ruxolitinib composition of matter patent, which expires on December 24, 2027.  We do not believe there is any kind of loss that is probable or estimable related to this matter at this time.

 

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.4.0.3
Subsequent Event
3 Months Ended
Mar. 31, 2016
Subsequent event  
Subsequent event

13.    Subsequent event

 

In April 2016, we entered into an amendment to the agreement with Novartis under which Novartis received exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in the GVHD field.  We are eligible to receive future additional payments from Novartis if defined development and regulatory milestones relating to ruxolitinib for GVHD outside of the United States are achieved. In addition, we remain eligible to receive potential milestone payments and royalties on total sales of ruxolitinib (including GVHD) by Novartis outside of the United States.

 

In April 2016, we closed on the agreement of sale with Augustine Land II, L.P. for the purchase of the previously leased land and office building. 

 

In May 2016, we entered into a share purchase agreement with ARIAD Pharmaceuticals, Inc. (“ARIAD”) and a wholly-owned subsidiary of ARIAD pursuant to which we will acquire all of the outstanding shares of a wholly-owned subsidiary of ARIAD that is the parent company of ARIAD’s European subsidiaries responsible for the development and commercialization of Iclusig® (ponatinib) in the European Union and 22 other countries (the “Territory”) for an upfront payment of $140.0 million.  In addition, we agreed upon the terms of a license agreement to be entered into by ARIAD and us, pursuant to which we will be granted an exclusive license to develop and commercialize Iclusig in the Territory.  ARIAD will be eligible to receive from us tiered royalties on net sales of Iclusig in the Territory and up to $135.0 million in potential future oncology development and regulatory approval milestone payments.  The closing under the share purchase agreement and effectiveness of the license agreement is expected to occur on June 1, 2016, pending satisfaction of customary closing conditions.  We believe that the transaction will be accounted for as a business combination.  Please see Item 5(a) of Part II of this Quarterly Report on Form 10-Q for a more detailed description of the share purchase agreement and license agreement.

 

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2016
Summary of significant accounting policies  
Basis of presentation

Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  The condensed consolidated balance sheet as of March 31, 2016 and the condensed consolidated statements of operations, comprehensive income (loss) and cash flows for the three months ended March 31, 2016 and 2015, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.  The condensed consolidated balance sheet at December 31, 2015 has been derived from audited financial statements.

 

Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission.

 

Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.

 

Principles of Consolidation

Principles of Consolidation.  The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries, including Incyte Holdings Corporation, Incyte International Holdings S.a.r.l. and Incyte Europe S.a.r.l. All inter-company accounts, transactions, and profits have been eliminated in consolidation.

 

Foreign Currency Translation

Foreign Currency Translation. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month, which approximates the results that would be obtained using actual currency rates on the dates of individual transactions. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into the U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in interest and other income, net in the condensed consolidated statements of operations. To date, both the translation gains or losses in other comprehensive income (loss) and the transaction gains or losses in interest and other income, net have been immaterial.

 

Use of Estimates

Use of Estimates.  The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

 

Concentrations of Credit Risk

Concentrations of Credit Risk.  Cash, cash equivalents, marketable securities, trade receivables and restricted investments are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in corporate debt securities and, by policy, limit the amount of credit exposure to any one issuer and to any one type of investment, other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales of JAKAFI and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash, cash equivalents, marketable securities, trade receivables or restricted investments to date and do not require collateral on receivables.

 

Cash and Cash Equivalents

Cash and Cash Equivalents.  Cash and cash equivalents are held in U.S. banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.

 

Marketable Securities-Available-for-Sale

Marketable Securities—Available-for-Sale.  All marketable securities are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders’ equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in “Interest and other income, net.” The cost of securities sold is based on the specific identification method.

 

Accounts Receivable

Accounts Receivable.  As of March 31, 2016 and December 31, 2015, we had no allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.

 

Inventory

Inventory.  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. We began capitalizing inventory in mid-November 2011 once the U.S. Food and Drug Administration (“FDA”) approved JAKAFI as the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to approval of JAKAFI have been recorded as research and development expense in our statements of operations. As a result, cost of product revenues for the next 6 to 9 months will reflect a lower average per unit cost of materials.

 

The raw materials and work-in-process inventory is not subject to expiration and the shelf life for finished goods inventory is 36 months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.

 

Variable Interest Entities

Variable Interest Entities. We perform an initial and on-going evaluation of the entities with which we have variable interests, such as equity ownership, in order to identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (“VIE” or “VIEs”). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE’s economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE.  As of March 31, 2016, there were no entities in which we held a variable interest which we determined to be VIEs.

 

Equity Method Investments

Equity Method Investments.  In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option under U.S. GAAP.   In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Under the equity method of accounting, we record within our results of operations our share of income or loss of the investee company.  Under the fair value option, our investment is carried at fair value on our condensed consolidated balance sheets as a long term investment and all changes in fair value are reported in our condensed consolidated statements of operations as an unrealized gain (loss) on long term investment.

 

Property and Equipment

Property and Equipment.  Property and equipment is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets (generally three to five years). Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.

 

Management continually reviews the estimated useful lives of technologically sensitive equipment and believes that those estimates appropriately reflect the current useful life of our assets. In the event that a currently unknown significantly advanced technology became commercially available, we would re-evaluate the value and estimated useful lives of our existing equipment, possibly having a material impact on the financial statements.

 

Lease Accounting

Lease Accounting.  We account for operating leases by recording rent expense on a straight-line basis over the expected life of the lease, commencing on the date we gain possession of leased property. We include tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses as adjustments to straight-line rent expense over the expected life of the lease.

 

Capital leases are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets under capital leases are recorded in property and equipment, net on the condensed consolidated balance sheets and depreciated in a manner similar to other property and equipment.

 

Certain construction projects may be accounted for as direct financing arrangements, whereby we record, over the construction period, the full cost of the asset in property and equipment, net on the condensed consolidated balance sheets. A corresponding liability is also recorded, net of leasehold improvements paid for by us, and is amortized over the expected lease term through monthly rental payments using the effective interest method.

 

Income Taxes

Income Taxes.  We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. In addition, we follow the guidance related to accounting for uncertainty in income taxes. This guidance creates a single model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before it is recognized in the financial statements.

 

Financing Costs Related to Long-term Debt

Financing Costs Related to Long-term Debt.  Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the consolidated balance sheets.

 

Grant Accounting

Grant Accounting.  Grant amounts received from government agencies for operations are deferred and are amortized into income over the service period of the grant. Grant amounts received for purchases of capital assets are deferred and amortized into interest and other income, net over the useful life of the related capital assets. Such amounts are recorded in other liabilities on the condensed consolidated balance sheets.

 

Net Income (Loss) Per Share

Net Income (Loss) Per Share.  Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.

 

Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income (Loss).  Accumulated other comprehensive income (loss) consists of realized and unrealized gains or losses on marketable securities and restricted cash and investments.

 

Revenue Recognition

Revenue Recognition.  Revenues are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured. Revenues are deferred for fees received before earned or until no further obligations exist. We exercise judgment in determining that collectability is reasonably assured or that services have been delivered in accordance with the arrangement. We assess whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. We assess collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.

 

Product Revenues

 

Our product revenues consist of U.S. sales of JAKAFI and are recognized once we meet all four revenue recognition criteria described above. In November 2011, we began shipping JAKAFI to our customers, which include specialty pharmacies and wholesalers. 

 

We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and Medicare Part D coverage gap reimbursements. Product shipping and handling costs are included in cost of product revenues.

 

Customer Credits:  Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.

 

Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g. Medicaid) benefit providers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launch. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters’ unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Chargebacks:  Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received, we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel.  If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Medicare Part D Coverage Gap:  Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

 

Co-payment Assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.

 

Product Royalty Revenues

 

Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI® outside the United States) by Novartis Pharmaceutical International Ltd. (“Novartis”) are based on net sales of licensed products in licensed territories as provided by Novartis. We recognize royalty revenues in the period the sales occur.

 

Cost of Product Revenues

 

Cost of product revenues includes all JAKAFI related costs that are recoverable through the commercialization of the product. Beginning in October 2014, we became obligated to pay tiered, low single digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States which are included in cost of product revenues.

 

Contract and License Revenues

 

Under agreements involving multiple deliverables, services and/or rights to use assets that we entered into prior to January 1, 2011, the multiple elements are divided into separate units of accounting when certain criteria are met, including whether the delivered items have stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered items. When separate units of accounting exist, consideration is allocated among the separate elements based on their respective fair values. The determination of fair value of each element is based on objective evidence from historical sales of the individual elements by us to other customers. If such evidence of fair value for each undelivered element of the arrangement does not exist, all revenue from the arrangement is deferred until such time that evidence of fair value for each undelivered element does exist or until all elements of the arrangement are delivered. When elements are specifically tied to a separate earnings process, revenue is recognized when the specific performance obligation tied to the element is completed. When revenues for an element are not specifically tied to a separate earnings process, they are recognized ratably over the term of the agreement. We assess whether a substantive milestone exists at the inception of our agreements. For all milestones within our arrangements that are considered substantive, we recognize revenue upon the achievement of the associated milestone. If a milestone is not considered substantive, we would recognize the applicable milestone payment over the remaining period of performance under the arrangement. As of March 31, 2016, all remaining potential milestones under our collaborative arrangements are considered substantive.

 

On January 1, 2011, updated guidance on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements we may enter into on or after January 1, 2011. This updated guidance (i) relates to whether multiple deliverables exist, how the deliverables in a revenue arrangement should be separated and how the consideration should be allocated; (ii) requires companies to allocate revenues in an arrangement using estimated selling prices of deliverables if a vendor does not have vendor-specific objective evidence or third-party evidence of selling price; and (iii) eliminates the use of the residual method and requires companies to allocate revenues using the relative selling price method. During the three months ended March 31, 2016 and 2015, we did not enter into any agreements that are subject to this updated guidance. If we enter into an agreement with multiple deliverables after January 1, 2011 or amend existing agreements, this updated guidance could have a material effect on our financial statements.

 

Our collaborations often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events. These three categories of milestone events reflect the three stages of the life-cycle of our drugs, which we describe in more detail in the following paragraphs.

 

The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the FDA requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate’s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (“IND”), which must be reviewed by the FDA.

 

The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (“NDA”) or biologics license application (“BLA”) to the FDA for review and FDA approval of the NDA or BLA.

 

Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.

 

Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase I, Phase II or Phase III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.

 

Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.

 

Research and Development Costs

Research and Development Costs.  Our policy is to expense research and development costs as incurred. We often contract with clinical research organizations (“CROs”) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract.

 

These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period.

 

Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred.

 

Stock Compensation

Stock Compensation.  Share-based payment transactions with employees, which include stock options, restricted stock units (“RSUs”) and performance shares (“PSUs”), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates.  The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting.  The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method.  The fair value of RSUs, which are generally subject to cliff vesting, are recognized as compensation expense over the requisite service period using the straight line attribution method.  The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, over the remaining requisite service period. We recorded $20.8 million and $17.6 million of stock compensation expense on our condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015, respectively.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which provides a five step approach to be applied to all contracts with customers. ASU No. 2014-09 also requires expanded disclosures about revenue recognition. This guidance is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein.  Early adoption is permitted for reporting periods beginning after December 15, 2016.  We are currently analyzing the impact of ASU No. 2014-09 on our results of operations and, at this time, we are unable to determine the impact of the new standard, if any, on our condensed consolidated financial statements.

 

In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements—Going Concern,” to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about our ability to continue as a going concern within one year from the date the financial statements are issued. This guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. We do not believe the pending adoption of ASU No. 2014-15 will have a material impact on our condensed consolidated financial statements.

 

In February 2015, the FASB issued ASU No. 2015-02, “Amendments to the Consolidation Analysis,” which affects reporting entities that are required to evaluate whether they should consolidate certain legal entities.  The amendments place more emphasis in the consolidation evaluation on variable interests other than fee arrangements such as principal investment risk (including debt or equity interests), guarantees of the value of the assets or liabilities of the variable interest entity (“VIE”), written put options on the assets of the VIE, or similar obligations. Additionally, the amendments reduce the extent to which related party arrangements cause an entity to be considered a primary beneficiary. This guidance is to be applied using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The amendments are effective for fiscal years beginning after December 15, 2015, and interim periods therein. We have concluded ASU No. 2015-02 has no impact on our condensed consolidated financial statements. 

 

In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which changes the accounting for certain aspects of share-based payments to employees.  The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled.  In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows.  The standard also clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on the statement of cash flows, and provides an accounting policy election to account for forfeitures as they occur.  The new standard is effective for our calendar year beginning January 1, 2017.  Early adoption is permitted however all of the guidance must be adopted in the same period. 

 

We have elected to early adopt ASU No. 2016-09 as of the first quarter of 2016 which requires us to reflect any adjustments as of January 1, 2016, the beginning of the annual period that includes the interim period of adoption.  The primary impact of adoption was the recognition of $325.6 million of accumulated excess tax benefits as deferred tax assets that under the previous guidance could not be recognized until the benefits were realized through a reduction in cash taxes paid.  This part of the guidance was applied using a modified retrospective method with a cumulative-effect adjustment to the accumulated deficit for the excess tax benefits not previously recognized. However, given the full valuation allowance placed on the additional $325.6 million of deferred tax assets, the recognition upon adoption had no impact to our accumulated deficit as of January 1, 2016.

 

Adoption of the standard also resulted in the recognition of excess tax benefits in our income tax provision rather than as paid-in capital. This guidance is to be applied prospectively and resulted in the recognition of $0.3 million of excess tax benefits in our income tax provision rather than paid-in capital for the three months ended March 31, 2016.  Amendments to the minimum statutory withholding tax requirements had no impact to the accumulated deficit as of January 1, 2016. In addition, we have elected to continue to estimate forfeitures expected to occur when determining the amount of compensation cost to be recognized in each period.

 

We elected to apply the presentation requirements for cash flows related to excess tax benefits prospectively which resulted in classification within operating cash flows of the excess tax benefits recognized during the three months ended March 31, 2016.  This classification is now consistent with all other cash flow impacts from income taxes. In addition, the amendments to the cash flow statement presentation to classify cash payments made on behalf of employees for shares withheld as a financing activity had no impact on our previously reported cash flows, as this requirement is consistent with our previous presentation of these cash flows.

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair value of financial instruments (Tables)
3 Months Ended
Mar. 31, 2016
Marketable Securities  
Schedule of fair value of assets measured on recurring basis

The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurement at Reporting Date Using:

 

 

 

 

 

 

Quoted Prices in

 

Significant Other

 

Significant

 

 

 

 

 

 

Active Markets for

 

Observable

 

Unobservable

 

 

 

 

 

 

Identical Assets

 

Inputs

 

Inputs

 

Balance as of

 

 

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

March 31, 2016

 

Cash and cash equivalents

 

$

657,615

 

$

 —

 

$

 —

 

$

657,615

 

Corporate debt securities

 

 

 —

 

 

153,054

 

 

 —

 

 

153,054

 

Long term investment (Note 7)

 

 

32,298

 

 

 —

 

 

 —

 

 

32,298

 

Total assets

 

$

689,913

 

$

153,054

 

$

 —

 

$

842,967

 

 

The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis as of December 31, 2015 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurement at Reporting Date Using:

 

 

 

 

 

 

Quoted Prices in

 

Significant Other

 

Significant

 

 

 

 

 

 

Active Markets for

 

Observable

 

Unobservable

 

 

 

 

 

 

Identical Assets

 

Inputs

 

Inputs

 

Balance as of

 

 

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

December 31, 2015

 

Cash and cash equivalents

 

$

521,439

 

$

 —

 

$

 —

 

$

521,439

 

Corporate debt securities

 

 

 —

 

 

186,344

 

 

 —

 

 

186,344

 

Long term investment (Note 7)

 

 

35,248

 

 

 —

 

 

 —

 

 

35,248

 

Total assets

 

$

556,687

 

$

186,344

 

$

 —

 

$

743,031

 

 

Summary of marketable securities portfolio

The following is a summary of our marketable security portfolio as of March 31, 2016 and December 31, 2015, respectively.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net

 

Net

 

 

 

 

 

 

Amortized

 

Unrealized

 

Unrealized

 

Estimated

 

 

    

Cost

    

Gains

    

Losses

    

Fair Value

 

 

 

(in thousands)

 

March 31, 2016

    

 

 

    

 

 

    

 

 

    

 

 

 

Corporate debt securities

 

$

152,657

 

$

397

 

$

 —

 

$

153,054

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

187,153

 

$

 —

 

$

(809)

 

$

186,344

 

 

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
Concentration of Credit Risk (Tables)
3 Months Ended
Mar. 31, 2016
Concentration of Credit Risk  
Schedule of concentration of credit risk related to collaborative partners

 

 

 

 

 

 

 

 

 

 

 

Percentage of Total

 

 

 

Contract Revenues for the

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2016

    

2015

    

 

Collaboration Partner A

    

 —

%  

89

%  

 

Collaboration Partner B

 

100

%  

11

%  

 

 

Schedule of concentration of credit risk related to specialty pharmacy customers

 

 

 

 

 

 

 

 

 

 

 

Percentage of Total Net

 

 

 

Product Revenues for the

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2016

    

2015

    

 

Customer A

    

27

%  

28

%  

 

Customer B

 

18

%  

20

%  

 

Customer C

 

12

%  

13

%  

 

Customer D

 

8

%  

8

%  

 

 

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventory (Tables)
3 Months Ended
Mar. 31, 2016
Inventory  
Schedule of inventory

Our inventory balance consists of the following:

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

December 31,

 

 

    

2016

    

2015

 

 

 

(in thousands)

 

 

    

 

 

  

 

 

  

Work-in-process

 

$

17,277

 

$

17,555

 

Finished goods

 

 

1,309

 

 

1,783

 

 

 

 

18,586

 

 

19,338

 

Inventories-current

 

 

1,309

 

 

1,783

 

Inventories-non-current

 

$

17,277

 

$

17,555

 

 

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
Property and Equipment (Tables)
3 Months Ended
Mar. 31, 2016
Property and Equipment  
Schedule of property and equipment

Property and equipment consists of the following:

 

 

 

 

 

 

 

 

 

 

 

 

March 31,

December 31,

 

 

 

    

2016

    

2015

 

 

 

 

(in thousands)

 

 

Office equipment

    

$

8,115

 

$

6,753

    

 

Laboratory equipment

 

 

33,263

    

 

31,296

 

 

Computer equipment

 

 

26,186

 

 

22,491

 

 

Building and leasehold improvements

 

 

72,539

 

 

70,729

 

 

 

 

 

140,103

 

 

131,269

 

 

Less accumulated depreciation and amortization

 

 

(47,481)

 

 

(45,263)

 

 

 

 

$

92,622

 

$

86,006

 

 

 

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock compensation (Tables)
3 Months Ended
Mar. 31, 2016
Stock compensation  
Schedule of valuation assumptions used for valuation of fair value of stock compensation granted

We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee Stock Options For the Three Months Ended

 

Employee Stock Purchase Plan For the Three Months Ended

 

 

 

March 31,

 

March 31,

 

 

 

2016

       

2015

      

 

2016

      

2015

      

 

 

Average risk-free interest rates

1.50

%  

1.35

%  

 

0.73

%  

0.56

%  

 

 

Average expected life (in years)

5.00

 

5.05

 

 

0.25

 

0.25

 

 

 

Volatility

49

%  

50

%  

 

61

%  

38

%  

 

 

Weighted-average fair value (in dollars)

41.56

 

32.59

 

 

26.67

 

9.56

 

 

 

 

Schedule of option activity under the 2010 Stock Plan

Option activity under the 2010 Stock Plan was as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares Subject to

 

 

 

 

 

Outstanding Options

 

 

 

Shares Available

 

 

 

Weighted Average

 

 

    

for Grant

    

Shares

    

Exercise Price

 

Balance at December 31, 2015

 

3,846,717

 

11,052,279

 

$

33.55

 

Options granted

 

(1,412,583)

 

1,412,583

 

$

94.69

 

Options exercised

 

 —

 

(751,784)

 

$

14.06

 

Options cancelled

 

68,324

 

(68,324)

 

$

73.24

 

Options expired

 

 —

 

(1,834)

 

$

3.11

 

Balance at March 31, 2016

 

2,502,458

 

11,642,920

 

$

42.00

 

 

Schedule of RSU and PSU award activity under the 2010 Stock Plan

RSU and PSU award activity under the 2010 Stock Plan was as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares Subject to

 

 

 

Shares Available

 

Outstanding Awards

 

 

    

for Grant

    

Shares

    

Grant Date Value

 

Balance at December 31, 2015

    

834,433

    

565,567

    

 

 —

 

RSUs granted

 

(216,711)

 

216,711

 

$

88.28

 

PSUs granted

 

 —

 

 —

 

 

 —

 

RSUs cancelled

 

12,843

 

(12,843)

 

$

67.62

 

PSUs cancelled

 

 —

 

 —

 

 

 —

 

Balance at March 31, 2016

 

630,565

 

769,435

 

 

 —

 

 

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
Debt (Tables)
3 Months Ended
Mar. 31, 2016
Debt  
Schedule of components of convertible notes

The components of the convertible notes are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Carrying Amount,

 

 

 

Interest Rates

 

 

 

March 31,

 

December 31,

 

Debt

    

March 31, 2016

    

Maturities

    

2016

    

2015

 

0.375% Convertible Senior Notes due 2018

 

0.375

%  

2018

 

$

328,173

 

 

324,031

 

1.25% Convertible Senior Notes due 2020

 

1.25

%  

2020

 

 

299,469

 

 

295,862

 

 

 

 

 

 

 

 

627,642

 

 

619,893

 

Less current portion

 

 

 

 

 

 

 —

 

 

 —

 

 

 

 

 

 

 

$

627,642

 

$

619,893

 

 

Schedule of carrying amount and fair value of convertible notes

The carrying amount and fair value of our convertible notes are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2016

 

December 31, 2015

 

 

    

Carrying

    

 

 

    

Carrying

    

 

 

 

 

 

Amount

 

Fair Value

 

Amount

 

Fair Value

 

0.375% Convertible Senior Notes due 2018

 

 

328,173

 

 

574,922

 

 

324,031

 

 

807,422

 

1.25% Convertible Senior Notes due 2020

 

 

299,469

 

 

588,427

 

 

295,862

 

 

816,123

 

 

 

$

627,642

 

$

1,163,349

 

$

619,893

 

$

1,623,545

 

 

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.4.0.3
Net loss per share (Tables)
3 Months Ended
Mar. 31, 2016
Net income (loss) per share  
Schedule of calculation of net income (loss) per share

Net income (loss) per share was calculated as follows for the periods indicated:

 

 

 

 

 

 

 

 

  

Three Months Ended

 

 

March 31,

(in thousands, except per share data)

    

 

2016

    

2015

Basic Net Income (Loss) Per Share

  

 

 

  

 

 

Basic net income (loss)

 

$

24,047

 

$

(18,359)

Weighted average common shares outstanding

 

 

187,184

 

 

172,070

 

  

 

 

  

 

 

Basic net income (loss) per share

  

$

0.13

  

$

(0.11)

 

  

 

 

  

 

 

Diluted Net Income (Loss) Per Share

  

 

 

  

 

 

Diluted net income (loss)

 

$

24,047

  

$

(18,359)

Weighted average common shares outstanding

 

 

187,184

 

 

172,070

 

 

 

 

 

 

 

Dilutive stock options and RSU’s

 

 

5,441

 

 

 —

 

 

 

 

 

 

 

Weighted average shares used to compute diluted net income (loss) per share

  

 

192,625

 

 

172,070

 

 

 

 

 

 

 

Diluted net income (loss) per share

  

$

0.12

  

$

(0.11)

 

Schedule of antidilutive securities excluded from the computation of earnings per share

The following potential common shares were excluded from the calculations as their effect would be anti-dilutive:

 

 

 

 

 

 

 

Three Months Ended

 

 

March 31,

 

    

2016

    

2015

Outstanding stock options and awards

 

2,652,265

 

14,626,717

Common shares issuable upon conversion of the 4.75% Convertible Senior Notes due 2015

 

 —

 

10,353,076

Common shares issuable upon conversion of the 2018 Notes

 

7,245,244

 

7,245,263

Common shares issuable upon conversion of the 2020 Notes

 

7,241,284

 

7,245,263

Total potential common shares excluded from diluted net loss per share computation

 

17,138,793

 

39,470,319

 

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.4.0.3
Organization and business (Details)
3 Months Ended
Mar. 31, 2016
segment
Organization and Business  
Number of operating segments 1
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of significant accounting policies (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2016
USD ($)
item
issuer
instrument
Dec. 31, 2015
USD ($)
Concentrations of Credit Risk    
Number of issuer to which company limits the amount of credit exposure other than US Government guaranteed securities | issuer 1  
Number of financial investment to which company limits the amount of credit exposure other than US Government guaranteed securities | instrument 1  
Accounts Receivable    
Allowance for doubtful accounts | $ $ 0 $ 0
Inventory    
Shelf life for finished goods inventory, maximum 36 months  
Variable Interest Entities    
Number of entities in which variable interest held | item 0  
Minimum    
Property and Equipment    
Estimated useful life 3 years  
Maximum    
Property and Equipment    
Estimated useful life 5 years  
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of significant accounting policies (Details 2)
$ in Thousands
3 Months Ended
Mar. 31, 2016
USD ($)
item
category
Mar. 31, 2015
USD ($)
Revenue Recognition    
Percentage of Medicare Part D insurance coverage gap mandate to be funded by manufacturers 50.00%  
Categories of milestone events, number | category 3  
Number of stages of life-cycle drugs | item 3  
Stock-Based Compensation    
Stock-based compensation expense $ 20,800 $ 17,600
Recent Accounting Pronouncements    
Excess tax benefits (400) $ (367)
Impact of Adoption of ASU No. 2016-09    
Recent Accounting Pronouncements    
Excess tax benefit from stock based compensation 325,600  
Excess tax benefits $ 300  
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair value of financial instruments (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Fair value of financial instruments    
Long term investment (Note 7) $ 32,298 $ 35,248 [1]
Recurring | Fair Value    
Fair value of financial instruments    
Cash and cash equivalents 657,615 521,439
Corporate debt securities 153,054 186,344
Long term investment (Note 7) 32,298 35,248
Total assets 842,967 743,031
Recurring | Level 1    
Fair value of financial instruments    
Cash and cash equivalents 657,615 521,439
Long term investment (Note 7) 32,298 35,248
Total assets 689,913 556,687
Recurring | Level 2    
Fair value of financial instruments    
Corporate debt securities 153,054 186,344
Total assets $ 153,054 $ 186,344
[1] The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date.
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.4.0.3
Fair value of financial instruments (Details 2) - Corporate Debt Securities - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Summary of marketable security portfolio    
Amortized Cost $ 152,657 $ 187,153
Net Unrealized Gains 397  
Net Unrealized Losses   (809)
Estimated Fair Value $ 153,054 $ 186,344
Minimum    
Summary of marketable security portfolio    
Contractual maturity dates 12 months  
Maximum    
Summary of marketable security portfolio    
Contractual maturity dates 18 months  
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.4.0.3
Concentration of Credit Risk (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Contract Revenues | Customer Concentration Risk | Collaboration Partner A      
Concentration of risk      
Percentage of concentration risk   89.00%  
Contract Revenues | Customer Concentration Risk | Collaboration Partner B      
Concentration of risk      
Percentage of concentration risk 100.00% 11.00%  
Sales Revenue Goods Services Net | Customer Concentration Risk | Customer A      
Concentration of risk      
Percentage of concentration risk 27.00% 28.00%  
Sales Revenue Goods Services Net | Customer Concentration Risk | Customer B      
Concentration of risk      
Percentage of concentration risk 18.00% 20.00%  
Sales Revenue Goods Services Net | Customer Concentration Risk | Customer C      
Concentration of risk      
Percentage of concentration risk 12.00% 13.00%  
Sales Revenue Goods Services Net | Customer Concentration Risk | Customer D      
Concentration of risk      
Percentage of concentration risk 8.00% 8.00%  
Accounts Receivable | Credit Concentration Risk | Collaboration Partner A and B      
Concentration of risk      
Percentage of concentration risk 22.00%   39.00%
Accounts Receivable | Credit Concentration Risk | Customer A B C and D      
Concentration of risk      
Percentage of concentration risk 48.00%   40.00%
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.4.0.3
Inventory (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Inventory    
Work-in-process $ 17,277 $ 17,555
Finished goods 1,309 1,783
Total inventories 18,586 19,338
Inventories - current 1,309 1,783 [1]
Inventories - non -current $ 17,277 $ 17,555 [1]
Shelf life for finished goods inventory, maximum 36 months  
[1] The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date.
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.4.0.3
Property and Equipment (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2016
USD ($)
Dec. 31, 2013
ft²
Dec. 31, 2015
USD ($)
Property and Equipment      
Property and Equipment, gross $ 140,103   $ 131,269
Less accumulated depreciation and amortization (47,481)   (45,263)
Property and Equipment, net 92,622   86,006 [1]
Area of laboratory and office building on lease (in square feet) | ft²   190,000  
Term of lease   15 years  
Minimum monthly lease rental $ 500    
Initial term of lease over which minimum lease rent is required to be payable 10 years    
Last term of lease 5 years    
Letter of credit for posted for lease facility $ 15,000    
Restricted investments related to direct financing lease 13,900   14,000
Office Equipment      
Property and Equipment      
Property and Equipment, gross 8,115   6,753
Laboratory Equipment      
Property and Equipment      
Property and Equipment, gross 33,263   31,296
Computer Equipment      
Property and Equipment      
Property and Equipment, gross 26,186   22,491
Building And Leasehold Improvements      
Property and Equipment      
Property and Equipment, gross $ 72,539   $ 70,729
[1] The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date.
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.4.0.3
Property and Equipment (Details 2) - USD ($)
$ in Thousands
3 Months Ended
Aug. 21, 2015
Mar. 31, 2016
Mar. 31, 2015
Property and Equipment      
Capital expenditures   $ 5,562 $ 3,553
Pending Land and Building Acquisition | Agreement of Sale with Augustine Land II, L.P.      
Property and Equipment      
Purchase price of leased land and office building to be acquired $ 79,900    
Deposit with a third party escrow agent 4,000    
Deposit with seller $ 4,000    
Capital expenditures   $ 8,000  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.4.0.3
License agreements (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 76 Months Ended 77 Months Ended
Mar. 31, 2016
USD ($)
Jan. 31, 2016
USD ($)
Jul. 31, 2010
Jan. 31, 2010
USD ($)
Dec. 31, 2009
USD ($)
item
Nov. 30, 2009
USD ($)
Mar. 31, 2016
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2010
USD ($)
Mar. 31, 2016
USD ($)
Mar. 31, 2016
USD ($)
License agreements                                
Research and Development Expense             $ 156,824 $ 118,365                
Contract revenues             58,214 28,214                
Product royalty revenues             21,903 15,673                
Novartis                                
License agreements                                
Upfront and immediate milestone payment to be received under license agreement           $ 210,000                    
Product royalties in accounts receivable $ 21,800           21,800   $ 23,800           $ 21,800 $ 21,800
Upfront payment received under license agreement           150,000                    
Immediate milestone payment received under license agreement       $ 60,000                        
Reimbursable costs recorded as deferred revenue         $ 10,900                      
Reimbursable costs included in accounts receivable 100           100   300           100 100
Research and development expenses reimbursed             300 500                
Contract revenues             0 25,000                
Novartis | U.S.                                
License agreements                                
Royalties payable             5,200 2,500                
Novartis | Pre-specified Events | Maximum                                
License agreements                                
Upfront and immediate milestone payment to be received under license agreement           1,200,000                    
Novartis | Development Milestones                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                               102,000
Novartis | Development Milestones | Maximum                                
License agreements                                
Upfront and immediate milestone payment to be received under license agreement           174,000                    
Novartis | Regulatory Milestones                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                               175,000
Novartis | Regulatory Milestones | Maximum                                
License agreements                                
Upfront and immediate milestone payment to be received under license agreement           495,000                    
Novartis | Commercialization Milestones                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                               $ 20,000
Novartis | Commercialization Milestones | Maximum                                
License agreements                                
Upfront and immediate milestone payment to be received under license agreement           $ 500,000                    
Novartis | JAKAFI                                
License agreements                                
Product royalty revenues             21,900 15,700                
Novartis | JAKAFI | Development Milestones                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                 5,000 $ 7,000 $ 25,000   $ 15,000 $ 50,000    
Novartis | JAKAFI | Regulatory Milestones                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                         $ 10,000      
Novartis | JAKAFI | Regulatory Milestones | Europe                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                 25,000 60,000   $ 40,000        
Novartis | JAKAFI | Regulatory Milestones | JAPAN                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                   25,000            
Novartis | JAKAVI                                
License agreements                                
Net sales                 300,000              
Novartis | JAKAVI | Regulatory Milestones | Europe                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                   $ 60,000            
Novartis | JAKAVI | Regulatory Milestones | JAPAN                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                 15,000              
Novartis | JAKAVI | Commercialization Milestones                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                 $ 20,000              
Lilly                                
License agreements                                
Number of deliverables under license agreement | item         2                      
Upfront payment received under license agreement         $ 90,000                      
Research and development expenses reimbursed             5,100 11,600                
Contract revenues             $ 58,200 $ 3,200                
Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop, percentage     30.00%   30.00%   30.00% 30.00%                
Lilly | Europe                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone   $ 20,000                            
Lilly | U.S.                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone   $ 35,000                            
Lilly | Maximum                                
License agreements                                
Range of royalty payments on future global net sales (as a percent)             20.00%                  
Associated future royalty payments from the initiation of a Phase IIb trial, if elected to not co-develop, percentage             20.00%                  
Lilly | Pre-specified Events | Maximum                                
License agreements                                
Upfront and immediate milestone payment to be received under license agreement         $ 665,000                      
Lilly | Development Milestones                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                             99,000  
Lilly | Development Milestones | Maximum                                
License agreements                                
Upfront and immediate milestone payment to be received under license agreement         150,000                      
Lilly | Development Milestones | Phase Three                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                       $ 50,000        
Lilly | Development Milestones | Phase Two A                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                           30,000    
Lilly | Development Milestones | Phase Two B                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                           $ 19,000    
Lilly | Regulatory Milestones                                
License agreements                                
Amount recognized and received for the achievement of a predefined milestone                             $ 55,000  
Lilly | Regulatory Milestones | Maximum                                
License agreements                                
Upfront and immediate milestone payment to be received under license agreement         365,000                      
Lilly | Commercialization Milestones | Maximum                                
License agreements                                
Upfront and immediate milestone payment to be received under license agreement         $ 150,000                      
Lilly | GVHD                                
License agreements                                
Upfront payment received under license agreement 35,000                              
Research and Development Expense             $ 35,000                  
Additional milestone payment received under license agreement $ 40,000                              
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.4.0.3
License agreements (Details 2) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 18, 2015
Jan. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
License agreements          
Long term investment     $ 32,298   $ 35,248 [1]
Total revenues     263,464 $ 159,275  
Current assets     935,581   842,375 [1]
Current liabilities     200,319   168,007 [1]
Unrealized loss on long term investment     (2,950)    
Research and development expense     $ 156,824 118,365  
Agenus          
License agreements          
Fair value of common stock     $ 4.16    
Acquisition of outstanding voting stock of Agenus (as a percent)     9.00%    
Total revenues         24,800
Net loss         $ (87,900)
Unrealized loss on long term investment     $ (3,000)    
Research and development expense     4,100 $ 1,800  
Agenus | Accrued and other liabilities          
License agreements          
Research and development expense     $ 10,000    
Agenus | Development, Regulatory and Commercialization Milestones          
License agreements          
Reserved right to elect to co-fund of development costs (as a percent)     30.00%    
Agenus | Development, Regulatory and Commercialization Milestones | Minimum          
License agreements          
Range of royalty payments on future global net sales (as a percent)     6.00%    
Agenus | Development, Regulatory and Commercialization Milestones | Maximum          
License agreements          
Future contingent milestone payment     $ 155,000    
Range of royalty payments on future global net sales (as a percent)     12.00%    
Agenus | Development Milestones | Maximum          
License agreements          
Future contingent milestone payment     $ 20,000    
Agenus | Stock purchase agreement          
License agreements          
Purchase of common stock under Stock Purchase Agreement (in shares )   7,760      
Purchase price of common stock under Stock Purchase Agreement $ 39,800 $ 35,000      
Per share price of common stock under Stock Purchase Agreement $ 5.13 $ 4.51      
Minimum period for holding common stock of Agenus 12 months        
Total consideration paid $ 60,000        
Long term investment 39,800        
Research and development expense $ 20,200        
Agenus | Stock purchase agreement | Maximum          
License agreements          
Percentage of outstanding voting stock that may be acquired   15.00%      
[1] The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date.
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.4.0.3
License agreements (Details 3) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Sep. 01, 2015
License agreements        
Research and development expense $ 156,824 $ 118,365    
Hengrui        
License agreements        
Upfront payment made under license agreement     $ 25,000  
Potential milestone payments to be made       $ 770,000
Research and development expense $ 700      
Hengrui | Regulatory Milestones        
License agreements        
Potential milestone payments to be made       90,000
Hengrui | Commercialization Milestones        
License agreements        
Potential milestone payments to be made       530,000
Hengrui | Clinical Superiority Milestones        
License agreements        
Potential milestone payments to be made       $ 150,000
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock Compensation (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Stock compensation    
Stock compensation expense $ 20,800 $ 17,600
Weighted-average fair value assumptions    
Valuation method Black-Scholes valuation model  
Dividend yield (as a percent) 0.00%  
Research and Development Expense.    
Stock compensation    
Stock compensation expense $ 13,000 10,300
Selling, General and Administrative Expenses    
Stock compensation    
Stock compensation expense $ 7,800 $ 7,300
Stock Options    
Weighted-average fair value assumptions    
Average risk-free interest rates (as a percent) 1.50% 1.35%
Average expected life (in years) 5 years 5 years 18 days
Volatility (as a percent) 49.00% 50.00%
Weighted-average fair value (in dollars per share) $ 41.56 $ 32.59
Unrecognized compensation    
Unrecognized compensation cost for nonvested option (in dollars) $ 68,700  
Vesting period of recognition of the unrecognized compensation cost of nonvested awards 3 years  
Employee Stock Purchase Plan    
Weighted-average fair value assumptions    
Average risk-free interest rates (as a percent) 0.73% 0.56%
Average expected life (in years) 3 months 3 months
Volatility (as a percent) 61.00% 38.00%
Weighted-average fair value (in dollars per share) $ 26.67 $ 9.56
Restricted Stock Units (RSUs)    
Unrecognized compensation    
Unrecognized compensation cost for nonvested option (in dollars) $ 35,400  
Vesting period of recognition of the unrecognized compensation cost of nonvested awards 3 years  
Performance Stock Units (PSUs)    
Stock compensation    
Stock compensation expense $ 0  
Unrecognized compensation    
Unrecognized compensation cost for nonvested option (in dollars) $ 700  
Vesting period of recognition of the unrecognized compensation cost of nonvested awards 3 years  
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock Compensation (Details 2) - Stock Options
3 Months Ended
Mar. 31, 2016
$ / shares
shares
Shares Available For Grant  
Outstanding at the beginning of the period (in shares) 3,846,717
Options granted (in shares) (1,412,583)
Options cancelled (in shares) 68,324
Outstanding at the end of the period (in shares) 2,502,458
Shares Subject to Outstanding Options, Shares  
Outstanding at the beginning of the period (in shares) 11,052,279
Options granted (in shares) 1,412,583
Options exercised (in shares) (751,784)
Options cancelled (in shares) (68,324)
Options expired (in shares) (1,834)
Outstanding at the end of the period (in shares) 11,642,920
Shares Subject to Outstanding Options, Weighted Average Exercise Price  
Outstanding at the beginning of the period (in dollars per share) | $ / shares $ 33.55
Options granted (in dollars per share) | $ / shares 94.69
Options exercised (in dollars per share) | $ / shares 14.06
Options cancelled (in dollars per share) | $ / shares 73.24
Options expired (in dollars per share) | $ / shares 3.11
Outstanding at the end of the period (in dollars per share) | $ / shares $ 42.00
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.4.0.3
Stock Compensation (Details 3) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Jan. 31, 2014
Mar. 31, 2016
Mar. 31, 2015
Stock Compensation Plans      
Stock compensation expense   $ 20,800 $ 17,600
Other than options, disclosures      
Assumed annualized forfeiture rate (as a percent)   5.00%  
Stock compensation expense   $ 20,800 $ 17,600
Restricted Stock Units (RSUs)      
Stock Compensation Plans      
Number of shares awarded for each RSU (in shares)   1  
Shares Available For Grant      
Shares Available for Grant Beginning Balance (in shares)   834,433  
Granted (in shares)   (216,711)  
Cancelled (in shares)   12,843  
Shares Available for Grant Ending Balance (in shares)   630,565  
Shares Subject to Outstanding Options, Shares      
Outstanding at the beginning of the period (in shares)   565,567  
Granted (in shares)   216,711  
Cancelled (in shares)   (12,843)  
Outstanding at the end of the period (in shares)   769,435  
Shares Subject to Outstanding Options, Weighted Average Exercise Price      
Granted (in dollars per share)   $ 88.28  
Cancelled (in dollars per share)   $ 67.62  
Weighted-average fair value assumptions      
Cliff vesting period   3 years  
Other than options, disclosures      
Granted (in shares)   216,711  
Outstanding (in shares)   834,433  
Restricted Stock Units (RSUs) | President And Chief Executive Officer      
Shares Available For Grant      
Cancelled (in shares)   133,333  
Shares Available for Grant Ending Balance (in shares)   266,667  
Shares Subject to Outstanding Options, Shares      
Granted (in shares) 400,000    
Percentage of units vesting at the end of each calendar year (as a percent)   16.70%  
Other than options, disclosures      
Granted (in shares) 400,000    
Outstanding (in shares)   266,667  
Performance Stock Units (PSUs)      
Stock Compensation Plans      
Stock compensation expense   $ 0  
Other than options, disclosures      
Stock compensation expense   $ 0  
Performance Stock Units (PSUs) | Maximum      
Other than options, disclosures      
Multiplier conversion rate of units into common stock (as a percent)   125.00%  
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.4.0.3
Debt (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Convertible Notes    
Convertible senior notes noncurrent $ 627,642 $ 619,893 [1]
Carrying Amount    
Convertible Notes    
Convertible senior notes, total 627,642 619,893
Convertible senior notes noncurrent 627,642 619,893
Fair Value    
Convertible Notes    
Convertible senior notes, total $ 1,163,349 1,623,545
0.375% Convertible Senior Notes due 2018 and 1.25% Convertible Senior Notes due 2020    
Convertible Notes    
Number of days within 30 consecutive trading days in which the price of the entity's common stock must exceed the conversion price for the notes to be converted 20 days  
Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be convertible 30 days  
Percentage of the closing sales price of common stock that the conversion price must exceed in order for the notes to be convertible (as a percent) 130.00%  
Number of consecutive business days immediately after any five consecutive trading day period during the note measurement period 5 days  
Number of consecutive trading days before five consecutive business days during the note measurement period 5 days  
Conversion ratio, principal amount of note 1,000  
Percentage of the trading price to the product of the last reported sale price of the common stock and the conversion rate, maximum (as a percent) 98.00%  
0.375% Convertible Senior Notes due 2018    
Convertible Notes    
Interest rate of debt (as a percent) 0.375%  
0.375% Convertible Senior Notes due 2018 | Carrying Amount    
Convertible Notes    
Convertible senior notes, total $ 328,173 324,031
0.375% Convertible Senior Notes due 2018 | Fair Value    
Convertible Notes    
Convertible senior notes, total $ 574,922 807,422
1.25% Convertible Senior Notes due 2020    
Convertible Notes    
Interest rate of debt (as a percent) 1.25%  
1.25% Convertible Senior Notes due 2020 | Carrying Amount    
Convertible Notes    
Convertible senior notes, total $ 299,469 295,862
1.25% Convertible Senior Notes due 2020 | Fair Value    
Convertible Notes    
Convertible senior notes, total $ 588,427 $ 816,123
[1] The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited financial statements at that date.
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.4.0.3
Net income (loss) per share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Basic Net Income (Loss) Per Share    
Net income (loss) $ 24,047 $ (18,359)
Weighted average common shares outstanding 187,184 172,070
Basic net income (loss) per share $ 0.13 $ (0.11)
Diluted Net Income (Loss) Per Share    
Diluted net income (loss) $ 24,047 $ (18,359)
Weighted average common shares outstanding 187,184 172,070
Dilutive stock options and RSU’s 5,441,000  
Weighted average shares used to compute diluted net income (loss) per share 192,625 172,070
Diluted net income (loss) per share $ 0.12 $ (0.11)
Anti-dilutive securities    
Potential common shares excluded from diluted net loss per share computation 17,138,793 39,470,319
Stock Options    
Anti-dilutive securities    
Potential common shares excluded from diluted net loss per share computation 2,652,265 14,626,717
4.75% Convertible Senior Notes due 2015    
Anti-dilutive securities    
Potential common shares excluded from diluted net loss per share computation   10,353,076
Interest rate of debt (as a percent)   4.75%
0.375% Convertible Senior Notes due 2018    
Anti-dilutive securities    
Potential common shares excluded from diluted net loss per share computation 7,245,244 7,245,263
1.25% Convertible Senior Notes due 2020    
Anti-dilutive securities    
Potential common shares excluded from diluted net loss per share computation 7,241,284 7,245,263
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.4.0.3
Subsequent Event (Details) - Subsequent Event - Wholly-owned subsidiary of ARIAD Pharmaceuticals, Inc - Stock purchase agreement
$ in Millions
1 Months Ended
May. 31, 2016
USD ($)
Subsequent Event [Line Items]  
Purchase price of common stock under Stock Purchase Agreement $ 140
Development, Regulatory and Commercialization Milestones | Maximum  
Subsequent Event [Line Items]  
Potential milestone payments to be made $ 135
EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 161 255 1 true 65 0 false 10 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.incyte.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00405 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 7 false false R8.htm 10101 - Disclosure - Organization and business Sheet http://www.incyte.com/role/DisclosureOrganizationAndBusiness Organization and business Notes 8 false false R9.htm 10201 - Disclosure - Summary of significant accounting policies Sheet http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 9 false false R10.htm 10301 - Disclosure - Fair Value of Financial Instruments Sheet http://www.incyte.com/role/DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 10401 - Disclosure - Concentration of Credit Risk Sheet http://www.incyte.com/role/DisclosureConcentrationOfCreditRisk Concentration of Credit Risk Notes 11 false false R12.htm 10501 - Disclosure - Inventory Sheet http://www.incyte.com/role/DisclosureInventory Inventory Notes 12 false false R13.htm 10601 - Disclosure - Property and Equipment Sheet http://www.incyte.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 10701 - Disclosure - License Agreements Sheet http://www.incyte.com/role/DisclosureLicenseAgreements License Agreements Notes 14 false false R15.htm 10801 - Disclosure - Stock compensation Sheet http://www.incyte.com/role/DisclosureStockCompensation Stock compensation Notes 15 false false R16.htm 10901 - Disclosure - Debt Sheet http://www.incyte.com/role/DisclosureDebt Debt Notes 16 false false R17.htm 11001 - Disclosure - Income taxes Sheet http://www.incyte.com/role/DisclosureIncomeTaxes Income taxes Notes 17 false false R18.htm 11101 - Disclosure - Net income (loss) per share Sheet http://www.incyte.com/role/DisclosureNetIncomeLossPerShare Net income (loss) per share Notes 18 false false R19.htm 11201 - Disclosure - Contingencies Sheet http://www.incyte.com/role/DisclosureContingencies Contingencies Notes 19 false false R20.htm 11301 - Disclosure - Subsequent Event Sheet http://www.incyte.com/role/DisclosureSubsequentEvent Subsequent Event Notes 20 false false R21.htm 20102 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies 21 false false R22.htm 30303 - Disclosure - Fair value of financial instruments (Tables) Sheet http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables Fair value of financial instruments (Tables) Tables 22 false false R23.htm 30403 - Disclosure - Concentration of Credit Risk (Tables) Sheet http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskTables Concentration of Credit Risk (Tables) Tables http://www.incyte.com/role/DisclosureConcentrationOfCreditRisk 23 false false R24.htm 30503 - Disclosure - Inventory (Tables) Sheet http://www.incyte.com/role/DisclosureInventoryTables Inventory (Tables) Tables http://www.incyte.com/role/DisclosureInventory 24 false false R25.htm 30603 - Disclosure - Property and Equipment (Tables) Sheet http://www.incyte.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.incyte.com/role/DisclosurePropertyAndEquipment 25 false false R26.htm 30803 - Disclosure - Stock compensation (Tables) Sheet http://www.incyte.com/role/DisclosureStockCompensationTables Stock compensation (Tables) Tables http://www.incyte.com/role/DisclosureStockCompensation 26 false false R27.htm 30903 - Disclosure - Debt (Tables) Sheet http://www.incyte.com/role/DisclosureDebtTables Debt (Tables) Tables http://www.incyte.com/role/DisclosureDebt 27 false false R28.htm 31103 - Disclosure - Net loss per share (Tables) Sheet http://www.incyte.com/role/DisclosureNetLossPerShareTables Net loss per share (Tables) Tables 28 false false R29.htm 40101 - Disclosure - Organization and business (Details) Sheet http://www.incyte.com/role/DisclosureOrganizationAndBusinessDetails Organization and business (Details) Details http://www.incyte.com/role/DisclosureOrganizationAndBusiness 29 false false R30.htm 40201 - Disclosure - Summary of significant accounting policies (Details) Sheet http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of significant accounting policies (Details) Details http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPolicies 30 false false R31.htm 40202 - Disclosure - Summary of significant accounting policies (Details 2) Sheet http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2 Summary of significant accounting policies (Details 2) Details http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPolicies 31 false false R32.htm 40301 - Disclosure - Fair value of financial instruments (Details) Sheet http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsDetails Fair value of financial instruments (Details) Details http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables 32 false false R33.htm 40302 - Disclosure - Fair value of financial instruments (Details 2) Sheet http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsDetails2 Fair value of financial instruments (Details 2) Details http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables 33 false false R34.htm 40401 - Disclosure - Concentration of Credit Risk (Details) Sheet http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskDetails Concentration of Credit Risk (Details) Details http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskTables 34 false false R35.htm 40501 - Disclosure - Inventory (Details) Sheet http://www.incyte.com/role/DisclosureInventoryDetails Inventory (Details) Details http://www.incyte.com/role/DisclosureInventoryTables 35 false false R36.htm 40601 - Disclosure - Property and Equipment (Details) Sheet http://www.incyte.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.incyte.com/role/DisclosurePropertyAndEquipmentTables 36 false false R37.htm 40602 - Disclosure - Property and Equipment (Details 2) Sheet http://www.incyte.com/role/DisclosurePropertyAndEquipmentDetails2 Property and Equipment (Details 2) Details http://www.incyte.com/role/DisclosurePropertyAndEquipmentTables 37 false false R38.htm 40701 - Disclosure - License agreements (Details) Sheet http://www.incyte.com/role/DisclosureLicenseAgreementsDetails License agreements (Details) Details 38 false false R39.htm 40702 - Disclosure - License agreements (Details 2) Sheet http://www.incyte.com/role/DisclosureLicenseAgreementsDetails2 License agreements (Details 2) Details 39 false false R40.htm 40703 - Disclosure - License agreements (Details 3) Sheet http://www.incyte.com/role/DisclosureLicenseAgreementsDetails3 License agreements (Details 3) Details 40 false false R41.htm 40801 - Disclosure - Stock Compensation (Details) Sheet http://www.incyte.com/role/DisclosureStockCompensationDetails Stock Compensation (Details) Details 41 false false R42.htm 40802 - Disclosure - Stock Compensation (Details 2) Sheet http://www.incyte.com/role/DisclosureStockCompensationDetails2 Stock Compensation (Details 2) Details 42 false false R43.htm 40803 - Disclosure - Stock Compensation (Details 3) Sheet http://www.incyte.com/role/DisclosureStockCompensationDetails3 Stock Compensation (Details 3) Details 43 false false R44.htm 40901 - Disclosure - Debt (Details) Sheet http://www.incyte.com/role/DisclosureDebtDetails Debt (Details) Details http://www.incyte.com/role/DisclosureDebtTables 44 false false R45.htm 41101 - Disclosure - Net income (loss) per share (Details) Sheet http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails Net income (loss) per share (Details) Details http://www.incyte.com/role/DisclosureNetIncomeLossPerShare 45 false false R46.htm 41301 - Disclosure - Subsequent Event (Details) Sheet http://www.incyte.com/role/DisclosureSubsequentEventDetails Subsequent Event (Details) Details http://www.incyte.com/role/DisclosureSubsequentEvent 46 false false All Reports Book All Reports incy-20160331.xml incy-20160331.xsd incy-20160331_cal.xml incy-20160331_def.xml incy-20160331_lab.xml incy-20160331_pre.xml true true ZIP 65 0001558370-16-005699-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-16-005699-xbrl.zip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ͱ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end